Equity · KR Market · Single-Stock Deep Dive · Pharma & Biotech

K200 제약·바이오 12종목 — 국채 옆의 배당, 매출·이익 성장, R&D 자산화, 지분 구조K200 pharma and biotech, 12 companies — dividends next to government bonds, revenue and profit growth, R&D capitalisation, ownership structureK200製薬・バイオ12銘柄 — 国債と並べた配当、売上高・利益の成長、R&D資産化、持株構造

셀트리온·삼성바이오로직스·대웅(지주)을 중심으로 K200 제약·바이오 12종목의 DART 정기보고서(2019Q1~, 원문 표·주석 포함)를 같은 틀로 편다. 배당·이익수익률을 KTB/UST 10Y 옆에 놓고, 매출·영업이익·순이익 성장, 연구개발비와 개발비 자산화, CapEx·생산능력·가동률, 재고·매출채권, 특수관계자 매출(셀트리온↔헬스케어·삼바↔에피스), 최대주주·자기주식, 합병·분할 문장을 Raw Data 그대로 적는다.The DART periodic reports (2019Q1 onwards, original tables and notes included) of the 12 K200 pharma and biotech companies are laid out in one frame, centred on Celltrion, Samsung Biologics and Daewoong (hold.). Dividend and earnings yields sit next to KTB/UST 10Y; revenue, operating-profit and net-profit growth, R&D spending and capitalised development costs, capex, capacity and utilisation, inventories and receivables, related-party sales (Celltrion↔Celltrion Healthcare · Samsung Biologics↔Samsung Bioepis), largest shareholders and treasury shares, and merger and spin-off text are set down as in the Raw Data.Celltrion・Samsung Biologics・Daewoong (hold.)を中心に、K200製薬・バイオ12銘柄のDART定期報告書(2019Q1以降、原文の表・注記を含む)を同じ枠組みで並べる。配当利回り・益回りをKTB/UST 10Yと並べ、売上高・営業利益・純利益の成長、研究開発費と開発費の資産化、設備投資・生産能力・稼働率、棚卸資産・売上債権、関連当事者向け売上(Celltrion↔Celltrion Healthcare・Samsung Biologics↔Samsung Bioepis)、筆頭株主・自己株式、合併・分割の文章をRaw Dataのまま記す。

기준일 20261027As of 20261027基準日 20261027DART 정기보고서(원문·재무제표·주요정보)DART periodic reports (original text · financial statements · key information)DART定期報告書(原文・財務諸表・主要情報)12종목 · 심층 셀트리온 · 삼성바이오 · 대웅(지주)12 companies · deep dives: Celltrion · Samsung Bio · Daewoong (hold.)12銘柄 · 深掘り Celltrion · Samsung Bio · Daewoong (hold.)
먼저 보는 세 줄 · 2026-10-27Three lines first · 2026-10-27まず見る三行 · 2026-10-27
  1. 셀트리온 2026Q3 잠정 매출 15,755억 (YoY +53.1%) · 영업이익 5,253억 — 관세청 완제 수출 연결은 전진 검증 6분기 중 3분기만 직전 분기 유지를 이겨 우리 Fcst 를 내지 않았다.Celltrion 2026Q3 preliminary revenue 15,755 KRW 100mn (YoY +53.1%) · operating profit 5,253 KRW 100mn — the link to customs dose-form exports beat holding the previous quarter in only 3 of 6 forward-test quarters, so we did not publish our Fcst.Celltrion 2026Q3速報売上高15,755億ウォン(YoY +53.1%) · 営業利益5,253億ウォン — 関税庁の完成品輸出との連動はフォワードテスト6四半期中3四半期しか前四半期据え置きに勝てず、当サイトFcstは出さなかった。
  2. 삼성바이오로직스 2026Q3 잠정 매출 14,903억 (QoQ +12.8%) · 영업이익률 43.0% — 2026Q4 우리 Fcst 매출 14,576억 (±6%, 관세청 원료 수출).Samsung Biologics 2026Q3 preliminary revenue 14,903 KRW 100mn (QoQ +12.8%) · operating margin 43.0% — 2026Q4 our Fcst revenue 14,576 KRW 100mn (±6%, customs drug-substance exports).Samsung Biologics 2026Q3速報売上高14,903億ウォン(QoQ +12.8%) · 営業利益率43.0% — 2026Q4 当サイトFcst売上高14,576億ウォン(±6%、関税庁の原薬輸出)。
  3. 대웅(지주) 자기주식 27.7% — 자기주식 뺀 시총 0.68조 대비 보유 상장 지분 시가 0.65조 (96%) · P/E 3.8배 · P/B 0.54배(자기주식 뺀 시총).Daewoong (hold.) treasury shares 27.7% — market value of the listed stakes it holds KRW 0.65trn against its market cap excluding treasury shares KRW 0.68trn (96%) · P/E 3.8x · P/B 0.54x (market cap excluding treasury shares).Daewoong (hold.) 自己株式27.7% — 自己株式を除いた時価総額0.68兆ウォンに対し、保有上場株式の時価0.65兆ウォン(96%) · PER 3.8倍 · PBR 0.54倍(自己株式を除いた時価総額)。
셀트리온 매출 FY2025Celltrion revenue FY2025Celltrion 売上高 FY2025
4.16조KRW trn兆ウォン
YoY +17.0% · OPM +28.1%
셀트리온 2026Q3 잠정 매출Celltrion 2026Q3 preliminary revenueCelltrion 2026Q3 速報売上高
1.58조KRW trn兆ウォン
YoY +53.1% · OPM 33.3%
셀트리온 R&DCelltrion R&DCelltrion R&D
11.6%of sales
자산화 56.3% · CapEx/매출 +8.0%capitalised 56.3% · capex/revenue +8.0%資産化56.3% · 設備投資/売上高+8.0%
삼성바이오 2026Q3 잠정 매출Samsung Bio 2026Q3 preliminary revenueSamsung Bio 2026Q3 速報売上高
1.49조KRW trn兆ウォン
QoQ +12.8% · OPM 43.0%
대웅 상장 지분 시가 ÷ 시총Daewoong (hold.): listed stakes ÷ market capDaewoong (hold.):上場株式の時価 ÷ 時価総額
96%
자기주식 27.7% 뺀 시총 기준market cap excluding 27.7% treasury shares自己株式27.7%を除いた時価総額ベース
삼성바이오 2026Q4 우리 FcstSamsung Bio 2026Q4 our FcstSamsung Bio 2026Q4 当サイトFcst
1.46조KRW trn兆ウォン
관세청 원료 수출 · ±6%customs drug-substance exports · ±6%関税庁の原薬輸出 · ±6%
삼성바이오 매출 FY2025Samsung Bio revenue FY2025Samsung Bio 売上高 FY2025
4.56조KRW trn兆ウォン
YoY +0.2% · OPM +45.4%
숫자는 DART 정기보고서(원문 표·재무제표)와 영업(잠정)실적 공정공시에서 옮겼다. 분기 4분기 = 연간 − 9개월 누계. 삼성바이오로직스 분기는 에피스 분할 전후 범위를 맞추려 별도(CDMO) 기준. 관세청 수출은 한국 전체 합. 우리 Fcst 는 자체 추정(컨센서스 아님).Figures are taken from DART periodic reports (original tables and financial statements) and fair-disclosure filings of preliminary operating results. Quarterly Q4 = full year − nine-month cumulative. Samsung Biologics' quarters are on a separate (CDMO) basis to keep the scope the same before and after the Samsung Bioepis spin-off. Customs exports are Korea-wide totals. Our Fcst is our own estimate (not consensus).数値はDART定期報告書(原文の表・財務諸表)と営業(暫定)実績の公正開示から転記した。四半期の第4四半期 = 通期 − 9か月累計。Samsung Biologicsの四半期はSamsung Bioepis分割前後の範囲をそろえるため個別(CDMO)ベース。関税庁の輸出は韓国全体の合計。当サイトFcstは独自推計(コンセンサスではない)。
00

한 줄In one line一行で

관측: 매출 순 삼성바이오 4.6조 > 셀트리온 4.2조 > 유한양행 2.2조 > 대웅(지주) 2.1조 > GC녹십자 2.0조 > 종근당 1.7조. 배당수익률이 KTB10Y(연말)를 넘는 회사: 없음. 6년 매출 CAGR 상위: 삼성바이오 +36.6%, SK바이오팜 +33.7%, 셀트리온 +24.3%. R&D 자산화 비중 상위: 셀트리온 56.3%, 한올바이오파마 39.5%, SK바이오사이언스 37.3%.
Observation: by revenue Samsung Bio KRW 4.6trn > Celltrion KRW 4.2trn > Yuhan KRW 2.2trn > Daewoong (hold.) KRW 2.1trn > GC Biopharma KRW 2.0trn > Chong Kun Dang KRW 1.7trn. Companies whose dividend yield exceeds KTB10Y (year-end): none. Highest 6-year revenue CAGR: Samsung Bio +36.6%, SK Biopharm +33.7%, Celltrion +24.3%. Highest share of R&D capitalised: Celltrion 56.3%, HanAll 39.5%, SK Bioscience 37.3%.
観測:売上高順 Samsung Bio 4.6兆ウォン > Celltrion 4.2兆ウォン > Yuhan 2.2兆ウォン > Daewoong (hold.) 2.1兆ウォン > GC Biopharma 2.0兆ウォン > Chong Kun Dang 1.7兆ウォン。配当利回りがKTB10Y(年末)を上回る会社:なし。6年売上高CAGR上位:Samsung Bio +36.6%、SK Biopharm +33.7%、Celltrion +24.3%。R&D資産化比率上位:Celltrion 56.3%、HanAll 39.5%、SK Bioscience 37.3%。
01

한 표 — 12종목을 같은 잣대로One table — 12 companies on the same yardstick一覧表 — 12銘柄を同じ物差しで

한 표One table一覧表K200 pharma & biotech: growth, profitability, R&D, capital return, ownership (latest fiscal year)

회사FY매출YoYCAGR영업이익률순이익ROER&D/매출R&D 자산화CapEx/매출배당수익률배당−KTB(연말)이익수익률최대주주자기주식
삼성바이오FY20254.56조+0.2%+36.6% (2019~)+45.4%1.78조+19.4%3.7%—+32.4%무배당——삼성물산 43.1%0.1%
셀트리온FY20254.16조+17.0%+24.3% (2019~)+28.1%1.03조+5.9%11.6%56.3%+8.0%0.4% (FY2025)-2.98%p2.5%(주)셀트리온홀딩스 25.9%1.7%
유한양행FY20252.19조+5.7%+6.7% (2019~)+4.8%0.19조+8.8%11.1%3.3%+6.1%0.5% (FY2025)-2.88%p2.2%유한재단 15.9%7.6%
대웅(지주)FY20252.07조+6.8%+7.2% (2019~)+12.7%0.23조+16.1%n/a—+16.8%0.9% (FY2025)-2.48%p19.3%윤재승 11.6%27.7%
GC녹십자FY20251.99조+18.5%+6.4% (2019~)+3.5%-0.03조-0.4%8.6%3.6%+5.3%0.9% (FY2025)-2.48%p-0.2%㈜녹십자홀딩스 50.1%2.3%
종근당FY20251.69조+6.7%+7.8% (2019~)+4.8%0.08조+8.2%11.0%16.5%+10.6%0.6% (FY2025)-2.78%p7.1%(주)종근당홀딩스 26.7%4.5%
대웅제약FY20251.57조+10.4%+5.9% (2019~)+12.5%0.19조+21.8%15.8%11.0%+15.4%0.3% (FY2025)-3.08%p8.5%(주)대웅 52.3%0.7%
한미약품FY20251.55조+3.5%+5.6% (2019~)+16.7%0.19조+14.5%14.8%8.0%+4.9%0.8% (FY2025)-2.58%p5.3%한미사이언스(주) 41.4%1.0%
SD바이오센서FY20250.71조+2.3%-15.9% (2020~)-11.4%-0.51조-19.5%n/a—+8.1%2.2% (FY2025)-1.18%p-47.8%조영식 27.2%0.9%
SK바이오팜FY20250.71조+29.1%+33.7% (2019~)+28.9%0.25조+39.3%24.7%—+4.2%무배당——SK(주) 50.1%n/a
SK바이오사이언스FY20250.65조+143.5%-8.5% (2021~)-19.0%-0.06조-3.2%23.9%37.3%+40.0%무배당——SK케미칼(주) 66.3%0.5%
한올바이오파마FY20250.16조+11.7%+6.2% (2019~)-0.6%-0.01조-3.4%20.9%39.5%+9.1%무배당——(주)대웅제약 30.8%2.6%
CompanyFYRevenueYoYCAGROperating marginNet profitROER&D / revenueR&D capitalisedCapex / revenueDividend yieldDividend − KTB (year-end)Earnings yieldLargest shareholderTreasury shares
Samsung BioFY2025KRW 4.56trn+0.2%+36.6% (from 2019)+45.4%KRW 1.78trn+19.4%3.7%—+32.4%no dividend——Samsung C&T 43.1%0.1%
CelltrionFY2025KRW 4.16trn+17.0%+24.3% (from 2019)+28.1%KRW 1.03trn+5.9%11.6%56.3%+8.0%0.4% (FY2025)-2.98pp2.5%Selteurionholdingseu 25.9%1.7%
YuhanFY2025KRW 2.19trn+5.7%+6.7% (from 2019)+4.8%KRW 0.19trn+8.8%11.1%3.3%+6.1%0.5% (FY2025)-2.88pp2.2%Yuhanjaedan 15.9%7.6%
Daewoong (hold.)FY2025KRW 2.07trn+6.8%+7.2% (from 2019)+12.7%KRW 0.23trn+16.1%n/a—+16.8%0.9% (FY2025)-2.48pp19.3%Yun Jaeseung 11.6%27.7%
GC BiopharmaFY2025KRW 1.99trn+18.5%+6.4% (from 2019)+3.5%KRW -0.03trn-0.4%8.6%3.6%+5.3%0.9% (FY2025)-2.48pp-0.2%GC 50.1%2.3%
Chong Kun DangFY2025KRW 1.69trn+6.7%+7.8% (from 2019)+4.8%KRW 0.08trn+8.2%11.0%16.5%+10.6%0.6% (FY2025)-2.78pp7.1%Chongkundang Holdings 26.7%4.5%
Daewoong PharmFY2025KRW 1.57trn+10.4%+5.9% (from 2019)+12.5%KRW 0.19trn+21.8%15.8%11.0%+15.4%0.3% (FY2025)-3.08pp8.5%Daewoong 52.3%0.7%
HanmiFY2025KRW 1.55trn+3.5%+5.6% (from 2019)+16.7%KRW 0.19trn+14.5%14.8%8.0%+4.9%0.8% (FY2025)-2.58pp5.3%Hanmi Science 41.4%1.0%
SD BiosensorFY2025KRW 0.71trn+2.3%-15.9% (from 2020)-11.4%KRW -0.51trn-19.5%n/a—+8.1%2.2% (FY2025)-1.18pp-47.8%Jo Yeongsik 27.2%0.9%
SK BiopharmFY2025KRW 0.71trn+29.1%+33.7% (from 2019)+28.9%KRW 0.25trn+39.3%24.7%—+4.2%no dividend——SK 50.1%n/a
SK BioscienceFY2025KRW 0.65trn+143.5%-8.5% (from 2021)-19.0%KRW -0.06trn-3.2%23.9%37.3%+40.0%no dividend——SK Chemicals 66.3%0.5%
HanAllFY2025KRW 0.16trn+11.7%+6.2% (from 2019)-0.6%KRW -0.01trn-3.4%20.9%39.5%+9.1%no dividend——Daewoong Pharma 30.8%2.6%
会社FY売上高YoYCAGR営業利益率純利益ROER&D/売上高R&D資産化設備投資/売上高配当利回り配当−KTB(年末)益回り筆頭株主自己株式
Samsung BioFY20254.56兆ウォン+0.2%+36.6%(2019〜)+45.4%1.78兆ウォン+19.4%3.7%—+32.4%無配——Samsung C&T 43.1%0.1%
CelltrionFY20254.16兆ウォン+17.0%+24.3%(2019〜)+28.1%1.03兆ウォン+5.9%11.6%56.3%+8.0%0.4%(FY2025)-2.98%pt2.5%Selteurionholdingseu 25.9%1.7%
YuhanFY20252.19兆ウォン+5.7%+6.7%(2019〜)+4.8%0.19兆ウォン+8.8%11.1%3.3%+6.1%0.5%(FY2025)-2.88%pt2.2%Yuhanjaedan 15.9%7.6%
Daewoong (hold.)FY20252.07兆ウォン+6.8%+7.2%(2019〜)+12.7%0.23兆ウォン+16.1%n/a—+16.8%0.9%(FY2025)-2.48%pt19.3%Yun Jaeseung 11.6%27.7%
GC BiopharmaFY20251.99兆ウォン+18.5%+6.4%(2019〜)+3.5%-0.03兆ウォン-0.4%8.6%3.6%+5.3%0.9%(FY2025)-2.48%pt-0.2%GC 50.1%2.3%
Chong Kun DangFY20251.69兆ウォン+6.7%+7.8%(2019〜)+4.8%0.08兆ウォン+8.2%11.0%16.5%+10.6%0.6%(FY2025)-2.78%pt7.1%Chongkundang Holdings 26.7%4.5%
Daewoong PharmFY20251.57兆ウォン+10.4%+5.9%(2019〜)+12.5%0.19兆ウォン+21.8%15.8%11.0%+15.4%0.3%(FY2025)-3.08%pt8.5%Daewoong 52.3%0.7%
HanmiFY20251.55兆ウォン+3.5%+5.6%(2019〜)+16.7%0.19兆ウォン+14.5%14.8%8.0%+4.9%0.8%(FY2025)-2.58%pt5.3%Hanmi Science 41.4%1.0%
SD BiosensorFY20250.71兆ウォン+2.3%-15.9%(2020〜)-11.4%-0.51兆ウォン-19.5%n/a—+8.1%2.2%(FY2025)-1.18%pt-47.8%Jo Yeongsik 27.2%0.9%
SK BiopharmFY20250.71兆ウォン+29.1%+33.7%(2019〜)+28.9%0.25兆ウォン+39.3%24.7%—+4.2%無配——SK 50.1%n/a
SK BioscienceFY20250.65兆ウォン+143.5%-8.5%(2021〜)-19.0%-0.06兆ウォン-3.2%23.9%37.3%+40.0%無配——SK Chemicals 66.3%0.5%
HanAllFY20250.16兆ウォン+11.7%+6.2%(2019〜)-0.6%-0.01兆ウォン-3.4%20.9%39.5%+9.1%無配——Daewoong Pharma 30.8%2.6%

매출·이익은 DART 연결 재무제표, R&D 는 원문 '연구개발비용' 표(회사 기재 매출 대비 비율·개발비 자산화), 배당수익률은 DART 배당표의 회사 기재값(배당기준일 전 1주일 평균 종가), 이익수익률은 그 수익률로 역산한 주가에 연결 EPS. 오늘 KTB10Y 3.94% · UST10Y 4.98%.

Revenue and profit are from DART consolidated financial statements; R&D from the 'R&D expenses' table in the filings (the ratio to revenue the company reports, and capitalised development costs); dividend yield is the company-reported figure in the DART dividend table (average closing price over the week before the record date); earnings yield is consolidated EPS over the price implied by that yield. Today KTB10Y 3.94% · UST10Y 4.98%.

売上高・利益はDART連結財務諸表、R&Dは原文の「研究開発費用」表(会社記載の対売上高比率・開発費の資産化)、配当利回りはDART配当表の会社記載値(配当基準日前1週間の平均終値)、益回りはその利回りから逆算した株価に対する連結EPS。本日のKTB10Y 3.94% · UST10Y 4.98%。

⚠ 규율: 무배당 회사(삼성바이오로직스 등)는 주가를 역산할 수 없어 이익수익률이 비어 있다. R&D 자산화 = 개발비(무형자산) ÷ 연구개발비용 계.

⚠ Discipline: For companies that pay no dividend (Samsung Biologics and others) the price cannot be backed out, so the earnings yield is blank. R&D capitalised = development costs (intangible assets) ÷ total R&D expenses.

⚠ 規律:無配の会社(Samsung Biologicsなど)は株価を逆算できないため益回りが空欄である。R&D資産化 = 開発費(無形資産)÷ 研究開発費用の合計。

Source: DART, Financial Supervisory Service.
Limitations: 회사 공시 원문 값을 옮겼다 — 재표시·서식 변경·합병·분할이 있는 해는 앞뒤가 같은 범위가 아니다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: Values are taken from the companies' own filings — years with restatements, format changes, mergers or spin-offs do not cover the same scope as the years around them.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 企業の開示原文の値を転記した — 再表示・様式変更・合併・分割のある年は前後と同じ範囲ではない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

02

배당·이익수익률 — 국채 10Y 옆에Dividend and earnings yields — next to the 10-year government bond配当利回り・益回り — 10年国債と並べて

수익률Yield利回りDividend yield vs. KTB 10Y (fiscal year-end) — latest dividend year of each company

Dividend yield vs. sovereign 10Ypercent · Data as of 2025-12 · Created 2026-11-130%1%2%3%4%5%SamsungBioCelltrionYuhanDW HoldGC BioChongKDDW PharmHanmiSD BioSKBiopharmSKBioSciHanAll%Dividend yield (company-reported)KTB 10Y at that year-endUST 10Y at that year-end

셀트리온 0.4% (KTB 3.38%) · 유한양행 0.5% (KTB 3.38%) · 대웅(지주) 0.9% (KTB 3.38%) · GC녹십자 0.9% (KTB 3.38%) · 종근당 0.6% (KTB 3.38%) · 대웅제약 0.3% (KTB 3.38%) · 한미약품 0.8% (KTB 3.38%) · SD바이오센서 2.2% (KTB 3.38%). 무배당: 삼성바이오, SK바이오팜, SK바이오사이언스, 한올바이오파마.

Celltrion 0.4% (KTB 3.38%) · Yuhan 0.5% (KTB 3.38%) · Daewoong (hold.) 0.9% (KTB 3.38%) · GC Biopharma 0.9% (KTB 3.38%) · Chong Kun Dang 0.6% (KTB 3.38%) · Daewoong Pharm 0.3% (KTB 3.38%) · Hanmi 0.8% (KTB 3.38%) · SD Biosensor 2.2% (KTB 3.38%). No dividend: Samsung Bio, SK Biopharm, SK Bioscience, HanAll.

Celltrion 0.4%(KTB 3.38%) · Yuhan 0.5%(KTB 3.38%) · Daewoong (hold.) 0.9%(KTB 3.38%) · GC Biopharma 0.9%(KTB 3.38%) · Chong Kun Dang 0.6%(KTB 3.38%) · Daewoong Pharm 0.3%(KTB 3.38%) · Hanmi 0.8%(KTB 3.38%) · SD Biosensor 2.2%(KTB 3.38%)。無配:Samsung Bio、SK Biopharm、SK Bioscience、HanAll。

⚠ 규율: 제약·바이오는 배당으로 국채를 이기는 회사가 거의 없다 — 이 섹터의 '주식으로서의 의미'는 성장과 이익수익률 열에서 찾아야 한다.

⚠ Discipline: Almost no pharma or biotech company beats government bonds on dividends — the sector's 'meaning as an equity' has to be found in the growth and earnings-yield columns.

⚠ 規律:製薬・バイオで配当が国債を上回る会社はほとんどない — このセクターの「株式としての意味」は成長と益回りの列に求めるべきである。

Source: DART, Financial Supervisory Service.
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis.
Limitations: 배당수익률은 회사가 배당표에 적은 값(배당기준일 전 1주일 평균 종가 기준)이다. 국채는 그 회계연도 말 값. 무배당 회사는 빈칸.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis.
Limitations: Dividend yield is the figure the company reports in its dividend table (based on the average closing price over the week before the record date). Government bond yields are fiscal-year-end values. Companies that pay no dividend are left blank.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis.
Limitations: 配当利回りは会社が配当表に記した値(配当基準日前1週間の平均終値ベース)である。国債はその会計年度末の値。無配の会社は空欄。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

이익수익률Earnings yield益回りEarnings yield (EPS ÷ implied price) vs. KTB 10Y

Earnings yield vs. KTB 10Ypercent · Data as of 2025-12 · Created 2026-11-13-60%-40%-20%0%20%40%CelltrionYuhanDW HoldGC BioChongKDDW PharmHanmiSD Bio%Earnings yieldKTB 10Y

셀트리온 EY 2.5% vs KTB 3.38% → -0.9%p · 유한양행 EY 2.2% vs KTB 3.38% → -1.2%p · 대웅(지주) EY 19.3% vs KTB 3.38% → +15.9%p · GC녹십자 EY -0.2% vs KTB 3.38% → -3.6%p · 종근당 EY 7.1% vs KTB 3.38% → +3.7%p · 대웅제약 EY 8.5% vs KTB 3.38% → +5.1%p · 한미약품 EY 5.3% vs KTB 3.38% → +2.0%p · SD바이오센서 EY -47.8% vs KTB 3.38% → -51.2%p.

Celltrion EY 2.5% vs KTB 3.38% → -0.9pp · Yuhan EY 2.2% vs KTB 3.38% → -1.2pp · Daewoong (hold.) EY 19.3% vs KTB 3.38% → +15.9pp · GC Biopharma EY -0.2% vs KTB 3.38% → -3.6pp · Chong Kun Dang EY 7.1% vs KTB 3.38% → +3.7pp · Daewoong Pharm EY 8.5% vs KTB 3.38% → +5.1pp · Hanmi EY 5.3% vs KTB 3.38% → +2.0pp · SD Biosensor EY -47.8% vs KTB 3.38% → -51.2pp.

Celltrion 益回り2.5% vs KTB 3.38% → -0.9%pt · Yuhan 益回り2.2% vs KTB 3.38% → -1.2%pt · Daewoong (hold.) 益回り19.3% vs KTB 3.38% → +15.9%pt · GC Biopharma 益回り-0.2% vs KTB 3.38% → -3.6%pt · Chong Kun Dang 益回り7.1% vs KTB 3.38% → +3.7%pt · Daewoong Pharm 益回り8.5% vs KTB 3.38% → +5.1%pt · Hanmi 益回り5.3% vs KTB 3.38% → +2.0%pt · SD Biosensor 益回り-47.8% vs KTB 3.38% → -51.2%pt。

Source: DART, Financial Supervisory Service.
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
Limitations: 주가는 시세 Raw Data 가 아니라 회사가 적은 배당수익률로 역산했다(주당배당금 ÷ 배당수익률) — 배당하는 회사만.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
Limitations: The price is not from the market-price Raw Data; it is backed out from the dividend yield the company reports (dividend per share ÷ dividend yield) — dividend payers only.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13
Limitations: 株価は株価のRaw Dataではなく、会社が記した配当利回りから逆算した(1株当たり配当金 ÷ 配当利回り) — 配当する会社のみ。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

03

성장 — 매출·이익Growth — revenue and profit成長 — 売上高・利益

매출Revenue売上高Revenue index (FY2018 = 100) — Biotech / CDMO / new-drug companies

Revenue indexindex, FY2018 = 100 · Data as of 2025-12 · Created 2026-11-130100200300400500FY18FY19FY20FY21FY22FY23FY24FY25indexCelltrionHanAll424169

셀트리온: FY2018 0.98조 → FY2025 4.16조 (+24.3% CAGR) · 한올바이오파마: FY2018 0.09조 → FY2025 0.16조 (+6.2% CAGR).

Celltrion: FY2018 KRW 0.98trn → FY2025 KRW 4.16trn (+24.3% CAGR) · HanAll: FY2018 KRW 0.09trn → FY2025 KRW 0.16trn (+6.2% CAGR).

Celltrion:FY2018 0.98兆ウォン → FY2025 4.16兆ウォン(+24.3% CAGR) · HanAll:FY2018 0.09兆ウォン → FY2025 0.16兆ウォン(+6.2% CAGR)。

⚠ 규율: 합병·분할이 있는 회사는 지수가 사업 성장이 아니라 범위 변화를 담는다(셀트리온 2023 헬스케어 합병, 삼성바이오로직스 2025 에피스 분할).

⚠ Discipline: For companies with a merger or spin-off, the index captures a change of scope, not business growth (Celltrion 2023 Celltrion Healthcare merger, Samsung Biologics 2025 Samsung Bioepis spin-off).

⚠ 規律:合併・分割のある会社では、指数は事業の成長ではなく範囲の変化を含む(Celltrion 2023年 Celltrion Healthcare合併、Samsung Biologics 2025年 Samsung Bioepis分割)。

Source: DART, Financial Supervisory Service.
Limitations: 연결 매출 · 재표시된 해는 최신 공시 값을 따른다 · 합병·분할이 있는 회사는 범위 변화가 섞인다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: Consolidated revenue · restated years follow the latest filing · companies with a merger or spin-off mix in a change of scope.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 連結売上高 · 再表示された年は最新の開示値に従う · 合併・分割のある会社は範囲の変化が混ざる。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

매출Revenue売上高Revenue index (FY2018 = 100) — Traditional pharma & holding

Revenue indexindex, FY2018 = 100 · Data as of 2025-12 · Created 2026-11-13050.0100150200FY18FY19FY20FY21FY22FY23FY24FY25indexYuhanDaewoong (hold.)GC BiopharmaChong Kun DangDaewoong PharmHanmi177168152152149144

유한양행: FY2018 1.52조 → FY2025 2.19조 (+6.7% CAGR) · 대웅(지주): FY2018 1.23조 → FY2025 2.07조 (+7.2% CAGR) · GC녹십자: FY2018 1.33조 → FY2025 1.99조 (+6.4% CAGR) · 종근당: FY2018 0.96조 → FY2025 1.69조 (+7.8% CAGR) · 대웅제약: FY2018 1.03조 → FY2025 1.57조 (+5.9% CAGR) · 한미약품: FY2018 1.02조 → FY2025 1.55조 (+5.6% CAGR).

Yuhan: FY2018 KRW 1.52trn → FY2025 KRW 2.19trn (+6.7% CAGR) · Daewoong (hold.): FY2018 KRW 1.23trn → FY2025 KRW 2.07trn (+7.2% CAGR) · GC Biopharma: FY2018 KRW 1.33trn → FY2025 KRW 1.99trn (+6.4% CAGR) · Chong Kun Dang: FY2018 KRW 0.96trn → FY2025 KRW 1.69trn (+7.8% CAGR) · Daewoong Pharm: FY2018 KRW 1.03trn → FY2025 KRW 1.57trn (+5.9% CAGR) · Hanmi: FY2018 KRW 1.02trn → FY2025 KRW 1.55trn (+5.6% CAGR).

Yuhan:FY2018 1.52兆ウォン → FY2025 2.19兆ウォン(+6.7% CAGR) · Daewoong (hold.):FY2018 1.23兆ウォン → FY2025 2.07兆ウォン(+7.2% CAGR) · GC Biopharma:FY2018 1.33兆ウォン → FY2025 1.99兆ウォン(+6.4% CAGR) · Chong Kun Dang:FY2018 0.96兆ウォン → FY2025 1.69兆ウォン(+7.8% CAGR) · Daewoong Pharm:FY2018 1.03兆ウォン → FY2025 1.57兆ウォン(+5.9% CAGR) · Hanmi:FY2018 1.02兆ウォン → FY2025 1.55兆ウォン(+5.6% CAGR)。

⚠ 규율: 합병·분할이 있는 회사는 지수가 사업 성장이 아니라 범위 변화를 담는다(셀트리온 2023 헬스케어 합병, 삼성바이오로직스 2025 에피스 분할).

⚠ Discipline: For companies with a merger or spin-off, the index captures a change of scope, not business growth (Celltrion 2023 Celltrion Healthcare merger, Samsung Biologics 2025 Samsung Bioepis spin-off).

⚠ 規律:合併・分割のある会社では、指数は事業の成長ではなく範囲の変化を含む(Celltrion 2023年 Celltrion Healthcare合併、Samsung Biologics 2025年 Samsung Bioepis分割)。

Source: DART, Financial Supervisory Service.
Limitations: 연결 매출 · 재표시된 해는 최신 공시 값을 따른다 · 합병·분할이 있는 회사는 범위 변화가 섞인다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: Consolidated revenue · restated years follow the latest filing · companies with a merger or spin-off mix in a change of scope.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 連結売上高 · 再表示された年は最新の開示値に従う · 合併・分割のある会社は範囲の変化が混ざる。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

이익률Margin利益率Operating margin, latest FY vs. 3 years earlier

Operating marginpercent · Data as of 2025-12 · Created 2026-11-13-75%-50%-25%0%25%50%SamsungBioCelltrionYuhanDW HoldGC BioChongKDDW PharmHanmiSD BioSKBiopharmSKBioSciHanAll%OPM FY2022OPM FY2025

삼성바이오 +45.4% · 셀트리온 +28.1% · 유한양행 +4.8% · 대웅(지주) +12.7% · GC녹십자 +3.5% · 종근당 +4.8% · 대웅제약 +12.5% · 한미약품 +16.7% · SD바이오센서 -11.4% · SK바이오팜 +28.9% · SK바이오사이언스 -19.0% · 한올바이오파마 -0.6%.

Samsung Bio +45.4% · Celltrion +28.1% · Yuhan +4.8% · Daewoong (hold.) +12.7% · GC Biopharma +3.5% · Chong Kun Dang +4.8% · Daewoong Pharm +12.5% · Hanmi +16.7% · SD Biosensor -11.4% · SK Biopharm +28.9% · SK Bioscience -19.0% · HanAll -0.6%.

Samsung Bio +45.4% · Celltrion +28.1% · Yuhan +4.8% · Daewoong (hold.) +12.7% · GC Biopharma +3.5% · Chong Kun Dang +4.8% · Daewoong Pharm +12.5% · Hanmi +16.7% · SD Biosensor -11.4% · SK Biopharm +28.9% · SK Bioscience -19.0% · HanAll -0.6%。

Source: DART, Financial Supervisory Service.
Limitations: 연결 영업이익 ÷ 연결 매출 · 음수 = 영업손실 · 결산이 다른 회사는 그 회사 최신 회계연도와 세 해 전.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: Consolidated operating profit ÷ consolidated revenue · negative = operating loss · for companies with a different year-end, that company's latest fiscal year and three years earlier.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 連結営業利益 ÷ 連結売上高 · マイナス = 営業損失 · 決算期が異なる会社はその会社の最新会計年度と3年前。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

이익Profit利益Net income and ROE, latest FY

회사FY18FY19FY20FY21FY22FY23FY24FY25
삼성바이오n/a0.20조0.24조0.39조0.80조0.86조1.08조1.78조
셀트리온0.24조0.30조0.53조0.60조0.54조0.54조0.42조1.03조
유한양행0.06조0.04조0.19조0.10조0.09조0.13조0.06조0.19조
대웅(지주)0.03조0.07조0.12조0.10조0.12조0.19조0.07조0.23조
GC녹십자0.03조-0.01조0.09조0.14조0.07조-0.02조-0.04조-0.03조
종근당0.04조0.05조0.09조0.04조0.08조0.21조0.11조0.08조
대웅제약-0.02조0.03조0.02조0.03조0.04조0.12조0.02조0.19조
한미약품0.03조0.06조0.02조0.08조0.10조0.17조0.14조0.19조
SD바이오센서n/an/a0.62조1.06조0.91조-0.47조-0.10조-0.51조
SK바이오팜n/a-0.07조-0.25조0.06조-0.14조-0.04조0.23조0.25조
SK바이오사이언스n/an/an/a0.36조0.12조0.02조-0.05조-0.06조
한올바이오파마0.00조0.02조0.02조0.01조0.00조0.00조-0.00조-0.01조

연결 당기순이익(조원). 기준 변경·합병·분할 해는 비교 불가.

CompanyFY18FY19FY20FY21FY22FY23FY24FY25
Samsung Bion/aKRW 0.20trnKRW 0.24trnKRW 0.39trnKRW 0.80trnKRW 0.86trnKRW 1.08trnKRW 1.78trn
CelltrionKRW 0.24trnKRW 0.30trnKRW 0.53trnKRW 0.60trnKRW 0.54trnKRW 0.54trnKRW 0.42trnKRW 1.03trn
YuhanKRW 0.06trnKRW 0.04trnKRW 0.19trnKRW 0.10trnKRW 0.09trnKRW 0.13trnKRW 0.06trnKRW 0.19trn
Daewoong (hold.)KRW 0.03trnKRW 0.07trnKRW 0.12trnKRW 0.10trnKRW 0.12trnKRW 0.19trnKRW 0.07trnKRW 0.23trn
GC BiopharmaKRW 0.03trnKRW -0.01trnKRW 0.09trnKRW 0.14trnKRW 0.07trnKRW -0.02trnKRW -0.04trnKRW -0.03trn
Chong Kun DangKRW 0.04trnKRW 0.05trnKRW 0.09trnKRW 0.04trnKRW 0.08trnKRW 0.21trnKRW 0.11trnKRW 0.08trn
Daewoong PharmKRW -0.02trnKRW 0.03trnKRW 0.02trnKRW 0.03trnKRW 0.04trnKRW 0.12trnKRW 0.02trnKRW 0.19trn
HanmiKRW 0.03trnKRW 0.06trnKRW 0.02trnKRW 0.08trnKRW 0.10trnKRW 0.17trnKRW 0.14trnKRW 0.19trn
SD Biosensorn/an/aKRW 0.62trnKRW 1.06trnKRW 0.91trnKRW -0.47trnKRW -0.10trnKRW -0.51trn
SK Biopharmn/aKRW -0.07trnKRW -0.25trnKRW 0.06trnKRW -0.14trnKRW -0.04trnKRW 0.23trnKRW 0.25trn
SK Biosciencen/an/an/aKRW 0.36trnKRW 0.12trnKRW 0.02trnKRW -0.05trnKRW -0.06trn
HanAllKRW 0.00trnKRW 0.02trnKRW 0.02trnKRW 0.01trnKRW 0.00trnKRW 0.00trnKRW -0.00trnKRW -0.01trn

Consolidated net profit (KRW trn). Years with a change of basis, a merger or a spin-off are not comparable.

会社FY18FY19FY20FY21FY22FY23FY24FY25
Samsung Bion/a0.20兆ウォン0.24兆ウォン0.39兆ウォン0.80兆ウォン0.86兆ウォン1.08兆ウォン1.78兆ウォン
Celltrion0.24兆ウォン0.30兆ウォン0.53兆ウォン0.60兆ウォン0.54兆ウォン0.54兆ウォン0.42兆ウォン1.03兆ウォン
Yuhan0.06兆ウォン0.04兆ウォン0.19兆ウォン0.10兆ウォン0.09兆ウォン0.13兆ウォン0.06兆ウォン0.19兆ウォン
Daewoong (hold.)0.03兆ウォン0.07兆ウォン0.12兆ウォン0.10兆ウォン0.12兆ウォン0.19兆ウォン0.07兆ウォン0.23兆ウォン
GC Biopharma0.03兆ウォン-0.01兆ウォン0.09兆ウォン0.14兆ウォン0.07兆ウォン-0.02兆ウォン-0.04兆ウォン-0.03兆ウォン
Chong Kun Dang0.04兆ウォン0.05兆ウォン0.09兆ウォン0.04兆ウォン0.08兆ウォン0.21兆ウォン0.11兆ウォン0.08兆ウォン
Daewoong Pharm-0.02兆ウォン0.03兆ウォン0.02兆ウォン0.03兆ウォン0.04兆ウォン0.12兆ウォン0.02兆ウォン0.19兆ウォン
Hanmi0.03兆ウォン0.06兆ウォン0.02兆ウォン0.08兆ウォン0.10兆ウォン0.17兆ウォン0.14兆ウォン0.19兆ウォン
SD Biosensorn/an/a0.62兆ウォン1.06兆ウォン0.91兆ウォン-0.47兆ウォン-0.10兆ウォン-0.51兆ウォン
SK Biopharmn/a-0.07兆ウォン-0.25兆ウォン0.06兆ウォン-0.14兆ウォン-0.04兆ウォン0.23兆ウォン0.25兆ウォン
SK Biosciencen/an/an/a0.36兆ウォン0.12兆ウォン0.02兆ウォン-0.05兆ウォン-0.06兆ウォン
HanAll0.00兆ウォン0.02兆ウォン0.02兆ウォン0.01兆ウォン0.00兆ウォン0.00兆ウォン-0.00兆ウォン-0.01兆ウォン

連結当期純利益(兆ウォン)。基準変更・合併・分割の年は比較できない。

삼성바이오 순이익 1.78조 (YoY +64.7%) ROE +19.4% · 셀트리온 순이익 1.03조 (YoY +146.2%) ROE +5.9% · 유한양행 순이익 0.19조 (YoY +235.9%) ROE +8.8% · 대웅(지주) 순이익 0.23조 (YoY +231.0%) ROE +16.1% · GC녹십자 순이익 -0.03조 (YoY n/a) ROE -0.4% · 종근당 순이익 0.08조 (YoY -30.2%) ROE +8.2% · 대웅제약 순이익 0.19조 (YoY +726.3%) ROE +21.8% · 한미약품 순이익 0.19조 (YoY +33.3%) ROE +14.5% · SD바이오센서 순이익 -0.51조 (YoY n/a) ROE -19.5% · SK바이오팜 순이익 0.25조 (YoY +11.6%) ROE +39.3% · SK바이오사이언스 순이익 -0.06조 (YoY n/a) ROE -3.2% · 한올바이오파마 순이익 -0.01조 (YoY n/a) ROE -3.4%.

Samsung Bio net profit KRW 1.78trn (YoY +64.7%) ROE +19.4% · Celltrion net profit KRW 1.03trn (YoY +146.2%) ROE +5.9% · Yuhan net profit KRW 0.19trn (YoY +235.9%) ROE +8.8% · Daewoong (hold.) net profit KRW 0.23trn (YoY +231.0%) ROE +16.1% · GC Biopharma net profit KRW -0.03trn (YoY n/a) ROE -0.4% · Chong Kun Dang net profit KRW 0.08trn (YoY -30.2%) ROE +8.2% · Daewoong Pharm net profit KRW 0.19trn (YoY +726.3%) ROE +21.8% · Hanmi net profit KRW 0.19trn (YoY +33.3%) ROE +14.5% · SD Biosensor net profit KRW -0.51trn (YoY n/a) ROE -19.5% · SK Biopharm net profit KRW 0.25trn (YoY +11.6%) ROE +39.3% · SK Bioscience net profit KRW -0.06trn (YoY n/a) ROE -3.2% · HanAll net profit KRW -0.01trn (YoY n/a) ROE -3.4%.

Samsung Bio 純利益1.78兆ウォン(YoY +64.7%) ROE +19.4% · Celltrion 純利益1.03兆ウォン(YoY +146.2%) ROE +5.9% · Yuhan 純利益0.19兆ウォン(YoY +235.9%) ROE +8.8% · Daewoong (hold.) 純利益0.23兆ウォン(YoY +231.0%) ROE +16.1% · GC Biopharma 純利益-0.03兆ウォン(YoY n/a) ROE -0.4% · Chong Kun Dang 純利益0.08兆ウォン(YoY -30.2%) ROE +8.2% · Daewoong Pharm 純利益0.19兆ウォン(YoY +726.3%) ROE +21.8% · Hanmi 純利益0.19兆ウォン(YoY +33.3%) ROE +14.5% · SD Biosensor 純利益-0.51兆ウォン(YoY n/a) ROE -19.5% · SK Biopharm 純利益0.25兆ウォン(YoY +11.6%) ROE +39.3% · SK Bioscience 純利益-0.06兆ウォン(YoY n/a) ROE -3.2% · HanAll 純利益-0.01兆ウォン(YoY n/a) ROE -3.4%。

Source: DART, Financial Supervisory Service.
Limitations: 연결 당기순이익 · 기준 변경·합병·분할 해는 앞뒤 비교가 안 된다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: Consolidated net profit · years with a change of basis, a merger or a spin-off cannot be compared with the years around them.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 連結当期純利益 · 基準変更・合併・分割の年は前後の比較ができない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

04

R&D 와 설비 — 돈을 어디에 쓰나R&D and plant — where the money goesR&Dと設備 — 資金をどこに使うか

R&DR&D spend as % of revenue and the share capitalized as development costs

R&D intensity and capitalizationpercent · Data as of 2025-12 · Created 2026-11-130%20%40%60%80%SamsungBioCelltrionYuhanDW HoldGC BioChongKDDW PharmHanmiSD BioSKBiopharmSKBioSciHanAll%R&D / revenue (%)Capitalized share of R&D (%)

삼성바이오 R&D 1,674억 (3.7%), 자산화 — · 셀트리온 R&D 4,824억 (11.6%), 자산화 56.3% · 유한양행 R&D 2,424억 (11.1%), 자산화 3.3% · GC녹십자 R&D 1,719억 (8.6%), 자산화 3.6% · 종근당 R&D 1,858억 (11.0%), 자산화 16.5% · 대웅제약 R&D 2,199억 (15.8%), 자산화 11.0% · 한미약품 R&D 2,290억 (14.8%), 자산화 8.0% · SK바이오팜 R&D 1,743억 (24.7%), 자산화 — · SK바이오사이언스 R&D 1,558억 (23.9%), 자산화 37.3% · 한올바이오파마 R&D 325억 (20.9%), 자산화 39.5%.

Samsung Bio R&D 1,674 KRW 100mn (3.7%), capitalised — · Celltrion R&D 4,824 KRW 100mn (11.6%), capitalised 56.3% · Yuhan R&D 2,424 KRW 100mn (11.1%), capitalised 3.3% · GC Biopharma R&D 1,719 KRW 100mn (8.6%), capitalised 3.6% · Chong Kun Dang R&D 1,858 KRW 100mn (11.0%), capitalised 16.5% · Daewoong Pharm R&D 2,199 KRW 100mn (15.8%), capitalised 11.0% · Hanmi R&D 2,290 KRW 100mn (14.8%), capitalised 8.0% · SK Biopharm R&D 1,743 KRW 100mn (24.7%), capitalised — · SK Bioscience R&D 1,558 KRW 100mn (23.9%), capitalised 37.3% · HanAll R&D 325 KRW 100mn (20.9%), capitalised 39.5%.

Samsung Bio R&D 1,674億ウォン(3.7%)、資産化— · Celltrion R&D 4,824億ウォン(11.6%)、資産化56.3% · Yuhan R&D 2,424億ウォン(11.1%)、資産化3.3% · GC Biopharma R&D 1,719億ウォン(8.6%)、資産化3.6% · Chong Kun Dang R&D 1,858億ウォン(11.0%)、資産化16.5% · Daewoong Pharm R&D 2,199億ウォン(15.8%)、資産化11.0% · Hanmi R&D 2,290億ウォン(14.8%)、資産化8.0% · SK Biopharm R&D 1,743億ウォン(24.7%)、資産化— · SK Bioscience R&D 1,558億ウォン(23.9%)、資産化37.3% · HanAll R&D 325億ウォン(20.9%)、資産化39.5%。

⚠ 규율: 자산화 비중이 높으면 그해 영업이익이 그만큼 커진다 — 개발비는 뒤에 상각·손상으로 돌아온다.

⚠ Discipline: The higher the capitalised share, the larger that year's operating profit — development costs come back later as amortisation and impairment.

⚠ 規律:資産化の比率が高いほど、その年の営業利益はそれだけ大きくなる — 開発費は後に償却・減損として戻ってくる。

Source: DART, Financial Supervisory Service.
Limitations: 각 회사 사업보고서 '연구개발비용' 표 · 자산화 = 개발비(무형자산) ÷ 연구개발비용 계 · 표 서식이 다른 옛 해·일부 회사는 빠졌다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: The 'R&D expenses' table in each company's annual report · capitalised = development costs (intangible assets) ÷ total R&D expenses · older years and some companies with a different table format are missing.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 各社事業報告書の「研究開発費用」表 · 資産化 = 開発費(無形資産)÷ 研究開発費用の合計 · 表の様式が異なる古い年・一部の会社は抜けている。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

CapExCapex / revenue and free cash flow, latest FY

Capex and free cash flow intensitypercent · Data as of 2025-12 · Created 2026-11-13-40%-20%0%20%40%60%SamsungBioCelltrionYuhanDW HoldGC BioChongKDDW PharmHanmiSD BioSKBiopharmSKBioSciHanAll%Capex / revenue (%)FCF / revenue (%)

삼성바이오 CapEx 1.48조 FCF 0.77조 · 셀트리온 CapEx 0.33조 FCF 0.31조 · 유한양행 CapEx 0.13조 FCF -0.03조 · 대웅(지주) CapEx 0.35조 FCF -0.09조 · GC녹십자 CapEx 0.11조 FCF -0.01조 · 종근당 CapEx 0.18조 FCF -0.11조 · 대웅제약 CapEx 0.24조 FCF -0.09조 · 한미약품 CapEx 0.08조 FCF 0.10조 · SD바이오센서 CapEx 0.06조 FCF 0.30조 · SK바이오팜 CapEx 0.03조 FCF 0.15조 · SK바이오사이언스 CapEx 0.26조 FCF -0.16조 · 한올바이오파마 CapEx 0.01조 FCF -0.02조.

Samsung Bio capex KRW 1.48trn FCF KRW 0.77trn · Celltrion capex KRW 0.33trn FCF KRW 0.31trn · Yuhan capex KRW 0.13trn FCF KRW -0.03trn · Daewoong (hold.) capex KRW 0.35trn FCF KRW -0.09trn · GC Biopharma capex KRW 0.11trn FCF KRW -0.01trn · Chong Kun Dang capex KRW 0.18trn FCF KRW -0.11trn · Daewoong Pharm capex KRW 0.24trn FCF KRW -0.09trn · Hanmi capex KRW 0.08trn FCF KRW 0.10trn · SD Biosensor capex KRW 0.06trn FCF KRW 0.30trn · SK Biopharm capex KRW 0.03trn FCF KRW 0.15trn · SK Bioscience capex KRW 0.26trn FCF KRW -0.16trn · HanAll capex KRW 0.01trn FCF KRW -0.02trn.

Samsung Bio 設備投資1.48兆ウォン FCF 0.77兆ウォン · Celltrion 設備投資0.33兆ウォン FCF 0.31兆ウォン · Yuhan 設備投資0.13兆ウォン FCF -0.03兆ウォン · Daewoong (hold.) 設備投資0.35兆ウォン FCF -0.09兆ウォン · GC Biopharma 設備投資0.11兆ウォン FCF -0.01兆ウォン · Chong Kun Dang 設備投資0.18兆ウォン FCF -0.11兆ウォン · Daewoong Pharm 設備投資0.24兆ウォン FCF -0.09兆ウォン · Hanmi 設備投資0.08兆ウォン FCF 0.10兆ウォン · SD Biosensor 設備投資0.06兆ウォン FCF 0.30兆ウォン · SK Biopharm 設備投資0.03兆ウォン FCF 0.15兆ウォン · SK Bioscience 設備投資0.26兆ウォン FCF -0.16兆ウォン · HanAll 設備投資0.01兆ウォン FCF -0.02兆ウォン。

Source: DART, Financial Supervisory Service.
Limitations: CapEx = 유형·무형자산 취득 현금(현금흐름표) · FCF = 영업현금흐름 − CapEx · 리스로 들인 자산과 기업 인수는 빠진다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: Capex = cash spent on acquiring tangible and intangible assets (cash-flow statement) · FCF = operating cash flow − capex · leased assets and acquisitions are excluded.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 設備投資 = 有形・無形資産の取得による現金支出(キャッシュフロー計算書) · FCF = 営業キャッシュフロー − 設備投資 · リースで取得した資産と企業買収は含まない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

05

셀트리온 — 심층Celltrion — deep diveCelltrion — 深掘り

분기Quarterly四半期Celltrion: quarterly revenue and operating income

Celltrion — quarterlyKRW trillions · Data as of 2026-06-30 · Created 2026-11-1300.51.01.52.022Q323Q123Q324Q124Q325Q125Q326Q2KRW tnRevenueOperating income

최근 분기 26Q2: 매출 1.39조 (YoY +45.0%, QoQ +21.7%), 영업이익 0.45조, TTM 매출 4.90조 (TTM QoQ +9.7%).

Latest quarter 26Q2: revenue KRW 1.39trn (YoY +45.0%, QoQ +21.7%), operating profit KRW 0.45trn, TTM revenue KRW 4.90trn (TTM QoQ +9.7%).

直近四半期26Q2:売上高1.39兆ウォン(YoY +45.0%、QoQ +21.7%)、営業利益0.45兆ウォン、TTM売上高4.90兆ウォン(TTM QoQ +9.7%)。

Source: DART, Financial Supervisory Service.
Limitations: 연결 분기 손익 · 4분기 = 연간 − 9개월 누계 · 합병 해(셀트리온 2023)는 앞뒤 범위가 다르다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: Consolidated quarterly income statement · Q4 = full year − nine-month cumulative · the merger year (Celltrion 2023) differs in scope from the years around it.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 連結四半期損益 · 第4四半期 = 通期 − 9か月累計 · 合併年(Celltrion 2023年)は前後と範囲が異なる。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

잠정Preliminary速報Celltrion: preliminary results 2026Q3 (fair-disclosure filing 2026-10-27)

항목2026Q3 잠정직전 분기QoQ전년 동기YoY누계누계 YoY
매출액15,755억13,937억+13.0%10,290억+53.1%41,142억+45.3%
영업이익5,253억4,518억+16.3%3,014억+74.3%12,989억+87.4%

억원 · 연결 · 회사 공시 표 그대로(증감률은 다시 계산)

Item2026Q3 preliminaryPrior quarterQoQSame quarter last yearYoYYear to dateYTD YoY
Revenue15,755 KRW 100mn13,937 KRW 100mn+13.0%10,290 KRW 100mn+53.1%41,142 KRW 100mn+45.3%
Operating profit5,253 KRW 100mn4,518 KRW 100mn+16.3%3,014 KRW 100mn+74.3%12,989 KRW 100mn+87.4%

KRW 100mn · consolidated · as in the company's filing table (growth rates recalculated)

項目2026Q3 速報前四半期QoQ前年同期YoY累計累計 YoY
売上高15,755億ウォン13,937億ウォン+13.0%10,290億ウォン+53.1%41,142億ウォン+45.3%
営業利益5,253億ウォン4,518億ウォン+16.3%3,014億ウォン+74.3%12,989億ウォン+87.4%

億ウォン · 連結 · 会社開示の表のまま(増減率は再計算)

2026Q3 잠정: 매출 15,755억 (QoQ +13.0% · YoY +53.1%) · 영업이익 5,253억 (이익률 33.3% · YoY +74.3%). 누계 매출 41,142억 (YoY +45.3%). 세전·순이익 칸은 '-'(미기재). 공시 이력: 2026-07-03 2026Q2 잠정: 매출 13,000억 · 영업이익 4,300억 → 2026-07-27 2026Q2 기재정정: 매출 13,937억 · 영업이익 4,518억 → 2026-10-12 2026Q3 잠정: 매출 15,000억 · 영업이익 5,100억 → 2026-10-27 2026Q3 기재정정: 매출 15,755억 · 영업이익 5,253억. 2026Q2 분기보고서 매출 13,937억 · 영업이익 4,518억.

2026Q3 preliminary: revenue 15,755 KRW 100mn (QoQ +13.0% · YoY +53.1%) · operating profit 5,253 KRW 100mn (margin 33.3% · YoY +74.3%). Year-to-date revenue 41,142 KRW 100mn (YoY +45.3%). The pre-tax and net profit fields are '-' (not stated). Filing history: 2026-07-03 2026Q2 preliminary: revenue 13,000 KRW 100mn · operating profit 4,300 KRW 100mn → 2026-07-27 2026Q2 amended: revenue 13,937 KRW 100mn · operating profit 4,518 KRW 100mn → 2026-10-12 2026Q3 preliminary: revenue 15,000 KRW 100mn · operating profit 5,100 KRW 100mn → 2026-10-27 2026Q3 amended: revenue 15,755 KRW 100mn · operating profit 5,253 KRW 100mn. 2026Q2 quarterly report: revenue 13,937 KRW 100mn · operating profit 4,518 KRW 100mn.

2026Q3速報:売上高15,755億ウォン(QoQ +13.0% · YoY +53.1%) · 営業利益5,253億ウォン(利益率33.3% · YoY +74.3%)。累計売上高41,142億ウォン(YoY +45.3%)。税引前・純利益の欄は「-」(記載なし)。開示履歴:2026-07-03 2026Q2 速報:売上高13,000億ウォン · 営業利益4,300億ウォン → 2026-07-27 2026Q2 訂正:売上高13,937億ウォン · 営業利益4,518億ウォン → 2026-10-12 2026Q3 速報:売上高15,000億ウォン · 営業利益5,100億ウォン → 2026-10-27 2026Q3 訂正:売上高15,755億ウォン · 営業利益5,253億ウォン。2026Q2四半期報告書:売上高13,937億ウォン · 営業利益4,518億ウォン。

Source: DART, Financial Supervisory Service.
Limitations: 영업(잠정)실적(공정공시) — 외부감사인 검토 전 회사 발표값이다. 직전 분기·전년 동기 열은 회사가 같은 공시에 적은 비교값. 세전·순이익은 이번 공시에 없다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: Preliminary operating results (fair-disclosure filing) — company-announced figures before review by the external auditor. The prior-quarter and same-quarter-last-year columns are the comparatives the company gave in the same filing. Pre-tax and net profit are not in this filing.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 営業(暫定)実績(公正開示) — 外部監査人のレビュー前の会社発表値である。前四半期・前年同期の列は会社が同じ開示に記した比較値。税引前・純利益は今回の開示にない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

수출Exports輸出Celltrion: revenue vs. Korea immunological-product exports in measured doses, and the Hungary-bound part

Celltrion — revenue vs. exportsKRW trillions · Data as of 2026-09 · Created 2026-11-1300.51.01.52.021Q121Q322Q122Q323Q123Q324Q124Q325Q125Q326Q126Q3PKRW tnRevenue (consolidated)Revenue — preliminaryKorea dose-form exports, all exporters (KRW)of which to Hungary (KRW)

합병 뒤(2024Q1~) 11분기: 매출과 수출 수준의 로그 상관 — 완제 전체(같은 분기) +0.27 · 헝가리행(전 분기) +0.35. 그 분기 전 자료로만 맞춘 전진 검증 6분기: 최선 '헝가리행 완제 · 전 분기' 평균 오차 13.1% vs 직전 분기 유지 14.5% · 이긴 분기 3/6 → 과반이 아니어서 우리 Fcst 를 내지 않는다. 헝가리행 비중(완제 수출 중): 2022 14% · 2023 21% · 2024 44% · 2025 29% · 2026 YTD 39%.

After the merger (2024Q1 onwards), 11 quarters: log correlation of revenue with export levels — all dose-form exports (same quarter) +0.27 · Hungary-bound (previous quarter) +0.35. Forward test over 6 quarters, each fitted only on data before that quarter: best 'Hungary-bound dose-form exports · previous quarter', mean error 13.1% vs 14.5% for holding the previous quarter · quarters won 3/6 → not a majority, so we do not publish our Fcst. Hungary's share of dose-form exports: 2022 14% · 2023 21% · 2024 44% · 2025 29% · 2026 YTD 39%.

合併後(2024Q1以降)11四半期:売上高と輸出水準の対数相関 — 完成品全体(同じ四半期)+0.27 · ハンガリー向け(前四半期)+0.35。その四半期より前のデータだけで当てはめたフォワードテスト6四半期:最良「ハンガリー向け完成品輸出 · 前四半期」の平均誤差13.1% vs 前四半期据え置き14.5% · 勝った四半期3/6 → 過半ではないため当サイトFcstは出さない。完成品輸出に占めるハンガリー向けの比率:2022 14% · 2023 21% · 2024 44% · 2025 29% · 2026 YTD 39%。

⚠ 규율: 삼성바이오로직스(원료 수출 ≈ CDMO 매출)와 달리 이 세번엔 다른 회사 완제 출하가 섞이고, 셀트리온은 헝가리 100% 자회사(셀트리온헬스케어 헝가리 — 타법인 출자 현황)를 거쳐 판다 — 출하 시점과 매출 인식 시점이 어긋난다는 것은 가설이다. 2023Q4 이전 매출은 셀트리온헬스케어에 판 값이라 범위가 다르다.

⚠ Discipline: Unlike Samsung Biologics (drug-substance exports ≈ CDMO revenue), this tariff line also carries other companies' finished-product shipments, and Celltrion sells through a wholly owned subsidiary in Hungary (Celltrion Healthcare Hungary — investments in other companies) — that shipment timing and revenue recognition diverge is a hypothesis. Revenue before 2023Q4 was sales to Celltrion Healthcare, so its scope differs.

⚠ 規律:Samsung Biologics(原薬輸出 ≈ CDMO売上高)と違い、この税番には他社の完成品出荷も混じり、Celltrionはハンガリーの100%子会社(Celltrion Healthcare Hungary — 他法人出資状況)を通じて販売する — 出荷時点と売上計上時点がずれるというのは仮説である。2023Q4以前の売上高はCelltrion Healthcareへの販売額なので範囲が異なる。

Source: DART, Financial Supervisory Service.
Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
KRW/USD: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis.
Limitations: 완제 = 관세청 '면역물품(일정한 투여량으로 한 것·소매 포장)' 세번의 한국 전체 수출(모든 수출자), 원/달러 월평균 환산 · 헝가리행 = 최종 목적국 신고 기준 · 'P' = 잠정(외부감사인 검토 전) · 전진 검증 표본이 6분기뿐이다 · 합병(2023-12-28) 앞뒤 매출 범위가 다르다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
KRW/USD: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis.
Limitations: Dose-form = Korea's total exports (all exporters) under the customs tariff line for 'immunological products, put up in measured doses or for retail sale', converted at the monthly average KRW/USD rate · Hungary-bound = by declared country of final destination · 'P' = preliminary (before the external auditor's review) · the forward test covers only 6 quarters · revenue before and after the merger (2023-12-28) differs in scope.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
KRW/USD: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis.
Limitations: 完成品 = 関税庁「免疫物品(一定の投与量にしたもの・小売包装)」税番の韓国全体の輸出(すべての輸出者)、ウォン/ドル月平均で換算 · ハンガリー向け = 最終仕向国申告ベース · 「P」= 暫定(外部監査人のレビュー前) · フォワードテストの標本は6四半期しかない · 合併(2023-12-28)の前後で売上高の範囲が異なる。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

모델ModelモデルCelltrion: does export timing explain revenue? (one-quarter-ahead test, after the merger)

수출 계열·시점평균 |오차|직전 분기 유지이긴 분기수준 상관분기 변화 상관
한국 완제 수출 · 같은 분기15.8%14.5%2/6+0.27+0.46
한국 완제 수출 · 전 분기14.2%14.5%3/6+0.13-0.10
헝가리행 완제 · 같은 분기13.4%14.5%3/6+0.25+0.30
헝가리행 완제 · 전 분기13.1%14.5%3/6+0.35+0.26
Export series · timingMean |error|Hold previous quarterQuarters wonLevel correlationQoQ-change correlation
Korea dose-form exports · same quarter15.8%14.5%2/6+0.27+0.46
Korea dose-form exports · previous quarter14.2%14.5%3/6+0.13-0.10
Hungary-bound dose-form exports · same quarter13.4%14.5%3/6+0.25+0.30
Hungary-bound dose-form exports · previous quarter13.1%14.5%3/6+0.35+0.26
輸出系列・時点平均|誤差|前四半期据え置き勝った四半期水準の相関四半期変化の相関
韓国の完成品輸出 · 同じ四半期15.8%14.5%2/6+0.27+0.46
韓国の完成品輸出 · 前四半期14.2%14.5%3/6+0.13-0.10
ハンガリー向け完成品輸出 · 同じ四半期13.4%14.5%3/6+0.25+0.30
ハンガリー向け完成品輸出 · 前四半期13.1%14.5%3/6+0.35+0.26

그 분기 전 자료로만 맞추고 그 분기를 맞힌 오차. 직전 분기 유지보다 평균 오차가 작고 검증 분기 과반에서 더 가까워야 Fcst 를 낸다 — 이번엔 못 미쳤다.

Errors from fitting only on data before each quarter and then predicting that quarter. We publish a Fcst only when the mean error is below that of holding the previous quarter and the model is closer in a majority of test quarters — this time it fell short.

各四半期より前のデータだけで当てはめ、その四半期を予測した誤差。前四半期据え置きより平均誤差が小さく、検証四半期の過半でより近い場合にだけFcstを出す — 今回は届かなかった。

Source: DART, Financial Supervisory Service.
Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
KRW/USD: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis.
Limitations: 합병 뒤 11분기(마지막은 잠정)로 맞추고 6분기를 검증했다 · 표본이 작아 모델 간 차이는 우연일 수 있다 · 수출 계열은 한국 전체 합.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
KRW/USD: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis.
Limitations: Fitted on 11 post-merger quarters (the last one preliminary) and tested on 6 · the sample is small, so differences between models may be chance · the export series are Korea-wide totals.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
KRW/USD: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis.
Limitations: 合併後11四半期(最後は暫定)で当てはめ、6四半期を検証した · 標本が小さくモデル間の差は偶然でありうる · 輸出系列は韓国全体の合計。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

목적국Destinations仕向国Korea dose-form immunological-product exports by destination (value share)

Dose-form exports by destinationpercent of export value · Data as of 2026-09 · Created 2026-11-13025.050.075.01001252017201820192020202120222023202420252026 YTD%HungaryUnited StatesGermanyJapanBrazilBelgiumNetherlandsOther26.111.79.245.910029.419.48.339.710033.39.039.71009.025.08.537.710010.529.941.110014.329.49.633.410020.630.733.110043.929.815.710029.037.98.819.310039.126.024.1100

헝가리 비중: 2017 26% · 2018 29% · 2019 33% · 2020 9% · 2021 6% · 2022 14% · 2023 21% · 2024 44% · 2025 29% · 2026 39%. 2024(합병 첫해)에 헝가리가 가장 컸다 — 유럽 거점으로 보내는 물량인지, 회사 몫인지는 이 자료로 못 가른다.

Hungary's share: 2017 26% · 2018 29% · 2019 33% · 2020 9% · 2021 6% · 2022 14% · 2023 21% · 2024 44% · 2025 29% · 2026 39%. Hungary's share was largest in 2024 (the first full year after the merger) — whether these are volumes sent to a European hub or the company's own cannot be told from this data.

ハンガリーの比率:2017 26% · 2018 29% · 2019 33% · 2020 9% · 2021 6% · 2022 14% · 2023 21% · 2024 44% · 2025 29% · 2026 39%。ハンガリーの比率が最も大きかったのは2024(合併後最初の通年)だ — 欧州拠点へ送る数量なのか会社の分なのかは、この資料では区別できない。

Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
Limitations: 최종 목적국 신고 기준 · 한국 전체 수출 · 전 기간 금액 상위 나라만 따로, 나머지는 Other · 마지막 해가 연중이면 누계.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
Limitations: By declared country of final destination · Korea-wide exports · only the countries with the largest value over the whole period are shown separately, the rest as Other · if the last year is incomplete it is year to date.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
Limitations: 最終仕向国申告ベース · 韓国全体の輸出 · 全期間の金額上位国だけを個別に、残りはOther · 最終年が年途中なら累計。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

수익률Returns収益率Celltrion: ROIC with and without merger intangibles, ROE and incremental ROI (consolidated)

Celltrion — returnspercent · Data as of 2026-09-30 · Created 2026-11-13-40%-20%0%20%40%60%FY20FY21FY22FY23*FY24FY25TTM%ROIC — all operating capitalROIC — tangible operating capitalROEIncremental ROI on prior capex

FY2025: ROIC 5.4% (무형자산 포함) vs 유형 영업자본 기준 18.5% · ROE 5.9%. 최근 4분기 ROIC 7.7% · 유형 기준 24.4% · ROE 9.0%. 합병 해(FY2023) 말 무형자산이 1.62조 → 13.34조로 11.71조 늘었다 — 같은 영업이익을 그만큼 큰 자본으로 나눈다. 유형 기준 ROIC 는 FY2020 31.6% → FY2025 18.5%.

FY2025: ROIC 5.4% (including intangibles) vs 18.5% on tangible operating capital · ROE 5.9%. Last four quarters: ROIC 7.7% · tangible basis 24.4% · ROE 9.0%. At the end of the merger year (FY2023) intangible assets went from KRW 1.62trn to KRW 13.34trn, up KRW 11.71trn — the same operating profit is divided by that much more capital. ROIC on a tangible basis: FY2020 31.6% → FY2025 18.5%.

FY2025:ROIC 5.4%(無形資産を含む) vs 有形営業資本ベース18.5% · ROE 5.9%。直近4四半期:ROIC 7.7% · 有形ベース24.4% · ROE 9.0%。合併年(FY2023)末に無形資産が1.62兆ウォンから13.34兆ウォンへ11.71兆ウォン増えた — 同じ営業利益をそれだけ大きな資本で割ることになる。有形ベースのROICはFY2020 31.6% → FY2025 18.5%。

⚠ 규율: * FY2023 = 합병 해: 그해 말 재무상태표엔 헬스케어가 들어가고 손익엔 없다 — 그해와 다음 해 평균 자본 지표는 범위가 섞인다. 증분 ROI 는 합병이 낀 창(FY2023~)이라 설비만의 수익률이 아니다.

⚠ Discipline: * FY2023 = merger year: Celltrion Healthcare is in that year-end balance sheet but not in the income statement — average-capital measures for that year and the next mix scopes. The incremental ROI window includes the merger (FY2023 onwards), so it is not a return on plant alone.

⚠ 規律:* FY2023 = 合併年:その年末の貸借対照表にはCelltrion Healthcareが入り、損益には入らない — その年と翌年の平均資本の指標は範囲が混ざる。増分ROIは合併を含む窓(FY2023以降)なので設備だけの収益率ではない。

Source: DART, Financial Supervisory Service.
Limitations: 연결 · ROIC = 영업이익 × (1 − 그해 유효세율) ÷ 평균 영업 투하자본(유형·무형자산 + 매출채권 + 계약자산 + 재고 − 매입채무 − 계약부채) · 유형 기준 = 무형자산(합병으로 생긴 것 포함) 제외 · ROE = 지배주주 순이익 ÷ 평균 지배주주 자본 · 증분 ROI = 세후 영업이익 증가(세 해 전 대비) ÷ 그 사이 설비투자 · TTM 영업이익은 마지막 분기 잠정 포함.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: Consolidated · ROIC = operating profit × (1 − that year's effective tax rate) ÷ average operating invested capital (tangible and intangible assets + receivables + contract assets + inventories − payables − contract liabilities) · tangible basis = excluding intangibles (including those created by the merger) · ROE = net profit attributable to owners of the parent ÷ average equity attributable to owners · incremental ROI = increase in after-tax operating profit (vs three years earlier) ÷ capex in between · TTM operating profit includes the last quarter's preliminary figure.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 連結 · ROIC = 営業利益 ×(1 − その年の実効税率)÷ 平均営業投下資本(有形・無形資産 + 売上債権 + 契約資産 + 棚卸資産 − 仕入債務 − 契約負債) · 有形ベース = 無形資産(合併で生じたものを含む)を除く · ROE = 親会社株主に帰属する当期純利益 ÷ 平均親会社株主資本 · 増分ROI = 税引後営業利益の増加(3年前比)÷ その間の設備投資 · TTM営業利益は最終四半期の暫定値を含む。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

투입·산출Inputs vs outputs投入と産出Celltrion: growth of inputs (plant, people) vs. outputs (revenue, profit), FY2019–FY2025

Celltrion — annual growth ratepercent per year (compound) · Data as of 2025-12 · Created 2026-11-130%10%20%30%RevenueOperating incomeNet PP&EHeadcountPayroll%+24.3%+20.5%+10.7%+6.9%+16.0%
FY매출영업이익설비투자유형자산인원인건비1인당 매출인건비/매출판정
FY2019——————5.3억11.7%—
FY202063.9%88.3%89.2%2.5%2.2%22.8%8.6억8.8%미달
FY20213.4%5.3%-40.6%0.4%2.3%4.9%8.7억8.9%미달
FY202219.5%-14.5%-3.0%6.0%2.5%5.0%10.1억7.8%미달
FY2023 *-4.7%0.7%13.4%20.6%11.8%13.4%8.6억9.3%미달
FY2024 *63.4%-24.5%-5.7%2.5%14.7%36.9%12.3억7.8%미달
FY202517.0%137.5%-0.5%36.8%8.7%16.0%13.2억7.7%미달

전년 대비 증가율 · 매출·영업이익·설비투자·유형자산 = 연결 · 인원·인건비 = 사업보고서 '직원 등의 현황'(그 회사 자신, 기간제 포함) · * = 합병이 낀 해

FYRevenueOperating profitCapexPP&EHeadcountPayrollRevenue per headPayroll / revenueVerdict
FY2019——————5.3 KRW 100mn11.7%—
FY202063.9%88.3%89.2%2.5%2.2%22.8%8.6 KRW 100mn8.8%fail
FY20213.4%5.3%-40.6%0.4%2.3%4.9%8.7 KRW 100mn8.9%fail
FY202219.5%-14.5%-3.0%6.0%2.5%5.0%10.1 KRW 100mn7.8%fail
FY2023 *-4.7%0.7%13.4%20.6%11.8%13.4%8.6 KRW 100mn9.3%fail
FY2024 *63.4%-24.5%-5.7%2.5%14.7%36.9%12.3 KRW 100mn7.8%fail
FY202517.0%137.5%-0.5%36.8%8.7%16.0%13.2 KRW 100mn7.7%fail

Year-on-year growth · revenue, operating profit, capex and PP&E = consolidated · headcount and payroll = 'employee status' in the annual report (the company itself, fixed-term staff included) · * = year that includes a merger

FY売上高営業利益設備投資有形資産人員人件費1人当たり売上高人件費/売上高判定
FY2019——————5.3億ウォン11.7%—
FY202063.9%88.3%89.2%2.5%2.2%22.8%8.6億ウォン8.8%未達
FY20213.4%5.3%-40.6%0.4%2.3%4.9%8.7億ウォン8.9%未達
FY202219.5%-14.5%-3.0%6.0%2.5%5.0%10.1億ウォン7.8%未達
FY2023 *-4.7%0.7%13.4%20.6%11.8%13.4%8.6億ウォン9.3%未達
FY2024 *63.4%-24.5%-5.7%2.5%14.7%36.9%12.3億ウォン7.8%未達
FY202517.0%137.5%-0.5%36.8%8.7%16.0%13.2億ウォン7.7%未達

前年比増加率 · 売上高・営業利益・設備投資・有形資産 = 連結 · 人員・人件費 = 事業報告書「従業員等の現況」(その会社自身、期間雇用を含む) · * = 合併を含む年

연평균(FY2019→FY2025): 매출 24.3% · 영업이익 20.5% · 유형자산 10.7% · 인원 6.9% · 인건비 16.0% · 1인당 매출 5.3억 → 13.2억. 해마다 판정: 통과 없음 · 미달 2020, 2021, 2022, 2023, 2024, 2025. 합병 전 매출은 셀트리온헬스케어에 판 값이라 연평균 매출 증가에 범위 변화가 섞인다.

Average annual growth (FY2019→FY2025): revenue 24.3% · operating profit 20.5% · PP&E 10.7% · headcount 6.9% · payroll 16.0% · revenue per head 5.3 KRW 100mn → 13.2 KRW 100mn. Year-by-year verdict: pass none · fail 2020, 2021, 2022, 2023, 2024, 2025. Pre-merger revenue was sales to Celltrion Healthcare, so the average revenue growth mixes in a change of scope.

年平均(FY2019→FY2025):売上高24.3% · 営業利益20.5% · 有形資産10.7% · 人員6.9% · 人件費16.0% · 1人当たり売上高5.3億ウォン → 13.2億ウォン。年ごとの判定:通過なし · 未達2020, 2021, 2022, 2023, 2024, 2025。合併前の売上高はCelltrion Healthcareへの販売額なので、年平均の売上高増加には範囲の変化が混ざる。

⚠ 규율: 판정 = 그해 매출·영업이익 증가율(작은 쪽)이 설비투자·유형자산·인원·인건비 증가율(큰 쪽)을 넘었나 — 엄격한 잣대다. 표에서 어느 투입이 막았는지 본다.

⚠ Discipline: Verdict = did that year's growth in revenue and operating profit (the smaller of the two) exceed the growth in capex, PP&E, headcount and payroll (the largest)? It is a strict test. The table shows which input held it back.

⚠ 規律:判定 = その年の売上高・営業利益の増加率(小さい方)が設備投資・有形資産・人員・人件費の増加率(大きい方)を上回ったか — 厳しい基準である。どの投入が妨げたかは表で見る。

Source: DART, Financial Supervisory Service.
Limitations: 매출·영업이익·설비투자·유형자산 = 연결 재무제표 · 인원·인건비 = 사업보고서 '직원 등의 현황'(그 회사 자신만 — 해외 판매법인 인원은 빠진다) · 연평균 = 첫 해와 마지막 해의 복리 증가율 · 합병이 낀 해는 범위 변화가 섞인다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: Revenue, operating profit, capex and PP&E = consolidated financial statements · headcount and payroll = 'employee status' in the annual report (the company itself only — staff at overseas sales subsidiaries are excluded) · average annual = compound growth between the first and last year · years that include a merger mix in a change of scope.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 売上高・営業利益・設備投資・有形資産 = 連結財務諸表 · 人員・人件費 = 事業報告書「従業員等の現況」(その会社自身のみ — 海外販売法人の人員は含まない) · 年平均 = 初年と最終年の複利増加率 · 合併を含む年は範囲の変化が混ざる。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

밸류ValuationバリュエーションCelltrion: trailing P/E and P/B on KRX market cap (treasury shares excluded)

2026-11-10 시가총액 47.11조 · 자기주식 1.7% 빼면 46.30조 · 최근 4분기(2025Q3~2026Q2) 지배주주 순이익 15,761억 → P/E 29.4배(KRX 시총 그대로면 29.9배) · 세후 영업이익 기준(2025Q4~2026Q3 영업이익 17,741억, 잠정 포함) 29.2배 · 지배주주 자본(2026Q2) 17.90조 → P/B 2.59배 · 이익수익률 3.4%.

Market cap on 2026-11-10 KRW 47.11trn · excluding 1.7% treasury shares KRW 46.30trn · net profit attributable to owners over the last four quarters (2025Q3–2026Q2) 15,761 KRW 100mn → P/E 29.4x (29.9x on the full KRX market cap) · on after-tax operating profit (2025Q4–2026Q3 operating profit 17,741 KRW 100mn, preliminary included) 29.2x · equity attributable to owners (2026Q2) KRW 17.90trn → P/B 2.59x · earnings yield 3.4%.

2026-11-10の時価総額47.11兆ウォン · 自己株式1.7%を除くと46.30兆ウォン · 直近4四半期(2025Q3〜2026Q2)の親会社株主に帰属する純利益15,761億ウォン → PER 29.4倍(KRX時価総額のままなら29.9倍) · 税引後営業利益ベース(2025Q4〜2026Q3の営業利益17,741億ウォン、暫定を含む)29.2倍 · 親会社株主資本(2026Q2)17.90兆ウォン → PBR 2.59倍 · 益回り3.4%。

Source: DART, Financial Supervisory Service.
Source: Korea Exchange (KRX). 본 차트는 “한국거래소 통계정보”를 사용한 결과임.
Limitations: KRX 시가총액(상장주식 전체) × (1 − 자기주식 비율) · 순이익 = 분기보고서 지배주주 순이익(잠정엔 순이익이 없어 마지막 분기 제외) · 세후 영업이익 = 영업이익 × (1 − FY 유효세율).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Source: Korea Exchange (KRX). 본 차트는 “한국거래소 통계정보”를 사용한 결과임.
Limitations: KRX market cap (all listed shares) × (1 − treasury-share ratio) · net profit = net profit attributable to owners from the quarterly reports (the last quarter is left out because the preliminary filing has no net profit) · after-tax operating profit = operating profit × (1 − FY effective tax rate).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Source: Korea Exchange (KRX). 본 차트는 “한국거래소 통계정보”를 사용한 결과임.
Limitations: KRX時価総額(上場株式全体)×(1 − 自己株式比率) · 純利益 = 四半期報告書の親会社株主に帰属する純利益(速報には純利益がないため最終四半期を除く) · 税引後営業利益 = 営業利益 ×(1 − FY実効税率)。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

지분 사슬Ownership chain持株チェーンCelltrion: economic interest of the controlling family vs. voting control (look-through)

첫 단계 보유자관계지분율자기주식 뺀 몫그 경로로 가족에게경로
(주)셀트리온홀딩스본인25.85%26.30%0.00%비상장 법인(위 확인 안 함)
서정진최대주주4.20%4.27%4.27%가족
(주)셀트리온스킨큐어계열회사2.18%2.22%0.00%비상장 법인(위 확인 안 함)

경제적 몫 = 경로마다 (지분율 ÷ (1 − 그 회사 자기주식)) 을 곱해 더한 값 · 2026H1 기준

First-tier holderRelationStakeShare ex-treasuryTo the family via this pathPath
Selteurionholdingseuself25.85%26.30%0.00%unlisted corporate (owners not checked)
Seo Jeongjinlargest shareholder4.20%4.27%4.27%family
Selteurionseukinkyueoaffiliate2.18%2.22%0.00%unlisted corporate (owners not checked)

Economic interest = sum over paths of the product of (stake ÷ (1 − that company's treasury shares)) · as of 2026H1

第1段階の保有者関係持株比率自己株式を除いた持分この経路で家族へ経路
Selteurionholdingseu本人25.85%26.30%0.00%非上場法人(上位は未確認)
Seo Jeongjin筆頭株主4.20%4.27%4.27%家族
Selteurionseukinkyueo系列会社2.18%2.22%0.00%非上場法人(上位は未確認)

経済的持分 = 経路ごとに(持株比率 ÷(1 − その会社の自己株式))を掛け合わせて足した値 · 2026H1基準

최대주주 측 32.6% · 자기주식 1.7% → 의결권 기준 33.2%. 지배 가족(사슬 어느 표에서든 본인·친인척·특수관계인)의 이 회사 이익에 대한 경제적 몫 4.4% (서정진 4.3% · 박준성 0.1% · 이종관 0.0% · 이명숙 0.0% · 박상현 0.0%) → 지배-소유 괴리 28.8%p. 위를 모르는 비상장 법인 (주)셀트리온홀딩스, (주)셀트리온스킨큐어 몫 28.5%는 그 주주가 Raw Data 에 없어 가족 몫에 넣지 못했다(확인 안 함) — 가족 몫은 하한이다. 추이: 2019Q1 최대주주 본인 20.07% · 측 합 22.74% → 2026H1 25.85% · 32.69%. 이 회사가 가진 상장 지분 시가 0.97조 = 자기주식 뺀 시총의 2%.

Largest-shareholder group 32.6% · treasury shares 1.7% → 33.2% on a voting basis. The controlling family's economic interest in this company's earnings (anyone listed as self, relative or related party in any table along the chain) 4.4% (Seo Jeongjin 4.3% · Bak Junseong 0.1% · I Jonggwan 0.0% · I Myeongsuk 0.0% · Bak Sanghyeon 0.0%) → control–ownership wedge 28.8pp. The 28.5% held by unlisted corporates whose owners are unknown (Selteurionholdingseu, Selteurionseukinkyueo) could not be added to the family's share because their shareholders are not in the Raw Data (not checked) — the family share is a lower bound. Trend: 2019Q1 largest shareholder alone 20.07% · group total 22.74% → 2026H1 25.85% · 32.69%. Market value of the listed stakes this company owns: KRW 0.97trn = 2% of its market cap excluding treasury shares.

筆頭株主側32.6% · 自己株式1.7% → 議決権ベース33.2%。支配家族(チェーン上のどの表でも本人・親族・特別関係者とされた人)のこの会社の利益に対する経済的持分4.4%(Seo Jeongjin 4.3% · Bak Junseong 0.1% · I Jonggwan 0.0% · I Myeongsuk 0.0% · Bak Sanghyeon 0.0%) → 支配と所有の乖離28.8%pt。上位の株主が不明な非上場法人(Selteurionholdingseu、Selteurionseukinkyueo)の持分28.5%は、その株主がRaw Dataにないため家族の持分に入れられなかった(未確認) — 家族の持分は下限である。推移:2019Q1 筆頭株主本人20.07% · 側の合計22.74% → 2026H1 25.85% · 32.69%。この会社が保有する上場株式の時価0.97兆ウォン = 自己株式を除いた時価総額の2%。

⚠ 규율: 셀트리온홀딩스 지분이 늘어난 데에는 자기주식 소각도 있다 — 소각은 발행주식을 줄여 같은 주식 수로도 지분율을 올린다(최근 소각: 2024FY 3,429,737주; 2025FY 4,970,950주; 2026H1 9,598,977주).

⚠ Discipline: Part of the rise in Celltrion Holdings' stake comes from treasury-share cancellation — cancellation reduces the shares in issue, so the same number of shares gives a higher percentage (recent cancellations: 2024FY 3,429,737 shares; 2025FY 4,970,950 shares; 2026H1 9,598,977 shares).

⚠ 規律:Celltrion Holdingsの持分が増えた背景には自己株式の消却もある — 消却は発行済株式を減らし、同じ株数でも持株比率を上げる(最近の消却:2024FY 3,429,737株; 2025FY 4,970,950株; 2026H1 9,598,977株)。

Source: DART, Financial Supervisory Service.
Limitations: DART 최대주주 현황(보통주, 최신 분기)을 사슬 위 상장사까지 이었다 · 자기주식은 의결권·배당이 없어 분모에서 뺐다 · 우선주·전환사채·담보는 반영하지 않았다 · 비상장 법인의 주주는 Raw Data 에 없다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: DART largest-shareholder tables (common shares, latest quarter) linked up to the listed companies above in the chain · treasury shares carry no votes or dividends, so they are taken out of the denominator · preferred shares, convertible bonds and pledges are not reflected · the shareholders of unlisted corporates are not in the Raw Data.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: DART筆頭株主状況(普通株、最新四半期)をチェーン上位の上場会社までつないだ · 自己株式は議決権・配当がないので分母から除いた · 優先株・転換社債・担保は反映していない · 非上場法人の株主はRaw Dataにない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

품목Product lines品目Celltrion: sales by business line / product (annual report table)

Celltrion — sales by lineKRW trillions · Data as of 2025-12 · Created 2026-11-1301.02.03.04.05.0FY23FY24FY25KRW tnBiosimilars etc.OtherGodex (liver drug) etc.Other services etc.OtherOther1.92.23.20.323.63.94.2

바이오의약품 / 제품및용역등 / CT-P13바이오시밀러외: 3.88조 · 바이오의약품 / 기타 / 기타: n/a · 케미컬의약품 / 제품및상품등 / 고덱스외: 0.27조 · 케미컬의약품 / 용역 / 기타서비스등: 0.01조 · 케미컬의약품 / 기타 / 기타: 0.00조 · 기타 / 용역 / 기타: n/a.

Biosimilars etc.: KRW 3.88trn · Other: n/a · Godex (liver drug) etc.: KRW 0.27trn · Other services etc.: KRW 0.01trn · Other: KRW 0.00trn · Other: n/a.

Biosimilars etc.:3.88兆ウォン · Other:n/a · Godex (liver drug) etc.:0.27兆ウォン · Other services etc.:0.01兆ウォン · Other:0.00兆ウォン · Other:n/a。

⚠ 규율: 표의 3개 기수만 — 회사가 재표시하면 앞 기수 값이 바뀐다.

⚠ Discipline: Only the three periods in the table — if the company restates, earlier periods change.

⚠ 規律:表の3期分のみ — 会社が再表示すると前の期の値が変わる。

Source: DART, Financial Supervisory Service.
Limitations: 최신 사업보고서 '매출실적' 표의 세 기수 · 라벨은 회사 표기 · 회사가 재표시하면 앞 기수 값이 바뀐다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: The three periods in the 'sales results' table of the latest annual report · labels follow the company's categories · if the company restates, earlier periods change.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 最新事業報告書「売上実績」表の3期分 · ラベルは会社の区分に従う · 会社が再表示すると前の期の値が変わる。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

R&DCelltrion: R&D spend, capitalized development costs and R&D-to-sales

Celltrion — R&D and capitalizationKRW trillions · Data as of 2025-12 · Created 2026-11-1300.20.40.6FY18FY19FY20FY21FY22FY23FY24FY25KRW tnR&D totalof which capitalized (development costs)0.290.310.380.430.410.340.430.480.20.190.20.270.270.180.220.27

FY2018: R&D 2,936억 (매출 대비 34.06%), 자산화 1,980억 (67.5%) · FY2019: R&D 3,052억 (매출 대비 31.09%), 자산화 1,888억 (61.9%) · FY2020: R&D 3,750억 (매출 대비 22.19%), 자산화 2,024억 (54.0%) · FY2021: R&D 4,304억 (매출 대비 20.82%), 자산화 2,722억 (63.2%) · FY2022: R&D 4,124억 (매출 대비 18.05%), 자산화 2,726억 (66.1%) · FY2023: R&D 3,427억 (매출 대비 15.75%), 자산화 1,816억 (53.0%) · FY2024: R&D 4,347억 (매출 대비 12.22%), 자산화 2,202억 (50.7%) · FY2025: R&D 4,824억 (매출 대비 11.59%), 자산화 2,717억 (56.3%).

FY2018: R&D 2,936 KRW 100mn (34.06% of revenue), capitalised 1,980 KRW 100mn (67.5%) · FY2019: R&D 3,052 KRW 100mn (31.09% of revenue), capitalised 1,888 KRW 100mn (61.9%) · FY2020: R&D 3,750 KRW 100mn (22.19% of revenue), capitalised 2,024 KRW 100mn (54.0%) · FY2021: R&D 4,304 KRW 100mn (20.82% of revenue), capitalised 2,722 KRW 100mn (63.2%) · FY2022: R&D 4,124 KRW 100mn (18.05% of revenue), capitalised 2,726 KRW 100mn (66.1%) · FY2023: R&D 3,427 KRW 100mn (15.75% of revenue), capitalised 1,816 KRW 100mn (53.0%) · FY2024: R&D 4,347 KRW 100mn (12.22% of revenue), capitalised 2,202 KRW 100mn (50.7%) · FY2025: R&D 4,824 KRW 100mn (11.59% of revenue), capitalised 2,717 KRW 100mn (56.3%).

FY2018:R&D 2,936億ウォン(対売上高34.06%)、資産化1,980億ウォン(67.5%) · FY2019:R&D 3,052億ウォン(対売上高31.09%)、資産化1,888億ウォン(61.9%) · FY2020:R&D 3,750億ウォン(対売上高22.19%)、資産化2,024億ウォン(54.0%) · FY2021:R&D 4,304億ウォン(対売上高20.82%)、資産化2,722億ウォン(63.2%) · FY2022:R&D 4,124億ウォン(対売上高18.05%)、資産化2,726億ウォン(66.1%) · FY2023:R&D 3,427億ウォン(対売上高15.75%)、資産化1,816億ウォン(53.0%) · FY2024:R&D 4,347億ウォン(対売上高12.22%)、資産化2,202億ウォン(50.7%) · FY2025:R&D 4,824億ウォン(対売上高11.59%)、資産化2,717億ウォン(56.3%)。

⚠ 규율: 표 서식이 바뀐 옛 해(2019~2021)는 못 잡았다 — 원문 확인 필요.

⚠ Discipline: Older years whose table format changed (2019–2021) could not be captured — the original filings need checking.

⚠ 規律:表の様式が変わった古い年(2019〜2021年)は取得できなかった — 原文の確認が必要。

Source: DART, Financial Supervisory Service.
Limitations: 사업보고서 '연구개발비용' 표 · 자산화 = 개발비(무형자산) · 서식이 다른 옛 해는 빠졌다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: The 'R&D expenses' table in the annual report · capitalised = development costs (intangible assets) · older years with a different format are missing.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 事業報告書の「研究開発費用」表 · 資産化 = 開発費(無形資産) · 様式が異なる古い年は抜けている。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

운전자본Working capital運転資本Celltrion: inventory and receivable days, net debt

Celltrion — working capital daysdays · Data as of 2025-12 · Created 2026-11-1302505007501,0001,250FY18FY19FY20FY21FY22FY23FY24FY25daysInventory days (÷ COGS)Receivable days (÷ revenue)604157

FY2025: 재고 2.80조 (604일), 매출채권 1.79조 (157일), 순차입금 2.50조 (금융부채 기준(상한)).

FY2025: inventories KRW 2.80trn (604 days), receivables KRW 1.79trn (157 days), net debt KRW 2.50trn (financial-liabilities basis (upper bound)).

FY2025:棚卸資産2.80兆ウォン(604日)、売上債権1.79兆ウォン(157日)、純有利子負債2.50兆ウォン(金融負債ベース(上限))。

Source: DART, Financial Supervisory Service.
Limitations: 연말 잔액 ÷ 연간 흐름 × 365(재고는 매출원가, 매출채권은 매출) — 결산일 계절성이 섞인다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: Year-end balance ÷ annual flow × 365 (cost of sales for inventories, revenue for receivables) — year-end seasonality is mixed in.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 年末残高 ÷ 年間フロー × 365(棚卸資産は売上原価、売上債権は売上高) — 決算日の季節性が混ざる。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

특수관계자Related parties関連当事者Celltrion: sales to related parties (from the related-party note)

FY상대매출·수익연결매출 대비
FY2018셀트리온헬스케어0.66조67.1%
FY2019셀트리온헬스케어0.86조76.4%
FY2019셀트리온제약0.01조0.8%
FY2020셀트리온헬스케어1.48조80.1%
FY2020셀트리온제약0.02조1.3%
FY2021셀트리온헬스케어1.34조70.1%
FY2021셀트리온제약0.06조2.9%
FY2022셀트리온헬스케어1.57조68.5%
FY2022셀트리온제약0.04조1.8%
FY2023셀트리온제약0.04조1.8%
FY2024셀트리온제약0.04조1.1%
FY2025셀트리온제약0.11조2.7%
FYCounterpartySales / revenue% of consolidated revenue
FY2018Celltrion HealthcareKRW 0.66trn67.1%
FY2019Celltrion HealthcareKRW 0.86trn76.4%
FY2019Celltrion PharmKRW 0.01trn0.8%
FY2020Celltrion HealthcareKRW 1.48trn80.1%
FY2020Celltrion PharmKRW 0.02trn1.3%
FY2021Celltrion HealthcareKRW 1.34trn70.1%
FY2021Celltrion PharmKRW 0.06trn2.9%
FY2022Celltrion HealthcareKRW 1.57trn68.5%
FY2022Celltrion PharmKRW 0.04trn1.8%
FY2023Celltrion PharmKRW 0.04trn1.8%
FY2024Celltrion PharmKRW 0.04trn1.1%
FY2025Celltrion PharmKRW 0.11trn2.7%
FY相手先売上・収益連結売上高比
FY2018Celltrion Healthcare0.66兆ウォン67.1%
FY2019Celltrion Healthcare0.86兆ウォン76.4%
FY2019Celltrion Pharm0.01兆ウォン0.8%
FY2020Celltrion Healthcare1.48兆ウォン80.1%
FY2020Celltrion Pharm0.02兆ウォン1.3%
FY2021Celltrion Healthcare1.34兆ウォン70.1%
FY2021Celltrion Pharm0.06兆ウォン2.9%
FY2022Celltrion Healthcare1.57兆ウォン68.5%
FY2022Celltrion Pharm0.04兆ウォン1.8%
FY2023Celltrion Pharm0.04兆ウォン1.8%
FY2024Celltrion Pharm0.04兆ウォン1.1%
FY2025Celltrion Pharm0.11兆ウォン2.7%

FY2018 셀트리온헬스케어 0.66조 (67.1%) · FY2019 셀트리온헬스케어 0.86조 (76.4%) · FY2019 셀트리온제약 0.01조 (0.8%) · FY2020 셀트리온헬스케어 1.48조 (80.1%) · FY2020 셀트리온제약 0.02조 (1.3%) · FY2021 셀트리온헬스케어 1.34조 (70.1%) · FY2021 셀트리온제약 0.06조 (2.9%) · FY2022 셀트리온헬스케어 1.57조 (68.5%) · FY2022 셀트리온제약 0.04조 (1.8%) · FY2023 셀트리온제약 0.04조 (1.8%) · FY2024 셀트리온제약 0.04조 (1.1%) · FY2025 셀트리온제약 0.11조 (2.7%).

FY2018 Celltrion Healthcare KRW 0.66trn (67.1%) · FY2019 Celltrion Healthcare KRW 0.86trn (76.4%) · FY2019 Celltrion Pharm KRW 0.01trn (0.8%) · FY2020 Celltrion Healthcare KRW 1.48trn (80.1%) · FY2020 Celltrion Pharm KRW 0.02trn (1.3%) · FY2021 Celltrion Healthcare KRW 1.34trn (70.1%) · FY2021 Celltrion Pharm KRW 0.06trn (2.9%) · FY2022 Celltrion Healthcare KRW 1.57trn (68.5%) · FY2022 Celltrion Pharm KRW 0.04trn (1.8%) · FY2023 Celltrion Pharm KRW 0.04trn (1.8%) · FY2024 Celltrion Pharm KRW 0.04trn (1.1%) · FY2025 Celltrion Pharm KRW 0.11trn (2.7%).

FY2018 Celltrion Healthcare 0.66兆ウォン (67.1%) · FY2019 Celltrion Healthcare 0.86兆ウォン (76.4%) · FY2019 Celltrion Pharm 0.01兆ウォン (0.8%) · FY2020 Celltrion Healthcare 1.48兆ウォン (80.1%) · FY2020 Celltrion Pharm 0.02兆ウォン (1.3%) · FY2021 Celltrion Healthcare 1.34兆ウォン (70.1%) · FY2021 Celltrion Pharm 0.06兆ウォン (2.9%) · FY2022 Celltrion Healthcare 1.57兆ウォン (68.5%) · FY2022 Celltrion Pharm 0.04兆ウォン (1.8%) · FY2023 Celltrion Pharm 0.04兆ウォン (1.8%) · FY2024 Celltrion Pharm 0.04兆ウォン (1.1%) · FY2025 Celltrion Pharm 0.11兆ウォン (2.7%)。

⚠ 규율: 표의 첫 값 열(매출/수익)을 읽었다 — 열 정의는 연도별 헤더 참조. 셀트리온은 2023년 말 헬스케어 합병으로 이 매출이 내부거래로 사라졌다.

⚠ Discipline: We read the first value column of the table (sales/revenue) — see each year's header for the column definition. At Celltrion these sales became intra-group transactions after the Celltrion Healthcare merger at the end of 2023.

⚠ 規律:表の最初の値の列(売上/収益)を読んだ — 列の定義は年度ごとのヘッダーを参照。Celltrionでは2023年末のCelltrion Healthcare合併でこの売上が内部取引となり消えた。

Source: DART, Financial Supervisory Service.
Limitations: 특수관계자 주석 표의 첫 값 열 — 열 정의는 해마다 헤더를 따른다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: First value column of the related-party note table — the column definition follows each year's header.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 関連当事者注記の表の最初の値の列 — 列の定義は年ごとのヘッダーに従う。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

지분Ownership持株Celltrion: largest shareholder and treasury shares by quarter

Celltrion — ownershippercent of common shares · Data as of 2026H1 · Created 2026-11-130%10%20%30%40%19Q119Q420Q321Q222Q122Q423Q324Q225Q125Q426Q2%Largest holder + related (%)Largest holder alone (%)+32.7%+25.9%
기간취득소각기말 자기주식
2022FY1,689,37303,012,503
2023H11,047,30004,059,803
2023FY10,070,488013,082,991
2024H11,009,7453,429,73710,662,999
2024FY2,394,4273,429,73712,047,681
2025H13,567,4234,970,95010,642,579
2025FY5,284,8264,970,95012,347,845
2026H11,245,9669,598,9773,983,455
PeriodAcquiredCancelledTreasury shares at period end
2022FY1,689,37303,012,503
2023H11,047,30004,059,803
2023FY10,070,488013,082,991
2024H11,009,7453,429,73710,662,999
2024FY2,394,4273,429,73712,047,681
2025H13,567,4234,970,95010,642,579
2025FY5,284,8264,970,95012,347,845
2026H11,245,9669,598,9773,983,455
期間取得消却期末自己株式
2022FY1,689,37303,012,503
2023H11,047,30004,059,803
2023FY10,070,488013,082,991
2024H11,009,7453,429,73710,662,999
2024FY2,394,4273,429,73712,047,681
2025H13,567,4234,970,95010,642,579
2025FY5,284,8264,970,95012,347,845
2026H11,245,9669,598,9773,983,455

최신 2026H1: (주)셀트리온홀딩스(본인) 25.85% · (주)셀트리온스킨큐어(계열회사) 2.18% · 서정진(최대주주) 4.20%. 자기주식 1.7% · 최대주주 변동: - - n/a.

Latest 2026H1: Selteurionholdingseu (self) 25.85% · Selteurionseukinkyueo (affiliate) 2.18% · Seo Jeongjin (largest shareholder) 4.20%. Treasury shares 1.7% · changes of largest shareholder: - - n/a.

最新2026H1:Selteurionholdingseu(本人)25.85% · Selteurionseukinkyueo(系列会社)2.18% · Seo Jeongjin(筆頭株主)4.20%。自己株式1.7% · 筆頭株主の変動:- - n/a。

⚠ 규율: 대주주·특수관계자 수령 배당 FY2025 45444.0백만원(전기 30350.0백만원). 자기주식 소각은 발행주식을 줄여 최대주주 지분율을 올린다.

⚠ Discipline: Dividends received by major shareholders and related parties FY2025: KRW 45444.0 mn (prior year KRW 30350.0 mn). Cancelling treasury shares reduces the shares in issue and raises the largest shareholder's percentage.

⚠ 規律:大株主・関連当事者が受け取った配当 FY2025 45444.0百万ウォン(前期30350.0百万ウォン)。自己株式の消却は発行済株式を減らし、筆頭株主の持株比率を上げる。

Source: DART, Financial Supervisory Service.
Limitations: DART 최대주주 현황(보통주) · 개인 지배주주의 간접 지분은 이 표에 없다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: DART largest-shareholder table (common shares) · indirect stakes of individual controlling shareholders are not in this table.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: DART筆頭株主状況(普通株) · 個人の支配株主の間接持分はこの表にない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

지분도Ownership map持株関係図Celltrion: cross-shareholding map, FY2022 (7 affiliates in group '셀트리온')Celltrion: cross-shareholding map, FY2022 (7 affiliates in group 'Celltrion')Celltrion: cross-shareholding map, FY2022 (7 affiliates in group 'Celltrion')

Celltrion — domestic cross-shareholdings, FY2022percent · Data as of FY2022 · Created 2026-11-1354.9%20.0%2.1%SelteurionholdingseuSelteurionseukinkyueoCelltrionCelltrion Pharm

(주)셀트리온 → (주)셀트리온제약 54.85% · (주)셀트리온홀딩스 → (주)셀트리온 20.04% · (주)셀트리온스킨큐어 → (주)셀트리온 2.11%. 해외 계열 출자 0건.

Celltrion → Celltrion Pharm 54.85% · Selteurionholdingseu → Celltrion 20.04% · Selteurionseukinkyueo → Celltrion 2.11%. Investments in overseas affiliates: 0.

Celltrion → Celltrion Pharm 54.85% · Selteurionholdingseu → Celltrion 20.04% · Selteurionseukinkyueo → Celltrion 2.11%。海外系列会社への出資0件。

⚠ 규율: 개인 지배주주(예: 셀트리온홀딩스·삼성물산의 주주)는 이 표에 없다 — 각 회사의 공시에서 따로 봐야 한다. 행렬 방향은 최대주주 표와 대조해 정했다(row_investor).

⚠ Discipline: Individual controlling shareholders (for example the shareholders of Celltrion Holdings or Samsung C&T) are not in this table — they have to be looked up in each company's own filings. The direction of the matrix was set by checking it against the largest-shareholder table (row_investor).

⚠ 規律:個人の支配株主(例:Celltrion Holdings・Samsung C&Tの株主)はこの表にない — 各社の開示で別途見る必要がある。行列の向きは筆頭株主表と照合して決めた(row_investor)。

Source: DART, Financial Supervisory Service.
Limitations: 사업보고서 '계열회사간 출자현황' 행렬 · 화살표 = 출자 → 피출자 · 빨강 = 이 회사로 들어오는 지분, 남색 = 이 회사가 가진 지분 · 개인 지배주주는 없다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 'Cross-shareholdings among affiliates' matrix in the annual report · arrow = investor → investee · red = stakes held in this company, navy = stakes this company holds · individual controlling shareholders are not shown.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 事業報告書「系列会社間の出資状況」行列 · 矢印 = 出資者 → 出資先 · 赤 = この会社への持分、紺 = この会社が持つ持分 · 個人の支配株主は含まない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

지분도Ownership map持株関係図Celltrion: cross-shareholding map, FY2025 (9 affiliates in group '셀트리온')Celltrion: cross-shareholding map, FY2025 (9 affiliates in group 'Celltrion')Celltrion: cross-shareholding map, FY2025 (9 affiliates in group 'Celltrion')

Celltrion — domestic cross-shareholdings, FY2025percent · Data as of FY2025 · Created 2026-11-13100%54.8%24.4%2.1%SelteurionholdingseuSelteurionseukinkyueoCelltrionCelltrion PharmSelteurionbaiosollusyeonseu

(주)셀트리온 → (주)셀트리온바이오솔루션스 100.00% · (주)셀트리온 → (주)셀트리온제약 54.80% · (주)셀트리온홀딩스 → (주)셀트리온 24.44% · (주)셀트리온스킨큐어 → (주)셀트리온 2.08%. 해외 계열 출자 48건.

Celltrion → Selteurionbaiosollusyeonseu 100.00% · Celltrion → Celltrion Pharm 54.80% · Selteurionholdingseu → Celltrion 24.44% · Selteurionseukinkyueo → Celltrion 2.08%. Investments in overseas affiliates: 48.

Celltrion → Selteurionbaiosollusyeonseu 100.00% · Celltrion → Celltrion Pharm 54.80% · Selteurionholdingseu → Celltrion 24.44% · Selteurionseukinkyueo → Celltrion 2.08%。海外系列会社への出資48件。

⚠ 규율: 개인 지배주주(예: 셀트리온홀딩스·삼성물산의 주주)는 이 표에 없다 — 각 회사의 공시에서 따로 봐야 한다. 행렬 방향은 최대주주 표와 대조해 정했다(row_investor).

⚠ Discipline: Individual controlling shareholders (for example the shareholders of Celltrion Holdings or Samsung C&T) are not in this table — they have to be looked up in each company's own filings. The direction of the matrix was set by checking it against the largest-shareholder table (row_investor).

⚠ 規律:個人の支配株主(例:Celltrion Holdings・Samsung C&Tの株主)はこの表にない — 各社の開示で別途見る必要がある。行列の向きは筆頭株主表と照合して決めた(row_investor)。

Source: DART, Financial Supervisory Service.
Limitations: 사업보고서 '계열회사간 출자현황' 행렬 · 화살표 = 출자 → 피출자 · 빨강 = 이 회사로 들어오는 지분, 남색 = 이 회사가 가진 지분 · 개인 지배주주는 없다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 'Cross-shareholdings among affiliates' matrix in the annual report · arrow = investor → investee · red = stakes held in this company, navy = stakes this company holds · individual controlling shareholders are not shown.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 事業報告書「系列会社間の出資状況」行列 · 矢印 = 出資者 → 出資先 · 赤 = この会社への持分、紺 = この会社が持つ持分 · 個人の支配株主は含まない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

설비Plant設備Celltrion: capacity, output and utilization (annual report tables)

표항목당기전기전전기
capacity의약품제조 / 바이오시밀러(CT-P13 등) 외 / 제1공장133.0133.0
capacity의약품제조 / 바이오시밀러(CT-P13 등) 외 / 제2공장82.082.0
capacity의약품제조 / 바이오시밀러(CT-P13 등) 외 / 제3공장98.098.0
capacity의약품제조 / 바이오시밀러(CT-P13 등) 외 / 합 계313.0313.0
TableItemCurrent periodPrior periodTwo periods ago
Capacity의약품제조 / 바이오시밀러(CT-P13 등) 외 / 제1공장133.0133.0
Capacity의약품제조 / 바이오시밀러(CT-P13 등) 외 / 제2공장82.082.0
Capacity의약품제조 / 바이오시밀러(CT-P13 등) 외 / 제3공장98.098.0
Capacity의약품제조 / 바이오시밀러(CT-P13 등) 외 / 합 계313.0313.0
表項目当期前期前々期
生産能力의약품제조 / 바이오시밀러(CT-P13 등) 외 / 제1공장133.0133.0
生産能力의약품제조 / 바이오시밀러(CT-P13 등) 외 / 제2공장82.082.0
生産能力의약품제조 / 바이오시밀러(CT-P13 등) 외 / 제3공장98.098.0
生産能力의약품제조 / 바이오시밀러(CT-P13 등) 외 / 합 계313.0313.0

생산능력·생산실적·가동률 표(단위는 표 기준: 배치 등).

Capacity, output and utilisation tables (units as in each table: batches etc.).

生産能力・生産実績・稼働率の表(単位は表の基準:バッチ等)。

Source: DART, Financial Supervisory Service.
Limitations: 사업보고서 생산능력·생산실적·가동률 표 그대로(단위는 표 기준).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: Capacity, output and utilisation tables from the annual report as filed (units as in each table).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 事業報告書の生産能力・生産実績・稼働率の表のまま(単位は表の基準)。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

구조Structure構造Celltrion: structural events, pipeline and licenses (annual report text)

구분품목적응증연구시작일현재 진행 단계비고
바이오바이오시밀러CT-P44Multiple Myeloma2019년3상 진행 중
CT-P51Non Small Cell Lung Cancer2019년3상 진행 중--
CT-P53Multiple Sclerosis2021년3상 진행 중--
CT-P55Plaque Psoriasis2021년3상 진행 중--
신약CT-P27Flu2009년2상 완료-
CT-P70Non-small cell lung cancer2025년1상 진행 중--
CT-P71Urothelial Cancer2025년1상 진행 중--
CT-P72Gastric cancer2025년1상 진행 중--
CT-P73Cervical cancer2025년1상 진행 중--
화학합성신약CT-G20HCM(비후성 심근증) 치료제2018년1상 완료

사업결합: 38. 사업결합 (연결) (1) 지배기업의 종속기업 Celltrion USA, Inc.는 2025년 12월 31일자로 Imclone systems LLC의 지분 100%를 인수하였습니다.(2) 지배기업의 종속기업 Celltrion Healthcare Hungary, Kft는 전기 중 2024년 10월 14일자로 iQone Healthcare Switzerland SA의 지분 100%를 인수하였습니다. 사업결합에 대한 세부 정보 공시 당기 Imclone systems LLC iQone Healthcare Switzerland SA 피인수회사명 Imclone systems LLC 인수 목적 미국시장내 생산성 강화 본점소재 Branchburg, NJ <TE ACODE="ifrs-full_PrincipalPlaceOfBusiness" VALIGN="

Business combination: 38. 사업결합 (연결) (1) 지배기업의 종속기업 Celltrion USA, Inc.는 2025년 12월 31일자로 Imclone systems LLC의 지분 100%를 인수하였습니다.(2) 지배기업의 종속기업 Celltrion Healthcare Hungary, Kft는 전기 중 2024년 10월 14일자로 iQone Healthcare Switzerland SA의 지분 100%를 인수하였습니다. 사업결합에 대한 세부 정보 공시 당기 Imclone systems LLC iQone Healthcare Switzerland SA 피인수회사명 Imclone systems LLC 인수 목적 미국시장내 생산성 강화 본점소재 Branchburg, NJ <TE ACODE="ifrs-full_PrincipalPlaceOfBusiness" VALIGN="

企業結合:38. 사업결합 (연결) (1) 지배기업의 종속기업 Celltrion USA, Inc.는 2025년 12월 31일자로 Imclone systems LLC의 지분 100%를 인수하였습니다.(2) 지배기업의 종속기업 Celltrion Healthcare Hungary, Kft는 전기 중 2024년 10월 14일자로 iQone Healthcare Switzerland SA의 지분 100%를 인수하였습니다. 사업결합에 대한 세부 정보 공시 당기 Imclone systems LLC iQone Healthcare Switzerland SA 피인수회사명 Imclone systems LLC 인수 목적 미국시장내 생산성 강화 본점소재 Branchburg, NJ <TE ACODE="ifrs-full_PrincipalPlaceOfBusiness" VALIGN="

⚠ 규율: 파이프라인 10건 · 라이선스 아웃 0건 · 인 13건(원문 표 기준).

⚠ Discipline: Pipeline 10 · licence-out 0 · licence-in 13 (as in the original tables).

⚠ 規律:パイプライン10件 · ライセンスアウト0件 · イン13件(原文の表ベース)。

Source: DART, Financial Supervisory Service.
Limitations: 회사 공시 원문 값을 옮겼다 — 재표시·서식 변경·합병·분할이 있는 해는 앞뒤가 같은 범위가 아니다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: Values are taken from the companies' own filings — years with restatements, format changes, mergers or spin-offs do not cover the same scope as the years around them.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 企業の開示原文の値を転記した — 再表示・様式変更・合併・分割のある年は前後と同じ範囲ではない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

06

삼성바이오 — 심층Samsung Bio — deep diveSamsung Bio — 深掘り

분기Quarterly四半期Samsung Bio: quarterly revenue and operating income (separate = CDMO; last quarter preliminary)

Samsung Bio — quarterly (CDMO)KRW trillions · Data as of 2026-09-30 · Created 2026-11-1300.51.01.52.022Q423Q223Q424Q224Q425Q225Q426Q3PKRW tnRevenueOperating income

최근 분기 2026Q3(잠정): 매출 1.49조 · 영업이익 0.64조(이익률 43.0%).

Latest quarter 2026Q3 (preliminary): revenue KRW 1.49trn · operating profit KRW 0.64trn (margin 43.0%).

直近四半期2026Q3(速報):売上高1.49兆ウォン · 営業利益0.64兆ウォン(利益率43.0%)。

Source: DART, Financial Supervisory Service.
Limitations: 별도 재무제표(분할 전에도 CDMO 만) + 'P' 표시 분기는 영업(잠정)실적 공정공시(연결, 외부감사인 검토 전) — 분할 뒤엔 연결 ≈ 별도. 4분기 = 연간 − 9개월 누계.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: Separate financial statements (CDMO only, even before the spin-off) + quarters marked 'P' are preliminary operating results from fair-disclosure filings (consolidated, before the external auditor's review) — after the spin-off, consolidated ≈ separate. Q4 = full year − nine-month cumulative.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 個別財務諸表(分割前もCDMOのみ) + 「P」表示の四半期は営業(暫定)実績の公正開示(連結、外部監査人のレビュー前) — 分割後は連結 ≈ 個別。第4四半期 = 通期 − 9か月累計。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

잠정Preliminary速報Samsung Bio: preliminary results 2026Q3 (fair-disclosure filing 20261021)

항목2026Q3 잠정직전 분기QoQ전년 동기YoY누계누계 YoY
매출액14,903억13,209억+12.8%12,575억+18.5%40,684억+24.4%
영업이익6,401억5,864억+9.2%6,335억+1.0%18,073억+17.3%
법인세차감전이익5,320억5,846억-9.0%6,626억-19.7%17,573억+13.8%
당기순이익3,911억4,307억-9.2%4,964억-21.2%12,910억+11.2%

억원 · 연결 · 회사 공시 표 그대로(증감률은 다시 계산)

Item2026Q3 preliminaryPrior quarterQoQSame quarter last yearYoYYear to dateYTD YoY
Revenue14,903 KRW 100mn13,209 KRW 100mn+12.8%12,575 KRW 100mn+18.5%40,684 KRW 100mn+24.4%
Operating profit6,401 KRW 100mn5,864 KRW 100mn+9.2%6,335 KRW 100mn+1.0%18,073 KRW 100mn+17.3%
Pre-tax profit5,320 KRW 100mn5,846 KRW 100mn-9.0%6,626 KRW 100mn-19.7%17,573 KRW 100mn+13.8%
Net profit3,911 KRW 100mn4,307 KRW 100mn-9.2%4,964 KRW 100mn-21.2%12,910 KRW 100mn+11.2%

KRW 100mn · consolidated · as in the company's filing table (growth rates recalculated)

項目2026Q3 速報前四半期QoQ前年同期YoY累計累計 YoY
売上高14,903億ウォン13,209億ウォン+12.8%12,575億ウォン+18.5%40,684億ウォン+24.4%
営業利益6,401億ウォン5,864億ウォン+9.2%6,335億ウォン+1.0%18,073億ウォン+17.3%
税引前利益5,320億ウォン5,846億ウォン-9.0%6,626億ウォン-19.7%17,573億ウォン+13.8%
当期純利益3,911億ウォン4,307億ウォン-9.2%4,964億ウォン-21.2%12,910億ウォン+11.2%

億ウォン · 連結 · 会社開示の表のまま(増減率は再計算)

2026Q3 잠정: 매출 14,903억 · 영업이익 6,401억(이익률 43.0%) · 세전이익 5,320억 · 순이익 3,911억. 세전이익이 영업이익보다 1,081억 작다 — 잠정 공시에는 영업외 내역이 없어 원인은 분기보고서에서 본다. 지난 잠정과 확정의 차이: 2026Q2 매출 잠정 13,209억 vs 확정 13,209억 · 영업이익 5,864억 vs 5,864억.

2026Q3 preliminary: revenue 14,903 KRW 100mn · operating profit 6,401 KRW 100mn (margin 43.0%) · pre-tax profit 5,320 KRW 100mn · net profit 3,911 KRW 100mn. Pre-tax profit is 1,081 KRW 100mn lower than operating profit — the preliminary filing has no breakdown of non-operating items, so the cause has to be read from the quarterly report. Past preliminary vs final: 2026Q2 revenue preliminary 13,209 KRW 100mn vs final 13,209 KRW 100mn · operating profit 5,864 KRW 100mn vs 5,864 KRW 100mn.

2026Q3速報:売上高14,903億ウォン · 営業利益6,401億ウォン(利益率43.0%) · 税引前利益5,320億ウォン · 純利益3,911億ウォン。税引前利益が営業利益より1,081億ウォン小さい — 速報には営業外の内訳がないため、原因は四半期報告書で見る。過去の速報と確定の差:2026Q2 売上高 速報13,209億ウォン vs 確定13,209億ウォン · 営業利益5,864億ウォン vs 5,864億ウォン。

⚠ 규율: 잠정치는 회사 발표값(외부감사인 검토 전) — 분기보고서가 나오면 그 값으로 바꾼다.

⚠ Discipline: Preliminary figures are company announcements (before the external auditor's review) — they are replaced once the quarterly report is out.

⚠ 規律:速報値は会社発表値(外部監査人のレビュー前) — 四半期報告書が出ればその値に置き換える。

Source: DART, Financial Supervisory Service.
Limitations: 영업(잠정)실적(공정공시) — 외부감사인 검토 전 회사 발표값이다. 직전 분기·전년 동기 열은 회사가 같은 공시에 적은 비교값(에피스 분할 재표시 반영).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: Preliminary operating results (fair-disclosure filing) — company-announced figures before review by the external auditor. The prior-quarter and same-quarter-last-year columns are the comparatives the company gave in the same filing (restated for the Samsung Bioepis spin-off).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 営業(暫定)実績(公正開示) — 外部監査人のレビュー前の会社発表値である。前四半期・前年同期の列は会社が同じ開示に記した比較値(Samsung Bioepis分割の再表示を反映)。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

수출Exports輸出Samsung Bio: CDMO revenue vs. Korea biologic drug-substance exports, with Adrenalin Baby Fcst

Samsung Bio — revenue vs. exportsKRW trillions · Data as of 2026-09 · Created 2026-11-1301.02.03.022Q122Q323Q123Q324Q124Q325Q125Q326Q126Q4FKRW tnRevenue (separate = CDMO)Revenue — preliminaryKorea drug-substance exports (KRW)Adrenalin Baby Fcst (customs data)

원료(DS) 수출 = 관세청 '면역물품(일정한 투여량으로 하지 않은 것)' 두 세번의 한국 전체 수출(원화 환산). 수준은 같이 간다(로그 상관 +0.90). 분기 매출을 가장 잘 맞힌 것은 '한·두 분기 앞 수출 평균'(전진 평균 오차 6.0% vs 직전 분기 유지 6.6%, 7분기 검증) — 탄력성 0.71. 2026Q4 우리 Fcst: 매출 14,576억 (±6%) — 영업이익률이 직전 분기(43.0%)와 같다고 두면 영업이익 6,260억(가정).

Drug-substance (DS) exports = Korea's total exports (converted to KRW) under the two customs tariff lines for 'immunological products, not put up in measured doses'. The levels move together (log correlation +0.90). Quarterly revenue was best predicted by 'average of exports one and two quarters earlier' (forward mean error 6.0% vs 6.6% for holding the previous quarter, tested on 7 quarters) — elasticity 0.71. 2026Q4 our Fcst: revenue 14,576 KRW 100mn (±6%) — if the operating margin stays at the previous quarter's (43.0%), operating profit would be 6,260 KRW 100mn (assumption).

原薬(DS)輸出 = 関税庁「免疫物品(一定の投与量にしていないもの)」2税番の韓国全体の輸出(ウォン換算)。水準は連動する(対数相関+0.90)。四半期売上高を最もよく当てたのは「1・2四半期前の輸出平均」(フォワード平均誤差6.0% vs 前四半期据え置き6.6%、7四半期で検証) — 弾性値0.71。2026Q4 当サイトFcst:売上高14,576億ウォン(±6%) — 営業利益率が前四半期(43.0%)と同じとすると営業利益6,260億ウォン(仮定)。

⚠ 규율: 같은 세번에 다른 회사 출하가 섞이고, 통관가(제품 가치)와 CDMO 매출(위탁 생산료)은 기준이 다르다 — 회사 몫이 아니라 탄력성으로만 읽는다.

⚠ Discipline: The same tariff lines carry other companies' shipments, and customs value (product value) and CDMO revenue (contract-manufacturing fees) are on different bases — read this only as an elasticity, not the company's share.

⚠ 規律:同じ税番に他社の出荷も混じり、通関価格(製品価値)とCDMO売上高(受託生産料)は基準が異なる — 会社の取り分ではなく弾性値としてのみ読む。

Source: DART, Financial Supervisory Service.
Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
KRW/USD: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis.
Limitations: 원료 세번은 HS 2022 개정으로 생겨 2022년부터 있다. 관세청 수출은 한국 전체(모든 수출자) 합이고 원/달러 월평균으로 환산했다. 우리 Fcst 는 수출이 매출보다 한두 분기 앞선다는 과거 관계를 쓴 추정이지 회사 가이던스나 컨센서스가 아니다. 검증 분기 수가 적다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
KRW/USD: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis.
Limitations: The drug-substance tariff lines were created in the HS 2022 revision, so they exist only from 2022. Customs exports are Korea-wide totals (all exporters), converted at the monthly average KRW/USD rate. Our Fcst is an estimate using the past relationship in which exports lead revenue by one or two quarters — it is neither company guidance nor consensus. Few quarters have been tested.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
KRW/USD: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis.
Limitations: 原薬の税番はHS 2022改正で新設されたため2022年からしかない。関税庁の輸出は韓国全体(すべての輸出者)の合計で、ウォン/ドルの月平均で換算した。当サイトFcstは輸出が売上高に1〜2四半期先行するという過去の関係を使った推計であり、会社ガイダンスでもコンセンサスでもない。検証四半期の数が少ない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

모델ModelモデルSamsung Bio: which export timing explains revenue (one-quarter-ahead test)

수출 시점평균 |오차|직전 분기 유지검증 분기마지막 오차탄력성
같은 분기 수출12.5%9.2%92026Q3 -24.9%0.67
한 분기 앞 수출9.7%7.3%82026Q3 13.4%0.67
같은·앞 분기 수출 평균8.9%7.3%82026Q3 -6.2%0.74
한·두 분기 앞 수출 평균6.0%6.6%72026Q3 7.4%0.71
Export timingMean |error|Hold previous quarterTest quartersLast errorElasticity
exports in the same quarter12.5%9.2%92026Q3 -24.9%0.67
exports one quarter earlier9.7%7.3%82026Q3 13.4%0.67
average of same- and previous-quarter exports8.9%7.3%82026Q3 -6.2%0.74
average of exports one and two quarters earlier6.0%6.6%72026Q3 7.4%0.71
輸出の時点平均|誤差|前四半期据え置き検証四半期最後の誤差弾性値
同じ四半期の輸出12.5%9.2%92026Q3 -24.9%0.67
1四半期前の輸出9.7%7.3%82026Q3 13.4%0.67
同じ四半期と前四半期の輸出平均8.9%7.3%82026Q3 -6.2%0.74
1・2四半期前の輸出平均6.0%6.6%72026Q3 7.4%0.71

그 분기 전 자료로만 맞추고 그 분기를 맞힌 오차. 고른 모델: 한·두 분기 앞 수출 평균. 마지막 검증 분기(2026Q3)는 오늘 나온 잠정 매출로 채점했다.

Errors from fitting only on data before each quarter and then predicting that quarter. Model chosen: average of exports one and two quarters earlier. The last test quarter (2026Q3) was scored against the preliminary revenue released today.

各四半期より前のデータだけで当てはめ、その四半期を予測した誤差。選んだモデル:1・2四半期前の輸出平均。最後の検証四半期(2026Q3)は本日出た速報売上高で採点した。

Source: DART, Financial Supervisory Service.
Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
KRW/USD: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis.
Limitations: 검증 분기가 7~9개뿐이라 모델 간 차이가 우연일 수 있다. 수출이 매출을 앞선다는 것은 이 표본의 관계이지 출하·매출 인식 시점을 확인한 것이 아니다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
KRW/USD: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis.
Limitations: Only 7–9 test quarters, so differences between models may be chance. That exports lead revenue is a relationship in this sample, not a confirmed timing of shipments and revenue recognition.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
KRW/USD: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis.
Limitations: 検証四半期が7〜9個しかないため、モデル間の差は偶然でありうる。輸出が売上高に先行するというのはこの標本での関係であり、出荷・売上計上の時点を確認したものではない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

목적국Destinations仕向国Korea biologic drug-substance exports by destination (value share)

Drug-substance exports by destinationpercent of export value · Data as of 2026-09 · Created 2026-11-13025.050.075.010012520222023202420252026 YTD%SwitzerlandGermanyUnited StatesTurkeyNetherlandsBelgiumItalyOther25.815.820.912.912.81008.419.613.813.210.325.710011.816.414.111.711.68.319.710026.811.016.68.013.916.210024.312.111.29.715.215.1100

회사 지역별 매출(사업보고서)은 유럽 > 미국 순이다 — 원료 수출 목적국도 스위스·네덜란드·독일 등 유럽 비중이 크다. 같은 방향인지 보는 것이지 회사 몫이 아니다.

The company's revenue by region (annual report) ranks Europe ahead of the United States — the destinations of drug-substance exports also lean towards Europe (Switzerland, the Netherlands, Germany and others). This checks the direction, not the company's share.

会社の地域別売上高(事業報告書)は欧州 > 米国の順である — 原薬輸出の仕向国もスイス・オランダ・ドイツなど欧州の比率が大きい。方向が同じかを見るものであり、会社の取り分ではない。

Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
Limitations: 원료 세번은 HS 2022 개정으로 생겨 2022년부터 · 최종 목적국 신고 기준 · 한국 전체 수출 · 전 기간 금액 상위 나라만 따로, 나머지는 Other · 마지막 해가 연중이면 누계.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
Limitations: The drug-substance tariff lines exist only from 2022 (created in the HS 2022 revision) · by declared country of final destination · Korea-wide exports · only the countries with the largest value over the whole period are shown separately, the rest as Other · if the last year is incomplete it is year to date.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr).
Limitations: 原薬の税番はHS 2022改正で新設され2022年から · 最終仕向国申告ベース · 韓国全体の輸出 · 全期間の金額上位国だけを個別に、残りはOther · 最終年が年途中なら累計。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

밸류ValuationバリュエーションSamsung Bio: trailing P/E and P/B on KRX market cap

2026-11-10 시가총액 67.96조 · 최근 4분기(2025Q4~2026Q3) 순이익 17,585억 → P/E 38.6배 · 지배주주 자본(2026Q2) 8.36조 → P/B 8.13배.

Market cap on 2026-11-10 KRW 67.96trn · net profit over the last four quarters (2025Q4–2026Q3) 17,585 KRW 100mn → P/E 38.6x · equity attributable to owners (2026Q2) KRW 8.36trn → P/B 8.13x.

2026-11-10の時価総額67.96兆ウォン · 直近4四半期(2025Q4〜2026Q3)の純利益17,585億ウォン → PER 38.6倍 · 親会社株主資本(2026Q2)8.36兆ウォン → PBR 8.13倍。

Source: DART, Financial Supervisory Service.
Source: Korea Exchange (KRX). 본 차트는 “한국거래소 통계정보”를 사용한 결과임.
Limitations: 최근 4분기 순이익 = 별도 분기 + 마지막 분기 잠정(연결) — 분할 뒤엔 둘이 거의 같다. 자본은 마지막 분기보고서 연결 지배주주 자본. 무배당.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Source: Korea Exchange (KRX). 본 차트는 “한국거래소 통계정보”를 사용한 결과임.
Limitations: Net profit over the last four quarters = separate quarters + the last quarter's preliminary figure (consolidated) — after the spin-off the two are almost the same. Equity is consolidated equity attributable to owners from the latest quarterly report. No dividend.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Source: Korea Exchange (KRX). 본 차트는 “한국거래소 통계정보”를 사용한 결과임.
Limitations: 直近4四半期の純利益 = 個別の四半期 + 最終四半期の速報(連結) — 分割後は両者がほぼ同じ。資本は最新四半期報告書の連結親会社株主資本。無配。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

수익률Returns収益率Samsung Bio: ROE, ROIC and incremental return on capex (separate = CDMO)

Samsung Bio — returnspercent · Data as of 2026-09-30 · Created 2026-11-130%20%40%60%80%100%FY18FY19FY20FY21FY22FY23FY24FY25TTM%ROICROEIncremental ROI on prior capex+26.1%+22.3%+21.6%

FY2025: ROIC 21.1% · ROE 19.0% · 증분 ROI 26.1% — 최근 4분기(2025Q4~2026Q3) ROIC 21.6% · ROE 22.3%. ROE 가 ROIC 보다 낮았던 해는 자본에 에피스 지분·현금이 같이 들어 있던 때다(2025-11 분할로 빠짐). 증분 ROI 는 FY2022 정점(84.3%) 뒤 FY2025 26.1%로 내려왔다 — 그 사이 유형자산 증가율이 매출 증가율을 넘은 해가 있다(FY2024 유형자산 42.5% vs 매출 19.0%).

FY2025: ROIC 21.1% · ROE 19.0% · incremental ROI 26.1% — last four quarters (2025Q4–2026Q3) ROIC 21.6% · ROE 22.3%. The years when ROE was below ROIC were when equity still included the Samsung Bioepis stake and cash (removed by the 2025-11 spin-off). Incremental ROI came down from its FY2022 peak (84.3%) to FY2025 26.1% — in between there was a year when PP&E growth outpaced revenue growth (FY2024 PP&E 42.5% vs revenue 19.0%).

FY2025:ROIC 21.1% · ROE 19.0% · 増分ROI 26.1% — 直近4四半期(2025Q4〜2026Q3)ROIC 21.6% · ROE 22.3%。ROEがROICより低かった年は、資本にSamsung Bioepisの持分・現金が一緒に入っていた時期である(2025-11の分割で外れた)。増分ROIはFY2022のピーク(84.3%)の後、FY2025 26.1%に下がった — その間に有形資産の増加率が売上高の増加率を上回った年がある(FY2024 有形資産42.5% vs 売上高19.0%)。

⚠ 규율: 투하자본은 영업 쪽(유형·무형자산 + 운전자본) — 자본·부채 쪽 계산은 2017 부채 계정이 Raw Data 에 없어 쓰지 않았다.

⚠ Discipline: Invested capital is on the operating side (tangible and intangible assets + working capital) — the financing-side calculation was not used because the 2017 liability accounts are not in the Raw Data.

⚠ 規律:投下資本は営業側(有形・無形資産 + 運転資本) — 資本・負債側の計算は2017年の負債勘定がRaw Dataにないため使わなかった。

Source: DART, Financial Supervisory Service.
Limitations: 별도 재무제표(CDMO) · ROIC = 영업이익 × (1 − 그해 유효세율) ÷ 평균 영업 투하자본(유형·무형자산 + 매출채권 + 계약자산 + 재고 − 매입채무 − 계약부채) · ROE = 순이익 ÷ 평균 자본 · 증분 ROI = 세후 영업이익 증가(그해 vs 세 해 전) ÷ 그 앞 세 해 설비투자 누계 · TTM 은 마지막 분기 잠정 포함.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: Separate financial statements (CDMO) · ROIC = operating profit × (1 − that year's effective tax rate) ÷ average operating invested capital (tangible and intangible assets + receivables + contract assets + inventories − payables − contract liabilities) · ROE = net profit ÷ average equity · incremental ROI = increase in after-tax operating profit (that year vs three years earlier) ÷ cumulative capex over the three preceding years · TTM includes the last quarter's preliminary figure.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 個別財務諸表(CDMO) · ROIC = 営業利益 ×(1 − その年の実効税率)÷ 平均営業投下資本(有形・無形資産 + 売上債権 + 契約資産 + 棚卸資産 − 仕入債務 − 契約負債) · ROE = 純利益 ÷ 平均資本 · 増分ROI = 税引後営業利益の増加(その年 vs 3年前)÷ その前3年間の設備投資累計 · TTMは最終四半期の速報を含む。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

설비→매출Capex → revenue設備→売上高Samsung Bio: capex vs. revenue increase and operating income (separate)

Samsung Bio — capex and growthKRW trillions · Data as of 2025-12 · Created 2026-11-1300.51.01.52.02.5FY17FY18FY19FY20FY21FY22FY23FY24FY25KRW tnCapexRevenue increase vs. prior yearOperating income

설비투자와 매출 증가의 연간 상관: 0년 시차 +0.77(n 8) · 1년 시차 +0.56(n 8) · 2년 시차 +0.34(n 7) · 3년 시차 +0.58(n 6). 같은 해 상관이 가장 높다 — 확장기에는 짓는 것과 파는 것이 함께 는다. 표본이 짧아 시차를 확정하지 못한다.

Annual correlation between capex and revenue growth: 0-year lag +0.77 (n 8) · 1-year lag +0.56 (n 8) · 2-year lag +0.34 (n 7) · 3-year lag +0.58 (n 6). The same-year correlation is the highest — in an expansion phase building and selling rise together. The sample is short, so the lag cannot be pinned down.

設備投資と売上高増加の年次相関:0年ラグ+0.77(n 8) · 1年ラグ+0.56(n 8) · 2年ラグ+0.34(n 7) · 3年ラグ+0.58(n 6)。同じ年の相関が最も高い — 拡張期には建てることと売ることが一緒に増える。標本が短くラグを確定できない。

Source: DART, Financial Supervisory Service.
Limitations: 별도 · 설비투자 = 유형·무형자산 취득 현금 · 연간 상관은 표본이 작고(6~8년) 확장 국면이 겹쳐 인과를 말하지 않는다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: Separate · capex = cash spent on acquiring tangible and intangible assets · the annual correlations rest on a small sample (6–8 years) during overlapping expansion phases and say nothing about causation.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 個別 · 設備投資 = 有形・無形資産の取得による現金支出 · 年次相関は標本が小さく(6〜8年)拡張局面が重なるため因果を示さない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

투입·산출Inputs vs outputs投入と産出Samsung Bio: growth of inputs (plant, people) vs. outputs (revenue, profit), FY2017–FY2025

Samsung Bio — annual growth ratepercent per year (compound) · Data as of 2025-12 · Created 2026-11-130%20%40%60%RevenueOperating incomeNet PP&EHeadcountPayroll%+33.0%+53.8%+18.9%+12.5%+20.8%
FY매출영업이익설비투자유형자산인원인건비1인당 매출인건비/매출판정
FY2017——————2억29.0%—
FY201815.3%-15.6%-43.6%13.5%9.4%3.2%2억26.0%미달
FY201930.9%64.8%-36.3%-0.9%11.6%38.1%3억27.4%미달
FY202066.0%218.9%-19.0%1.8%11.6%18.7%4억19.6%통과
FY202134.6%83.4%184.7%27.0%37.2%23.1%4억17.9%미달
FY202255.4%80.4%129.7%40.0%14.5%40.4%5억16.2%미달
FY202320.6%24.4%4.3%14.9%-2.4%14.7%7억15.4%통과
FY202419.0%9.7%32.2%42.5%13.2%13.4%7억14.6%미달
FY202530.3%56.5%4.8%19.4%8.9%19.1%8억13.4%통과

전년 대비 증가율 · 인원·인건비 = 사업보고서 '직원 등의 현황'(별도, 기간제 포함) · 1인당 매출 = 매출 ÷ 연말 인원

FYRevenueOperating profitCapexPP&EHeadcountPayrollRevenue per headPayroll / revenueVerdict
FY2017——————2 KRW 100mn29.0%—
FY201815.3%-15.6%-43.6%13.5%9.4%3.2%2 KRW 100mn26.0%fail
FY201930.9%64.8%-36.3%-0.9%11.6%38.1%3 KRW 100mn27.4%fail
FY202066.0%218.9%-19.0%1.8%11.6%18.7%4 KRW 100mn19.6%pass
FY202134.6%83.4%184.7%27.0%37.2%23.1%4 KRW 100mn17.9%fail
FY202255.4%80.4%129.7%40.0%14.5%40.4%5 KRW 100mn16.2%fail
FY202320.6%24.4%4.3%14.9%-2.4%14.7%7 KRW 100mn15.4%pass
FY202419.0%9.7%32.2%42.5%13.2%13.4%7 KRW 100mn14.6%fail
FY202530.3%56.5%4.8%19.4%8.9%19.1%8 KRW 100mn13.4%pass

Year-on-year growth · headcount and payroll = 'employee status' in the annual report (separate, fixed-term staff included) · revenue per head = revenue ÷ year-end headcount

FY売上高営業利益設備投資有形資産人員人件費1人当たり売上高人件費/売上高判定
FY2017——————2億ウォン29.0%—
FY201815.3%-15.6%-43.6%13.5%9.4%3.2%2億ウォン26.0%未達
FY201930.9%64.8%-36.3%-0.9%11.6%38.1%3億ウォン27.4%未達
FY202066.0%218.9%-19.0%1.8%11.6%18.7%4億ウォン19.6%通過
FY202134.6%83.4%184.7%27.0%37.2%23.1%4億ウォン17.9%未達
FY202255.4%80.4%129.7%40.0%14.5%40.4%5億ウォン16.2%未達
FY202320.6%24.4%4.3%14.9%-2.4%14.7%7億ウォン15.4%通過
FY202419.0%9.7%32.2%42.5%13.2%13.4%7億ウォン14.6%未達
FY202530.3%56.5%4.8%19.4%8.9%19.1%8億ウォン13.4%通過

前年比増加率 · 人員・人件費 = 事業報告書「従業員等の現況」(個別、期間雇用を含む) · 1人当たり売上高 = 売上高 ÷ 年末人員

연평균(FY2017→FY2025): 매출 33.0% · 영업이익 53.8% · 유형자산 18.9% · 인원 12.5% · 인건비 20.8% — 누적으로는 산출(매출·이익)이 투입(설비·사람)을 넘는다. 해마다 보면 통과 2020, 2023, 2025 · 미달 2018, 2019, 2021, 2022, 2024.

Average annual growth (FY2017→FY2025): revenue 33.0% · operating profit 53.8% · PP&E 18.9% · headcount 12.5% · payroll 20.8% — cumulatively, outputs (revenue, profit) outgrow inputs (plant, people). Year by year: pass 2020, 2023, 2025 · fail 2018, 2019, 2021, 2022, 2024.

年平均(FY2017→FY2025):売上高33.0% · 営業利益53.8% · 有形資産18.9% · 人員12.5% · 人件費20.8% — 累積では産出(売上高・利益)が投入(設備・人)を上回る。年ごとに見ると通過2020, 2023, 2025 · 未達2018, 2019, 2021, 2022, 2024。

⚠ 규율: 판정 = 그해 매출·영업이익 증가율이 설비투자·유형자산·인원·인건비 증가율을 모두 넘었나. 공장을 짓는 해(설비 먼저)는 미달이 정상이다 — 몇 해 뒤 통과로 돌아오는지가 볼 점.

⚠ Discipline: Verdict = did that year's revenue and operating-profit growth exceed the growth in capex, PP&E, headcount and payroll on every count? In years when plants are being built (plant first) a fail is normal — what matters is whether it turns into a pass a few years later.

⚠ 規律:判定 = その年の売上高・営業利益の増加率が設備投資・有形資産・人員・人件費の増加率をすべて上回ったか。工場を建てる年(設備が先)は未達が普通だ — 数年後に通過へ戻るかが見どころ。

Source: DART, Financial Supervisory Service.
Limitations: 별도 재무제표 + 사업보고서 '직원 등의 현황'(연말 인원·연간 급여 총액, 기간제 포함) · 연평균 = 첫 해와 마지막 해의 복리 증가율 · 유형자산은 장부 순액(감가상각 뒤).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: Separate financial statements + 'employee status' in the annual report (year-end headcount and total annual pay, fixed-term staff included) · average annual = compound growth between the first and last year · PP&E is the net book amount (after depreciation).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 個別財務諸表 + 事業報告書「従業員等の現況」(年末人員・年間給与総額、期間雇用を含む) · 年平均 = 初年と最終年の複利増加率 · 有形資産は帳簿上の純額(減価償却後)。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

지분 사슬Ownership chain持株チェーンSamsung Bio: economic interest of the controlling family vs. voting control (look-through)

첫 단계 보유자관계지분율자기주식 뺀 몫그 경로로 가족에게경로
삼성물산최대주주43.06%43.11%15.39%상장사(사슬 위로)
삼성전자계열회사31.22%31.25%2.73%상장사(사슬 위로)

경제적 몫 = 경로마다 (지분율 ÷ (1 − 그 회사 자기주식)) 을 곱해 더한 값 · 2026H1 기준

First-tier holderRelationStakeShare ex-treasuryTo the family via this pathPath
Samsung C&Tlargest shareholder43.06%43.11%15.39%listed company (chain continues up)
Samsung Electronicsaffiliate31.22%31.25%2.73%listed company (chain continues up)

Economic interest = sum over paths of the product of (stake ÷ (1 − that company's treasury shares)) · as of 2026H1

第1段階の保有者関係持株比率自己株式を除いた持分この経路で家族へ経路
Samsung C&T筆頭株主43.06%43.11%15.39%上場会社(チェーンを上へ)
Samsung Electronics系列会社31.22%31.25%2.73%上場会社(チェーンを上へ)

経済的持分 = 経路ごとに(持株比率 ÷(1 − その会社の自己株式))を掛け合わせて足した値 · 2026H1基準

최대주주 측 74.3% · 자기주식 0.1% → 의결권 기준 74.4%. 지배 가족(사슬 어느 표에서든 본인·친인척·특수관계인)의 이 회사 이익에 대한 경제적 몫 18.1% (이재용 10.7% · 이서현 3.5% · 이부진 3.3% · 홍라희 0.4% · 이유정 0.2%) → 지배-소유 괴리 56.3%p. 추이: 2019Q1 최대주주 본인 43.44% · 측 합 75.09% → 2026H1 43.06% · 74.30%.

Largest-shareholder group 74.3% · treasury shares 0.1% → 74.4% on a voting basis. The controlling family's economic interest in this company's earnings (anyone listed as self, relative or related party in any table along the chain) 18.1% (I Jaeyong 10.7% · I Seohyeon 3.5% · I Bujin 3.3% · Hong Rahui 0.4% · I Yujeong 0.2%) → control–ownership wedge 56.3pp. Trend: 2019Q1 largest shareholder alone 43.44% · group total 75.09% → 2026H1 43.06% · 74.30%.

筆頭株主側74.3% · 自己株式0.1% → 議決権ベース74.4%。支配家族(チェーン上のどの表でも本人・親族・特別関係者とされた人)のこの会社の利益に対する経済的持分18.1%(I Jaeyong 10.7% · I Seohyeon 3.5% · I Bujin 3.3% · Hong Rahui 0.4% · I Yujeong 0.2%) → 支配と所有の乖離56.3%pt。推移:2019Q1 筆頭株主本人43.44% · 側の合計75.09% → 2026H1 43.06% · 74.30%。

⚠ 규율: 삼성물산·삼성생명은 보유 상장 지분 시가가 자기 시총보다 크다(물산 217% · 생명 235%) — 생명은 보험사라 보유 주식이 보험부채와 함께 있어 지주 할인과 같은 잣대로 읽지 않는다.

⚠ Discipline: Samsung C&T and Samsung Life hold listed stakes worth more than their own market caps (Samsung C&T 217% · Samsung Life 235%) — Samsung Life is an insurer, so its shareholdings sit alongside insurance liabilities and are not read on the same yardstick as a holding-company discount.

⚠ 規律:Samsung C&TとSamsung Lifeは保有上場株式の時価が自社の時価総額より大きい(Samsung C&T 217% · Samsung Life 235%) — Samsung Lifeは保険会社なので保有株式が保険負債と並んでおり、持株会社ディスカウントと同じ物差しでは読まない。

Source: DART, Financial Supervisory Service.
Limitations: DART 최대주주 현황(보통주, 최신 분기)을 사슬 위 상장사까지 이었다 · 자기주식은 의결권·배당이 없어 분모에서 뺐다 · 우선주·전환사채·담보는 반영하지 않았다 · 비상장 법인의 주주는 Raw Data 에 없다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: DART largest-shareholder tables (common shares, latest quarter) linked up to the listed companies above in the chain · treasury shares carry no votes or dividends, so they are taken out of the denominator · preferred shares, convertible bonds and pledges are not reflected · the shareholders of unlisted corporates are not in the Raw Data.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: DART筆頭株主状況(普通株、最新四半期)をチェーン上位の上場会社までつないだ · 自己株式は議決権・配当がないので分母から除いた · 優先株・転換社債・担保は反映していない · 非上場法人の株主はRaw Dataにない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

품목Product lines品目Samsung Bio: sales by business line / product (annual report table)

Samsung Bio — sales by lineKRW trillions · Data as of 2025-12 · Created 2026-11-1301.02.03.04.05.0FY23FY24FY25KRW tnAntibody drugs (CDMO)Other2.72.93.43.54.44.6

CDMO / 제품등 / 항체의약품: 4.36조 · CDMO / 서비스 / 기타: 0.20조.

Antibody drugs (CDMO): KRW 4.36trn · Other: KRW 0.20trn.

Antibody drugs (CDMO):4.36兆ウォン · Other:0.20兆ウォン。

⚠ 규율: 표의 3개 기수만 — 회사가 재표시하면 앞 기수 값이 바뀐다.

⚠ Discipline: Only the three periods in the table — if the company restates, earlier periods change.

⚠ 規律:表の3期分のみ — 会社が再表示すると前の期の値が変わる。

Source: DART, Financial Supervisory Service.
Limitations: 최신 사업보고서 '매출실적' 표의 세 기수 · 라벨은 회사 표기 · 회사가 재표시하면 앞 기수 값이 바뀐다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: The three periods in the 'sales results' table of the latest annual report · labels follow the company's categories · if the company restates, earlier periods change.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 最新事業報告書「売上実績」表の3期分 · ラベルは会社の区分に従う · 会社が再表示すると前の期の値が変わる。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

R&DSamsung Bio: R&D spend, capitalized development costs and R&D-to-sales

Samsung Bio — R&D and capitalizationKRW trillions · Data as of 2025-12 · Created 2026-11-1300.10.20.30.40.5FY19FY20FY21FY22FY23FY24FY25KRW tnR&D totalof which capitalized (development costs)0.050.080.090.270.330.390.170000.070.070.060

FY2019: R&D 485억 (매출 대비 6.9%), 자산화 n/a (n/a) · FY2020: R&D 786억 (매출 대비 6.7%), 자산화 n/a (n/a) · FY2021: R&D 919억 (매출 대비 5.9%), 자산화 n/a (n/a) · FY2022: R&D 2,682억 (매출 대비 8.9%), 자산화 687억 (25.6%) · FY2023: R&D 3,253억 (매출 대비 8.8%), 자산화 671억 (20.6%) · FY2024: R&D 3,929억 (매출 대비 8.6%), 자산화 609억 (15.5%) · FY2025: R&D 1,674억 (매출 대비 3.7%), 자산화 n/a (n/a).

FY2019: R&D 485 KRW 100mn (6.9% of revenue), capitalised n/a (n/a) · FY2020: R&D 786 KRW 100mn (6.7% of revenue), capitalised n/a (n/a) · FY2021: R&D 919 KRW 100mn (5.9% of revenue), capitalised n/a (n/a) · FY2022: R&D 2,682 KRW 100mn (8.9% of revenue), capitalised 687 KRW 100mn (25.6%) · FY2023: R&D 3,253 KRW 100mn (8.8% of revenue), capitalised 671 KRW 100mn (20.6%) · FY2024: R&D 3,929 KRW 100mn (8.6% of revenue), capitalised 609 KRW 100mn (15.5%) · FY2025: R&D 1,674 KRW 100mn (3.7% of revenue), capitalised n/a (n/a).

FY2019:R&D 485億ウォン(対売上高6.9%)、資産化n/a(n/a) · FY2020:R&D 786億ウォン(対売上高6.7%)、資産化n/a(n/a) · FY2021:R&D 919億ウォン(対売上高5.9%)、資産化n/a(n/a) · FY2022:R&D 2,682億ウォン(対売上高8.9%)、資産化687億ウォン(25.6%) · FY2023:R&D 3,253億ウォン(対売上高8.8%)、資産化671億ウォン(20.6%) · FY2024:R&D 3,929億ウォン(対売上高8.6%)、資産化609億ウォン(15.5%) · FY2025:R&D 1,674億ウォン(対売上高3.7%)、資産化n/a(n/a)。

⚠ 규율: 표 서식이 바뀐 옛 해(2019~2021)는 못 잡았다 — 원문 확인 필요.

⚠ Discipline: Older years whose table format changed (2019–2021) could not be captured — the original filings need checking.

⚠ 規律:表の様式が変わった古い年(2019〜2021年)は取得できなかった — 原文の確認が必要。

Source: DART, Financial Supervisory Service.
Limitations: 사업보고서 '연구개발비용' 표 · 자산화 = 개발비(무형자산) · 서식이 다른 옛 해는 빠졌다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: The 'R&D expenses' table in the annual report · capitalised = development costs (intangible assets) · older years with a different format are missing.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 事業報告書の「研究開発費用」表 · 資産化 = 開発費(無形資産) · 様式が異なる古い年は抜けている。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

운전자본Working capital運転資本Samsung Bio: inventory and receivable days, net debt

Samsung Bio — working capital daysdays · Data as of 2025-12 · Created 2026-11-130200400600800FY19FY20FY21FY22FY23FY24FY25daysInventory days (÷ COGS)Receivable days (÷ revenue)38154.2

FY2025: 재고 2.13조 (381일), 매출채권 0.68조 (54일), 순차입금 0.74조 (차입금 기준).

FY2025: inventories KRW 2.13trn (381 days), receivables KRW 0.68trn (54 days), net debt KRW 0.74trn (borrowings basis).

FY2025:棚卸資産2.13兆ウォン(381日)、売上債権0.68兆ウォン(54日)、純有利子負債0.74兆ウォン(借入金ベース)。

Source: DART, Financial Supervisory Service.
Limitations: 연말 잔액 ÷ 연간 흐름 × 365(재고는 매출원가, 매출채권은 매출) — 결산일 계절성이 섞인다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: Year-end balance ÷ annual flow × 365 (cost of sales for inventories, revenue for receivables) — year-end seasonality is mixed in.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 年末残高 ÷ 年間フロー × 365(棚卸資産は売上原価、売上債権は売上高) — 決算日の季節性が混ざる。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

특수관계자Related parties関連当事者Samsung Bio: sales to related parties (from the related-party note)

FY상대매출·수익연결매출 대비
FY2018삼성바이오에피스0.23조0.0%
FY2019삼성바이오에피스0.18조26.1%
FY2020삼성바이오에피스0.26조22.2%
FY2021삼성바이오에피스0.28조17.6%
FY2022삼성바이오에피스0.04조1.2%
FY2024삼성바이오에피스0.08조1.8%
FY2025삼성바이오에피스0.03조0.7%
FYCounterpartySales / revenue% of consolidated revenue
FY2018Samsung BioepisKRW 0.23trn0.0%
FY2019Samsung BioepisKRW 0.18trn26.1%
FY2020Samsung BioepisKRW 0.26trn22.2%
FY2021Samsung BioepisKRW 0.28trn17.6%
FY2022Samsung BioepisKRW 0.04trn1.2%
FY2024Samsung BioepisKRW 0.08trn1.8%
FY2025Samsung BioepisKRW 0.03trn0.7%
FY相手先売上・収益連結売上高比
FY2018Samsung Bioepis0.23兆ウォン0.0%
FY2019Samsung Bioepis0.18兆ウォン26.1%
FY2020Samsung Bioepis0.26兆ウォン22.2%
FY2021Samsung Bioepis0.28兆ウォン17.6%
FY2022Samsung Bioepis0.04兆ウォン1.2%
FY2024Samsung Bioepis0.08兆ウォン1.8%
FY2025Samsung Bioepis0.03兆ウォン0.7%

FY2018 삼성바이오에피스 0.23조 (0.0%) · FY2019 삼성바이오에피스 0.18조 (26.1%) · FY2020 삼성바이오에피스 0.26조 (22.2%) · FY2021 삼성바이오에피스 0.28조 (17.6%) · FY2022 삼성바이오에피스 0.04조 (1.2%) · FY2024 삼성바이오에피스 0.08조 (1.8%) · FY2025 삼성바이오에피스 0.03조 (0.7%).

FY2018 Samsung Bioepis KRW 0.23trn (0.0%) · FY2019 Samsung Bioepis KRW 0.18trn (26.1%) · FY2020 Samsung Bioepis KRW 0.26trn (22.2%) · FY2021 Samsung Bioepis KRW 0.28trn (17.6%) · FY2022 Samsung Bioepis KRW 0.04trn (1.2%) · FY2024 Samsung Bioepis KRW 0.08trn (1.8%) · FY2025 Samsung Bioepis KRW 0.03trn (0.7%).

FY2018 Samsung Bioepis 0.23兆ウォン (0.0%) · FY2019 Samsung Bioepis 0.18兆ウォン (26.1%) · FY2020 Samsung Bioepis 0.26兆ウォン (22.2%) · FY2021 Samsung Bioepis 0.28兆ウォン (17.6%) · FY2022 Samsung Bioepis 0.04兆ウォン (1.2%) · FY2024 Samsung Bioepis 0.08兆ウォン (1.8%) · FY2025 Samsung Bioepis 0.03兆ウォン (0.7%)。

⚠ 규율: 표의 첫 값 열(매출/수익)을 읽었다 — 열 정의는 연도별 헤더 참조. 셀트리온은 2023년 말 헬스케어 합병으로 이 매출이 내부거래로 사라졌다.

⚠ Discipline: We read the first value column of the table (sales/revenue) — see each year's header for the column definition. At Celltrion these sales became intra-group transactions after the Celltrion Healthcare merger at the end of 2023.

⚠ 規律:表の最初の値の列(売上/収益)を読んだ — 列の定義は年度ごとのヘッダーを参照。Celltrionでは2023年末のCelltrion Healthcare合併でこの売上が内部取引となり消えた。

Source: DART, Financial Supervisory Service.
Limitations: 특수관계자 주석 표의 첫 값 열 — 열 정의는 해마다 헤더를 따른다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: First value column of the related-party note table — the column definition follows each year's header.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 関連当事者注記の表の最初の値の列 — 列の定義は年ごとのヘッダーに従う。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

지분Ownership持株Samsung Bio: largest shareholder and treasury shares by quarter

Samsung Bio — ownershippercent of common shares · Data as of 2026H1 · Created 2026-11-130%20%40%60%80%100%19Q119Q420Q321Q222Q122Q423Q324Q225Q125Q426Q2%Largest holder + related (%)Largest holder alone (%)+74.3%+43.1%
기간취득소각기말 자기주식
2025FY0051,433
2026H10051,433
PeriodAcquiredCancelledTreasury shares at period end
2025FY0051,433
2026H10051,433
期間取得消却期末自己株式
2025FY0051,433
2026H10051,433

최신 2026H1: 삼성물산(최대주주) 43.06% · 삼성전자(계열회사) 31.22%. 자기주식 0.1% · 최대주주 변동: 2011년 04월 22일 삼성전자 40.00%; 2015년 09월 02일 삼성물산 51.04%; 2025년 11월 03일 삼성물산 43.06%.

Latest 2026H1: Samsung C&T (largest shareholder) 43.06% · Samsung Electronics (affiliate) 31.22%. Treasury shares 0.1% · changes of largest shareholder: 2011-04-22 Samsung Electronics 40.00%; 2015-09-02 Samsung C&T 51.04%; 2025-11-03 Samsung C&T 43.06%.

最新2026H1:Samsung C&T(筆頭株主)43.06% · Samsung Electronics(系列会社)31.22%。自己株式0.1% · 筆頭株主の変動:2011-04-22 Samsung Electronics 40.00%; 2015-09-02 Samsung C&T 51.04%; 2025-11-03 Samsung C&T 43.06%。

⚠ 규율: 자기주식 소각은 발행주식을 줄여 최대주주 지분율을 올린다.

⚠ Discipline: Cancelling treasury shares reduces the shares in issue and raises the largest shareholder's percentage.

⚠ 規律:自己株式の消却は発行済株式を減らし、筆頭株主の持株比率を上げる。

Source: DART, Financial Supervisory Service.
Limitations: DART 최대주주 현황(보통주) · 개인 지배주주의 간접 지분은 이 표에 없다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: DART largest-shareholder table (common shares) · indirect stakes of individual controlling shareholders are not in this table.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: DART筆頭株主状況(普通株) · 個人の支配株主の間接持分はこの表にない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

지분도Ownership map持株関係図Samsung Bio: cross-shareholding map, FY2025 (67 affiliates in group '삼성')Samsung Bio: cross-shareholding map, FY2025 (67 affiliates in its business group)Samsung Bio: cross-shareholding map, FY2025 (67 affiliates in its business group)

Samsung Bio — domestic cross-shareholdings, FY2025percent · Data as of FY2025 · Created 2026-11-1343.1%31.2%19.3%15.4%8.6%5.0%1.5%Samsung Fire & Marine InsuranceSamsung Life InsuranceSamsung C&TSamsung ElectronicsSamsung Biologics

삼성물산(주) → 삼성바이오로직스㈜ 43.10% · 삼성전자(주) → 삼성바이오로직스㈜ 31.20%. 해외 계열 출자 774건.

Samsung C&T → Samsung Biologics 43.10% · Samsung Electronics → Samsung Biologics 31.20%. Investments in overseas affiliates: 774.

Samsung C&T → Samsung Biologics 43.10% · Samsung Electronics → Samsung Biologics 31.20%。海外系列会社への出資774件。

⚠ 규율: 개인 지배주주(예: 셀트리온홀딩스·삼성물산의 주주)는 이 표에 없다 — 각 회사의 공시에서 따로 봐야 한다. 행렬 방향은 최대주주 표와 대조해 정했다(row_investor).

⚠ Discipline: Individual controlling shareholders (for example the shareholders of Celltrion Holdings or Samsung C&T) are not in this table — they have to be looked up in each company's own filings. The direction of the matrix was set by checking it against the largest-shareholder table (row_investor).

⚠ 規律:個人の支配株主(例:Celltrion Holdings・Samsung C&Tの株主)はこの表にない — 各社の開示で別途見る必要がある。行列の向きは筆頭株主表と照合して決めた(row_investor)。

Source: DART, Financial Supervisory Service.
Limitations: 사업보고서 '계열회사간 출자현황' 행렬 · 화살표 = 출자 → 피출자 · 빨강 = 이 회사로 들어오는 지분, 남색 = 이 회사가 가진 지분 · 개인 지배주주는 없다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 'Cross-shareholdings among affiliates' matrix in the annual report · arrow = investor → investee · red = stakes held in this company, navy = stakes this company holds · individual controlling shareholders are not shown.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 事業報告書「系列会社間の出資状況」行列 · 矢印 = 出資者 → 出資先 · 赤 = この会社への持分、紺 = この会社が持つ持分 · 個人の支配株主は含まない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

수주Orders受注Samsung Bio: contract total, delivered and backlog (order table, USD)

Samsung Bio — order bookUSD billions · Data as of 26Q2 · Created 2026-11-1305.010.015.020.025.018Q419Q320Q221Q121Q422Q323Q224Q124Q425Q326Q2USD bnContract totalDeliveredBacklog21.711.89.9

최신 26Q2: CDMO / 항체의약품 / 2015년~(계약별상이) / ~2037년(계약별상이) / 현 최소구매물량 기준 — 총액 21,689 · 기납품 11,766 · 잔고 9,923 (USD 백만) · 고객사 수요 증가 시 예상물량 기준 (제품개발 성공 등) — 총액 24,292 · 기납품 11,766 · 잔고 12,526 (USD 백만)

Latest 26Q2: CDMO / 항체의약품 / 2015년~(계약별상이) / ~2037년(계약별상이) / 현 최소구매물량 기준 — total 21,689 · delivered 11,766 · backlog 9,923 (USD mn) · 고객사 수요 증가 시 예상물량 기준 (제품개발 성공 등) — total 24,292 · delivered 11,766 · backlog 12,526 (USD mn)

最新26Q2:CDMO / 항체의약품 / 2015년~(계약별상이) / ~2037년(계약별상이) / 현 최소구매물량 기준 — 総額21,689 · 納品済み11,766 · 残高9,923(USD百万) · 고객사 수요 증가 시 예상물량 기준 (제품개발 성공 등) — 総額24,292 · 納品済み11,766 · 残高12,526(USD百万)

⚠ 규율: 삼성바이오로직스는 '최소구매물량 기준'과 '고객사 제품개발 성공 시 예상 수요물량 기준' 두 줄을 낸다 — 차트는 앞의 것(계약상 확정분).

⚠ Discipline: Samsung Biologics reports two lines, 'minimum purchase volume basis' and 'expected demand if the client's product development succeeds' — the chart uses the first (contractually committed).

⚠ 規律:Samsung Biologicsは「最低購入数量ベース」と「顧客の製品開発成功時の予想需要数量ベース」の2行を出す — チャートは前者(契約上の確定分)。

Source: DART, Financial Supervisory Service.
Limitations: 각 보고서 '수주상황' 표 · 삼성바이오로직스는 최소구매물량 기준 줄 · 수주 잔고 정의는 회사 기재 그대로.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: The 'order status' table in each report · for Samsung Biologics, the minimum-purchase-volume line · the backlog definition is as the company states it.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 各報告書の「受注状況」表 · Samsung Biologicsは最低購入数量ベースの行 · 受注残高の定義は会社記載のまま。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

설비Plant設備Samsung Bio: capacity, output and utilization (annual report tables)

표항목당기전기전전기
production생산능력1,034.0833.0733.0
production생산실적733.0626.0523.0
production가동률70.975.271.4
utilization생산능력1,034.0833.0733.0
utilization생산실적733.0626.0523.0
utilization가동률70.975.271.4
TableItemCurrent periodPrior periodTwo periods ago
Output생산능력1,034.0833.0733.0
Output생산실적733.0626.0523.0
Output가동률70.975.271.4
Utilisation생산능력1,034.0833.0733.0
Utilisation생산실적733.0626.0523.0
Utilisation가동률70.975.271.4
表項目当期前期前々期
生産実績생산능력1,034.0833.0733.0
生産実績생산실적733.0626.0523.0
生産実績가동률70.975.271.4
稼働率생산능력1,034.0833.0733.0
稼働率생산실적733.0626.0523.0
稼働率가동률70.975.271.4

생산능력·생산실적·가동률 표(단위는 표 기준: 배치 등).

Capacity, output and utilisation tables (units as in each table: batches etc.).

生産能力・生産実績・稼働率の表(単位は表の基準:バッチ等)。

Source: DART, Financial Supervisory Service.
Limitations: 사업보고서 생산능력·생산실적·가동률 표 그대로(단위는 표 기준).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: Capacity, output and utilisation tables from the annual report as filed (units as in each table).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 事業報告書の生産能力・生産実績・稼働率の表のまま(単位は表の基準)。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

구조Structure構造Samsung Bio: structural events, pipeline and licenses (annual report text)

인적분할: 34. 인적분할 (연결) 연결회사는 2025년 5월 22일 전문화된 사업영역에 역량을 집중하여 지속적인 성장 잠재력을 증대하고자 삼성바이오에피스㈜를 분할하여 분할회사를 설립하기로 결정하였으며, 2025년 10월 17일 주주총회 안건이 승인됨에 따라 2025년 11월 1일을 기일로 삼성에피스홀딩스㈜를 신설회사로 하는 인적분할을 진행했습니다. 비교표시 된 포괄손익계산서는 계속영업으로부터 분리된 중단영업을 보여주기 위해 재작성되었습니다. 분할의 주요 내용 공시금액 분할방법 인적분할 분할존속법인 삼성바이오로직스 주식회사 분할신설법인 삼성에피스홀딩스 주식회사 분할기일 <TE ACODE="entity00877059_EffectivedateofspinoffOfDisclosureOfKeyDetailsOfTheSpinOffLineItemsOfDisclosur 인적분할: 34. 인적분할 (별도) 회사는 2025년 5월 22일 전문화된 사업영역에 역량을 집중하여 지속적인 성장 잠재력을 증대하고자 삼성바이오에피스㈜를 분할하여 분할회사를 설립하기로 결정하였으며, 2025년 10월 17일 주주총회 안건이 승인됨에 따라 2025년 11월 1일을 기일로 삼성에피스홀딩스㈜를 신설회사로 하는 인적분할을 진행했습니다. 분할의 주요 내용 공시금액 분할방법 인적분할 분할존속법인 삼성바이오로직스 주식회사 분할신설법인 삼성에피스홀딩스 주식회사 분할기일 <TE ACODE="entity00877059_EffectivedateofspinoffOfDisclosureOfKeyDetailsOfTheSpinOffLineItemsOfDisclosureOfKeyDetailsOfTheSpinOffTableOfItems" ACONTEXT="CFY202

Spin-off: 34. 인적분할 (연결) 연결회사는 2025년 5월 22일 전문화된 사업영역에 역량을 집중하여 지속적인 성장 잠재력을 증대하고자 삼성바이오에피스㈜를 분할하여 분할회사를 설립하기로 결정하였으며, 2025년 10월 17일 주주총회 안건이 승인됨에 따라 2025년 11월 1일을 기일로 삼성에피스홀딩스㈜를 신설회사로 하는 인적분할을 진행했습니다. 비교표시 된 포괄손익계산서는 계속영업으로부터 분리된 중단영업을 보여주기 위해 재작성되었습니다. 분할의 주요 내용 공시금액 분할방법 인적분할 분할존속법인 삼성바이오로직스 주식회사 분할신설법인 삼성에피스홀딩스 주식회사 분할기일 <TE ACODE="entity00877059_EffectivedateofspinoffOfDisclosureOfKeyDetailsOfTheSpinOffLineItemsOfDisclosur Spin-off: 34. 인적분할 (별도) 회사는 2025년 5월 22일 전문화된 사업영역에 역량을 집중하여 지속적인 성장 잠재력을 증대하고자 삼성바이오에피스㈜를 분할하여 분할회사를 설립하기로 결정하였으며, 2025년 10월 17일 주주총회 안건이 승인됨에 따라 2025년 11월 1일을 기일로 삼성에피스홀딩스㈜를 신설회사로 하는 인적분할을 진행했습니다. 분할의 주요 내용 공시금액 분할방법 인적분할 분할존속법인 삼성바이오로직스 주식회사 분할신설법인 삼성에피스홀딩스 주식회사 분할기일 <TE ACODE="entity00877059_EffectivedateofspinoffOfDisclosureOfKeyDetailsOfTheSpinOffLineItemsOfDisclosureOfKeyDetailsOfTheSpinOffTableOfItems" ACONTEXT="CFY202

人的分割:34. 인적분할 (연결) 연결회사는 2025년 5월 22일 전문화된 사업영역에 역량을 집중하여 지속적인 성장 잠재력을 증대하고자 삼성바이오에피스㈜를 분할하여 분할회사를 설립하기로 결정하였으며, 2025년 10월 17일 주주총회 안건이 승인됨에 따라 2025년 11월 1일을 기일로 삼성에피스홀딩스㈜를 신설회사로 하는 인적분할을 진행했습니다. 비교표시 된 포괄손익계산서는 계속영업으로부터 분리된 중단영업을 보여주기 위해 재작성되었습니다. 분할의 주요 내용 공시금액 분할방법 인적분할 분할존속법인 삼성바이오로직스 주식회사 분할신설법인 삼성에피스홀딩스 주식회사 분할기일 <TE ACODE="entity00877059_EffectivedateofspinoffOfDisclosureOfKeyDetailsOfTheSpinOffLineItemsOfDisclosur 人的分割:34. 인적분할 (별도) 회사는 2025년 5월 22일 전문화된 사업영역에 역량을 집중하여 지속적인 성장 잠재력을 증대하고자 삼성바이오에피스㈜를 분할하여 분할회사를 설립하기로 결정하였으며, 2025년 10월 17일 주주총회 안건이 승인됨에 따라 2025년 11월 1일을 기일로 삼성에피스홀딩스㈜를 신설회사로 하는 인적분할을 진행했습니다. 분할의 주요 내용 공시금액 분할방법 인적분할 분할존속법인 삼성바이오로직스 주식회사 분할신설법인 삼성에피스홀딩스 주식회사 분할기일 <TE ACODE="entity00877059_EffectivedateofspinoffOfDisclosureOfKeyDetailsOfTheSpinOffLineItemsOfDisclosureOfKeyDetailsOfTheSpinOffTableOfItems" ACONTEXT="CFY202

⚠ 규율: 파이프라인 0건 · 라이선스 아웃 0건 · 인 24건(원문 표 기준).

⚠ Discipline: Pipeline 0 · licence-out 0 · licence-in 24 (as in the original tables).

⚠ 規律:パイプライン0件 · ライセンスアウト0件 · イン24件(原文の表ベース)。

Source: DART, Financial Supervisory Service.
Limitations: 회사 공시 원문 값을 옮겼다 — 재표시·서식 변경·합병·분할이 있는 해는 앞뒤가 같은 범위가 아니다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: Values are taken from the companies' own filings — years with restatements, format changes, mergers or spin-offs do not cover the same scope as the years around them.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 企業の開示原文の値を転記した — 再表示・様式変更・合併・分割のある年は前後と同じ範囲ではない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

07

대웅(지주) — 심층Daewoong (hold.) — deep diveDaewoong (hold.) — 深掘り

분기Quarterly四半期Daewoong (hold.): quarterly revenue and operating income

Daewoong (hold.) — quarterlyKRW trillions · Data as of 2026-06-30 · Created 2026-11-1300.20.40.60.822Q323Q123Q324Q124Q325Q125Q326Q2KRW tnRevenueOperating income

최근 분기 26Q2: 매출 0.57조 (YoY +8.0%, QoQ +15.9%), 영업이익 0.08조, TTM 매출 2.12조 (TTM QoQ +2.0%).

Latest quarter 26Q2: revenue KRW 0.57trn (YoY +8.0%, QoQ +15.9%), operating profit KRW 0.08trn, TTM revenue KRW 2.12trn (TTM QoQ +2.0%).

直近四半期26Q2:売上高0.57兆ウォン(YoY +8.0%、QoQ +15.9%)、営業利益0.08兆ウォン、TTM売上高2.12兆ウォン(TTM QoQ +2.0%)。

Source: DART, Financial Supervisory Service.
Limitations: 연결 분기 손익 · 4분기 = 연간 − 9개월 누계 · 합병 해(셀트리온 2023)는 앞뒤 범위가 다르다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: Consolidated quarterly income statement · Q4 = full year − nine-month cumulative · the merger year (Celltrion 2023) differs in scope from the years around it.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 連結四半期損益 · 第4四半期 = 通期 − 9か月累計 · 合併年(Celltrion 2023年)は前後と範囲が異なる。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

지주 가치Holding value持株会社の価値Daewoong (hold.): what the market pays for the holding vs. the market value of the listed stakes it owns

Daewoong (hold.) — holding value chainKRW trillions · Data as of 2026-11-10 · Created 2026-11-1300.51.01.5Hold. mcapHold. ex-treasuryListed stakesDW Pharm mcapHanAll stakeDW Pharm ex-HanAllKRW tn0.940.680.651.20.750.45
보유 상장 지분지분율시가피출자 시총지분율 출처
대웅제약52.29%0.630조1.21조피출자 최대주주 표
광동제약4.60%0.015조0.33조대웅 타법인 출자 현황
지구홀딩스15.00%0.008조0.05조대웅 타법인 출자 현황
(대웅제약 보유) 한올바이오파마30.80%0.751조2.44조피출자 최대주주 표
(대웅제약 보유) 인벤티지랩0.30%0.001조0.28조대웅제약 타법인 출자 현황
(대웅제약 보유) 씨어스2.60%0.015조0.57조대웅제약 타법인 출자 현황

KRX 시가총액 2026-11-10 · 지분율 = 피출자 최대주주 표 우선

Listed stake heldStakeMarket valueInvestee market capSource of the stake
Daewoong Pharma52.29%KRW 0.630trnKRW 1.21trninvestee's largest-shareholder table
Kwangdong Pharmaceutical4.60%KRW 0.015trnKRW 0.33trnDaewoong (hold.)'s investments in other companies
ZGOO Holdings15.00%KRW 0.008trnKRW 0.05trnDaewoong (hold.)'s investments in other companies
(held by Daewoong Pharm) Hanall Biopharma30.80%KRW 0.751trnKRW 2.44trninvestee's largest-shareholder table
(held by Daewoong Pharm) Inventage Lab0.30%KRW 0.001trnKRW 0.28trnDaewoong Pharm's investments in other companies
(held by Daewoong Pharm) Seers2.60%KRW 0.015trnKRW 0.57trnDaewoong Pharm's investments in other companies

KRX market cap 2026-11-10 · stake = the investee's largest-shareholder table first

保有上場株式持株比率時価出資先の時価総額持株比率の出所
Daewoong Pharma52.29%0.630兆ウォン1.21兆ウォン出資先の筆頭株主表
Kwangdong Pharmaceutical4.60%0.015兆ウォン0.33兆ウォンDaewoong (hold.)の他法人出資状況
ZGOO Holdings15.00%0.008兆ウォン0.05兆ウォンDaewoong (hold.)の他法人出資状況
(Daewoong Pharm保有)Hanall Biopharma30.80%0.751兆ウォン2.44兆ウォン出資先の筆頭株主表
(Daewoong Pharm保有)Inventage Lab0.30%0.001兆ウォン0.28兆ウォンDaewoong Pharmの他法人出資状況
(Daewoong Pharm保有)Seers2.60%0.015兆ウォン0.57兆ウォンDaewoong Pharmの他法人出資状況

KRX時価総額2026-11-10 · 持株比率 = 出資先の筆頭株主表を優先

대웅(지주) 시총 0.94조 중 자기주식이 27.7%다(12종목 중 1위 · 다음은 유한양행 7.6%). 자기주식 뺀 시총 0.68조 ≈ 상장 지분 시가 0.65조(대웅제약 52.29% = 0.63조 · 광동제약 4.60% = 0.015조 · 지구홀딩스 15.00% = 0.008조) → 96%. 비상장 100% 자회사 대웅바이오(최근 사업연도 순이익 569억 · 장부 589억)·대웅개발(장부 1,055억)과 지주 자체 순현금(138억, 2026H1)이 시총에 거의 값이 매겨지지 않은 셈이다. 한 층 아래 대웅제약도 시총 1.21조 중 한올바이오파마 지분(30.8%) 시가가 0.75조(62%) — 한올을 빼면 0.45조.

Of Daewoong (hold.)'s market cap of KRW 0.94trn, treasury shares are 27.7% (rank 1 of 12 companies · next is Yuhan at 7.6%). Market cap excluding treasury shares KRW 0.68trn ≈ market value of the listed stakes KRW 0.65trn (Daewoong Pharm 52.29% = KRW 0.63trn · Kwangdong Pharmaceutical 4.60% = KRW 0.015trn · ZGOO Holdings 15.00% = KRW 0.008trn) → 96%. The unlisted wholly owned subsidiaries Daewoong Bio (net profit in the latest fiscal year 569 KRW 100mn · book value 589 KRW 100mn) and Daewoong Development (book value 1,055 KRW 100mn), together with the holding company's own net cash (138 KRW 100mn, 2026H1), are in effect barely valued in the market cap. One level down, the stake in HanAll (30.8%) is worth KRW 0.75trn of Daewoong Pharm's KRW 1.21trn market cap (62%) — excluding HanAll, KRW 0.45trn.

Daewoong (hold.)の時価総額0.94兆ウォンのうち自己株式が27.7%である(12銘柄中1位 · 次はYuhan 7.6%)。自己株式を除いた時価総額0.68兆ウォン ≈ 上場株式の時価0.65兆ウォン(Daewoong Pharm 52.29% = 0.63兆ウォン · Kwangdong Pharmaceutical 4.60% = 0.015兆ウォン · ZGOO Holdings 15.00% = 0.008兆ウォン) → 96%。非上場の100%子会社Daewoong Bio(直近事業年度の純利益569億ウォン · 簿価589億ウォン)・Daewoong Development(簿価1,055億ウォン)と持株会社自体のネットキャッシュ(138億ウォン、2026H1)は、時価総額でほとんど値が付いていないことになる。一段下のDaewoong Pharmも時価総額1.21兆ウォンのうちHanAll株式(30.8%)の時価が0.75兆ウォン(62%) — HanAllを除くと0.45兆ウォン。

⚠ 규율: 자기주식은 의결권·배당이 없다 — 시총에서 빼고 견줘야 한다. 대웅의 자기주식은 소각이 아니라 처분으로 줄고 있다(최근: 2022FY 처분 15,649주; 2024FY 처분 690,630주; 2025FY 처분 581,420주). 비상장 자회사 가치는 평가하지 않았다(장부·순이익만 옮김).

⚠ Discipline: Treasury shares carry no votes or dividends — they have to be taken out of the market cap before comparing. Daewoong (hold.)'s treasury shares are falling through disposals, not cancellations (recent: 2022FY disposal 15,649 shares; 2024FY disposal 690,630 shares; 2025FY disposal 581,420 shares). The value of the unlisted subsidiaries is not assessed (only book value and net profit are carried over).

⚠ 規律:自己株式には議決権・配当がない — 時価総額から除いて比べる必要がある。Daewoong (hold.)の自己株式は消却ではなく処分で減っている(最近:2022FY 処分15,649株; 2024FY 処分690,630株; 2025FY 処分581,420株)。非上場子会社の価値は評価していない(簿価・純利益のみ転記)。

Source: DART, Financial Supervisory Service.
Source: Korea Exchange (KRX). 본 차트는 “한국거래소 통계정보”를 사용한 결과임.
Limitations: 시가 = 지분율 × 피출자 KRX 시가총액 · 대웅 시총은 상장주식 전체 × (1 − 자기주식 비율)로 견줬다 · 비상장 자회사는 '타법인 출자 현황'의 장부가·최근 사업연도 순이익만 옮겼다(평가 아님) · 세금·지배권 프리미엄은 따지지 않았다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Source: Korea Exchange (KRX). 본 차트는 “한국거래소 통계정보”를 사용한 결과임.
Limitations: Market value = stake × the investee's KRX market cap · Daewoong (hold.)'s market cap is compared as all listed shares × (1 − treasury-share ratio) · for unlisted subsidiaries only the book value and latest-fiscal-year net profit from 'investments in other companies' are carried over (not a valuation) · taxes and control premiums are not considered.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Source: Korea Exchange (KRX). 본 차트는 “한국거래소 통계정보”를 사용한 결과임.
Limitations: 時価 = 持株比率 × 出資先のKRX時価総額 · Daewoong (hold.)の時価総額は上場株式全体 ×(1 − 自己株式比率)で比べた · 非上場子会社は「他法人出資状況」の簿価・直近事業年度の純利益のみ転記した(評価ではない) · 税金・支配権プレミアムは考慮していない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

수익률Returns収益率Daewoong (holding, consolidated) and Daewoong Pharm: ROIC and ROE

Daewoong group — returnspercent · Data as of 2026-06-30 · Created 2026-11-130%5%10%15%20%25%FY20FY21FY22FY23FY24FY25TTM%DW Hold ROICDW Hold ROEDW Pharm ROICDW Pharm ROE

FY2025: 대웅 ROIC 13.3% · ROE 16.1% · 대웅제약 ROIC 14.4% · ROE 21.8%. 최근 4분기: 대웅 11.0%/14.8% · 대웅제약 12.3%/18.9%. FY24 에 ROE 가 꺼진 것은 영업이 아니라 영업외 — 대웅제약 세전 566억 vs 영업이익 1,479억.

FY2025: Daewoong (hold.) ROIC 13.3% · ROE 16.1% · Daewoong Pharm ROIC 14.4% · ROE 21.8%. Last four quarters: Daewoong (hold.) 11.0%/14.8% · Daewoong Pharm 12.3%/18.9%. ROE dipped in FY24 because of non-operating items, not operations — Daewoong Pharm pre-tax profit 566 KRW 100mn vs operating profit 1,479 KRW 100mn.

FY2025:Daewoong (hold.) ROIC 13.3% · ROE 16.1% · Daewoong Pharm ROIC 14.4% · ROE 21.8%。直近4四半期:Daewoong (hold.) 11.0%/14.8% · Daewoong Pharm 12.3%/18.9%。FY24にROEが落ち込んだのは営業ではなく営業外による — Daewoong Pharmの税引前利益566億ウォン vs 営業利益1,479億ウォン。

⚠ 규율: 지주(대웅) 연결엔 대웅제약·한올바이오파마·대웅바이오가 들어 있다 — 지주 ROE 의 상당 부분이 자회사 이익이다.

⚠ Discipline: The holding company's (Daewoong (hold.)) consolidated figures include Daewoong Pharm, HanAll and Daewoong Bio — a large part of the holding company's ROE is subsidiary earnings.

⚠ 規律:持株会社(Daewoong (hold.))の連結にはDaewoong Pharm・HanAll・Daewoong Bioが入っている — 持株会社のROEのかなりの部分は子会社の利益である。

Source: DART, Financial Supervisory Service.
Limitations: 연결 · ROIC = 영업이익 × (1 − 그해 유효세율) ÷ 평균 영업 투하자본(유형·무형자산·영업권 + 운전자본) · ROE = 지배주주 순이익 ÷ 평균 지배주주 자본 · TTM = 최근 4분기(분기보고서).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: Consolidated · ROIC = operating profit × (1 − that year's effective tax rate) ÷ average operating invested capital (tangible and intangible assets and goodwill + working capital) · ROE = net profit attributable to owners of the parent ÷ average equity attributable to owners · TTM = last four quarters (quarterly reports).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 連結 · ROIC = 営業利益 ×(1 − その年の実効税率)÷ 平均営業投下資本(有形・無形資産・のれん + 運転資本) · ROE = 親会社株主に帰属する当期純利益 ÷ 平均親会社株主資本 · TTM = 直近4四半期(四半期報告書)。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

투입·산출Inputs vs outputs投入と産出Daewoong Pharm: growth of inputs (plant, people) vs. outputs (revenue, profit), FY2019–FY2025

Daewoong Pharm — annual growth ratepercent per year (compound) · Data as of 2025-12 · Created 2026-11-130%10%20%30%40%RevenueOperating incomeNet PP&EHeadcountPayroll%+5.9%+28.0%+13.4%+3.4%+6.6%
FY매출영업이익설비투자유형자산인원인건비1인당 매출인건비/매출판정
FY2019——————7.6억8.5%—
FY2020-5.2%-62.0%19.1%-0.3%-3.3%-2.3%7.5억8.8%미달
FY20219.2%423.6%25.3%0.5%6.7%9.4%7.6억8.8%미달
FY202211.0%7.8%51.5%11.5%8.9%16.7%7.8억9.3%미달
FY20237.4%28.0%37.8%19.7%5.4%7.2%7.9억9.2%미달
FY20243.4%20.7%46.6%26.8%1.4%5.5%8.1억9.4%미달
FY202510.4%33.0%5.4%25.7%2.1%3.7%8.8억8.9%미달

전년 대비 증가율 · 매출·영업이익·설비투자·유형자산 = 연결 · 인원·인건비 = 사업보고서 '직원 등의 현황'(그 회사 자신, 기간제 포함) · * = 합병이 낀 해

FYRevenueOperating profitCapexPP&EHeadcountPayrollRevenue per headPayroll / revenueVerdict
FY2019——————7.6 KRW 100mn8.5%—
FY2020-5.2%-62.0%19.1%-0.3%-3.3%-2.3%7.5 KRW 100mn8.8%fail
FY20219.2%423.6%25.3%0.5%6.7%9.4%7.6 KRW 100mn8.8%fail
FY202211.0%7.8%51.5%11.5%8.9%16.7%7.8 KRW 100mn9.3%fail
FY20237.4%28.0%37.8%19.7%5.4%7.2%7.9 KRW 100mn9.2%fail
FY20243.4%20.7%46.6%26.8%1.4%5.5%8.1 KRW 100mn9.4%fail
FY202510.4%33.0%5.4%25.7%2.1%3.7%8.8 KRW 100mn8.9%fail

Year-on-year growth · revenue, operating profit, capex and PP&E = consolidated · headcount and payroll = 'employee status' in the annual report (the company itself, fixed-term staff included) · * = year that includes a merger

FY売上高営業利益設備投資有形資産人員人件費1人当たり売上高人件費/売上高判定
FY2019——————7.6億ウォン8.5%—
FY2020-5.2%-62.0%19.1%-0.3%-3.3%-2.3%7.5億ウォン8.8%未達
FY20219.2%423.6%25.3%0.5%6.7%9.4%7.6億ウォン8.8%未達
FY202211.0%7.8%51.5%11.5%8.9%16.7%7.8億ウォン9.3%未達
FY20237.4%28.0%37.8%19.7%5.4%7.2%7.9億ウォン9.2%未達
FY20243.4%20.7%46.6%26.8%1.4%5.5%8.1億ウォン9.4%未達
FY202510.4%33.0%5.4%25.7%2.1%3.7%8.8億ウォン8.9%未達

前年比増加率 · 売上高・営業利益・設備投資・有形資産 = 連結 · 人員・人件費 = 事業報告書「従業員等の現況」(その会社自身、期間雇用を含む) · * = 合併を含む年

연평균(FY2019→FY2025): 매출 5.9% · 영업이익 28.0% · 유형자산 13.4% · 인원 3.4% · 인건비 6.6% · 1인당 매출 7.6억 → 8.8억. 해마다 판정: 통과 없음 · 미달 2020, 2021, 2022, 2023, 2024, 2025.

Average annual growth (FY2019→FY2025): revenue 5.9% · operating profit 28.0% · PP&E 13.4% · headcount 3.4% · payroll 6.6% · revenue per head 7.6 KRW 100mn → 8.8 KRW 100mn. Year-by-year verdict: pass none · fail 2020, 2021, 2022, 2023, 2024, 2025.

年平均(FY2019→FY2025):売上高5.9% · 営業利益28.0% · 有形資産13.4% · 人員3.4% · 人件費6.6% · 1人当たり売上高7.6億ウォン → 8.8億ウォン。年ごとの判定:通過なし · 未達2020, 2021, 2022, 2023, 2024, 2025。

⚠ 규율: 판정 = 그해 매출·영업이익 증가율(작은 쪽)이 설비투자·유형자산·인원·인건비 증가율(큰 쪽)을 넘었나 — 엄격한 잣대다. 표에서 어느 투입이 막았는지 본다.

⚠ Discipline: Verdict = did that year's growth in revenue and operating profit (the smaller of the two) exceed the growth in capex, PP&E, headcount and payroll (the largest)? It is a strict test. The table shows which input held it back.

⚠ 規律:判定 = その年の売上高・営業利益の増加率(小さい方)が設備投資・有形資産・人員・人件費の増加率(大きい方)を上回ったか — 厳しい基準である。どの投入が妨げたかは表で見る。

Source: DART, Financial Supervisory Service.
Limitations: 매출·영업이익·설비투자·유형자산 = 연결 재무제표 · 인원·인건비 = 사업보고서 '직원 등의 현황'(그 회사 자신만 — 해외 판매법인 인원은 빠진다) · 연평균 = 첫 해와 마지막 해의 복리 증가율 · 합병이 낀 해는 범위 변화가 섞인다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: Revenue, operating profit, capex and PP&E = consolidated financial statements · headcount and payroll = 'employee status' in the annual report (the company itself only — staff at overseas sales subsidiaries are excluded) · average annual = compound growth between the first and last year · years that include a merger mix in a change of scope.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 売上高・営業利益・設備投資・有形資産 = 連結財務諸表 · 人員・人件費 = 事業報告書「従業員等の現況」(その会社自身のみ — 海外販売法人の人員は含まない) · 年平均 = 初年と最終年の複利増加率 · 合併を含む年は範囲の変化が混ざる。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

밸류ValuationバリュエーションDaewoong (holding) and Daewoong Pharm: trailing P/E and P/B on KRX market cap (treasury excluded)

회사KRX 시총자기주식자기주식 뺀 시총최근 4분기 순이익P/EP/E(세후 영업이익)P/B이익수익률
대웅(지주)0.94조27.7%0.68조1,794억3.8배3.0배0.54배26.5%
대웅제약1.21조0.7%1.20조1,955억6.1배6.3배1.12배16.3%

KRX 2026-11-10 · 순이익 = 지배주주

CompanyKRX market capTreasury sharesMarket cap ex-treasuryNet profit, last 4 quartersP/EP/E (after-tax operating profit)P/BEarnings yield
Daewoong (hold.)KRW 0.94trn27.7%KRW 0.68trn1,794 KRW 100mn3.8x3.0x0.54x26.5%
Daewoong PharmKRW 1.21trn0.7%KRW 1.20trn1,955 KRW 100mn6.1x6.3x1.12x16.3%

KRX 2026-11-10 · net profit = attributable to owners

会社KRX時価総額自己株式自己株式を除く時価総額直近4四半期の純利益PERPER(税引後営業利益)PBR益回り
Daewoong (hold.)0.94兆ウォン27.7%0.68兆ウォン1,794億ウォン3.8倍3.0倍0.54倍26.5%
Daewoong Pharm1.21兆ウォン0.7%1.20兆ウォン1,955億ウォン6.1倍6.3倍1.12倍16.3%

KRX 2026-11-10 · 純利益 = 親会社株主帰属

대웅: 자기주식 뺀 시총 0.68조 ÷ 최근 4분기(2025Q3~2026Q2) 지배주주 순이익 1,794억 = P/E 3.8배 · P/B 0.54배 · 이익수익률 26.5%. 대웅제약: P/E 6.1배 · P/B 1.12배.

Daewoong (hold.): market cap excluding treasury shares KRW 0.68trn ÷ net profit attributable to owners over the last four quarters (2025Q3–2026Q2) 1,794 KRW 100mn = P/E 3.8x · P/B 0.54x · earnings yield 26.5%. Daewoong Pharm: P/E 6.1x · P/B 1.12x.

Daewoong (hold.):自己株式を除いた時価総額0.68兆ウォン ÷ 直近4四半期(2025Q3〜2026Q2)の親会社株主に帰属する純利益1,794億ウォン = PER 3.8倍 · PBR 0.54倍 · 益回り26.5%。Daewoong Pharm:PER 6.1倍 · PBR 1.12倍。

Source: DART, Financial Supervisory Service.
Source: Korea Exchange (KRX). 본 차트는 “한국거래소 통계정보”를 사용한 결과임.
Limitations: KRX 시가총액 × (1 − 자기주식 비율) · 순이익 = 분기보고서 지배주주 순이익 최근 4분기 · 세후 영업이익 = 영업이익 × (1 − FY 유효세율) · 지주 연결 순이익엔 자회사 몫이 들어 있다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Source: Korea Exchange (KRX). 본 차트는 “한국거래소 통계정보”를 사용한 결과임.
Limitations: KRX market cap × (1 − treasury-share ratio) · net profit = net profit attributable to owners from the quarterly reports, last four quarters · after-tax operating profit = operating profit × (1 − FY effective tax rate) · the holding company's consolidated net profit includes the subsidiaries' share.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Source: Korea Exchange (KRX). 본 차트는 “한국거래소 통계정보”를 사용한 결과임.
Limitations: KRX時価総額 ×(1 − 自己株式比率) · 純利益 = 四半期報告書の親会社株主に帰属する純利益の直近4四半期 · 税引後営業利益 = 営業利益 ×(1 − FY実効税率) · 持株会社の連結純利益には子会社の分が入っている。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

지분 사슬Ownership chain持株チェーンDaewoong (hold.): economic interest of the controlling family vs. voting control (look-through)

첫 단계 보유자관계지분율자기주식 뺀 몫그 경로로 가족에게경로
윤재승본인11.64%16.10%16.10%가족
대웅재단재단9.98%13.80%0.00%재단
윤재용친인척7.01%9.70%9.70%가족
윤영친인척5.42%7.50%7.50%가족
(주)하나누리기타1.77%2.45%0.00%비상장 법인(위 확인 안 함)
(주)디엔홀딩스기타1.77%2.45%0.00%비상장 법인(위 확인 안 함)
(주)블루넷기타0.26%0.36%0.00%비상장 법인(위 확인 안 함)
윤재춘임원0.08%0.11%0.00%임원

경제적 몫 = 경로마다 (지분율 ÷ (1 − 그 회사 자기주식)) 을 곱해 더한 값 · 2026H1 기준

First-tier holderRelationStakeShare ex-treasuryTo the family via this pathPath
Yun Jaeseungself11.64%16.10%16.10%family
Daeungjaedanfoundation9.98%13.80%0.00%foundation
Yun Jaeyongrelative7.01%9.70%9.70%family
Yun Yeongrelative5.42%7.50%7.50%family
Hananuriother1.77%2.45%0.00%unlisted corporate (owners not checked)
Dienholdingseuother1.77%2.45%0.00%unlisted corporate (owners not checked)
Beul Runetother0.26%0.36%0.00%unlisted corporate (owners not checked)
Yun Jaechunexecutive0.08%0.11%0.00%executive

Economic interest = sum over paths of the product of (stake ÷ (1 − that company's treasury shares)) · as of 2026H1

第1段階の保有者関係持株比率自己株式を除いた持分この経路で家族へ経路
Yun Jaeseung本人11.64%16.10%16.10%家族
Daeungjaedan財団9.98%13.80%0.00%財団
Yun Jaeyong親族7.01%9.70%9.70%家族
Yun Yeong親族5.42%7.50%7.50%家族
Hananuriその他1.77%2.45%0.00%非上場法人(上位は未確認)
Dienholdingseuその他1.77%2.45%0.00%非上場法人(上位は未確認)
Beul Runetその他0.26%0.36%0.00%非上場法人(上位は未確認)
Yun Jaechun役員0.08%0.11%0.00%役員

経済的持分 = 経路ごとに(持株比率 ÷(1 − その会社の自己株式))を掛け合わせて足した値 · 2026H1基準

최대주주 측 38.0% · 자기주식 27.7% → 의결권 기준 52.6%. 지배 가족(사슬 어느 표에서든 본인·친인척·특수관계인)의 이 회사 이익에 대한 경제적 몫 33.3% (윤재승 16.1% · 윤재용 9.7% · 윤영 7.5% · 윤수민 0.0% · 윤수진 0.0%) → 지배-소유 괴리 19.3%p. 위를 모르는 비상장 법인 (주)블루넷, (주)하나누리, (주)디엔홀딩스 몫 5.3%는 그 주주가 Raw Data 에 없어 가족 몫에 넣지 못했다(확인 안 함) — 가족 몫은 하한이다. 추이: 2019Q1 최대주주 본인 11.61% · 측 합 38.14% → 2026H1 11.64% · 38.04%. 이 회사가 가진 상장 지분 시가 0.65조 = 자기주식 뺀 시총의 96%.

Largest-shareholder group 38.0% · treasury shares 27.7% → 52.6% on a voting basis. The controlling family's economic interest in this company's earnings (anyone listed as self, relative or related party in any table along the chain) 33.3% (Yun Jaeseung 16.1% · Yun Jaeyong 9.7% · Yun Yeong 7.5% · Yun Sumin 0.0% · Yun Sujin 0.0%) → control–ownership wedge 19.3pp. The 5.3% held by unlisted corporates whose owners are unknown (Beul Runet, Hananuri, Dienholdingseu) could not be added to the family's share because their shareholders are not in the Raw Data (not checked) — the family share is a lower bound. Trend: 2019Q1 largest shareholder alone 11.61% · group total 38.14% → 2026H1 11.64% · 38.04%. Market value of the listed stakes this company owns: KRW 0.65trn = 96% of its market cap excluding treasury shares.

筆頭株主側38.0% · 自己株式27.7% → 議決権ベース52.6%。支配家族(チェーン上のどの表でも本人・親族・特別関係者とされた人)のこの会社の利益に対する経済的持分33.3%(Yun Jaeseung 16.1% · Yun Jaeyong 9.7% · Yun Yeong 7.5% · Yun Sumin 0.0% · Yun Sujin 0.0%) → 支配と所有の乖離19.3%pt。上位の株主が不明な非上場法人(Beul Runet、Hananuri、Dienholdingseu)の持分5.3%は、その株主がRaw Dataにないため家族の持分に入れられなかった(未確認) — 家族の持分は下限である。推移:2019Q1 筆頭株主本人11.61% · 側の合計38.14% → 2026H1 11.64% · 38.04%。この会社が保有する上場株式の時価0.65兆ウォン = 自己株式を除いた時価総額の96%。

⚠ 규율: 윤재승 개인의 경제적 몫은 대웅 16.1% · 대웅제약 8.6% · 한올바이오파마 2.7% — 내려갈수록 줄고, 의결권 기준 지배 측은 52.6% · 61.8% · 32.0%로 그대로다.

⚠ Discipline: Yun Jaeseung's personal economic interest is 16.1% in Daewoong (hold.) · 8.6% in Daewoong Pharm · 2.7% in HanAll — it shrinks further down the chain, while the controlling side on a voting basis stays at 52.6% · 61.8% · 32.0%.

⚠ 規律:Yun Jaeseung個人の経済的持分はDaewoong (hold.) 16.1% · Daewoong Pharm 8.6% · HanAll 2.7% — 下に行くほど小さくなり、議決権ベースの支配側は52.6% · 61.8% · 32.0%のままである。

Source: DART, Financial Supervisory Service.
Limitations: DART 최대주주 현황(보통주, 최신 분기)을 사슬 위 상장사까지 이었다 · 자기주식은 의결권·배당이 없어 분모에서 뺐다 · 우선주·전환사채·담보는 반영하지 않았다 · 비상장 법인의 주주는 Raw Data 에 없다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: DART largest-shareholder tables (common shares, latest quarter) linked up to the listed companies above in the chain · treasury shares carry no votes or dividends, so they are taken out of the denominator · preferred shares, convertible bonds and pledges are not reflected · the shareholders of unlisted corporates are not in the Raw Data.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: DART筆頭株主状況(普通株、最新四半期)をチェーン上位の上場会社までつないだ · 自己株式は議決権・配当がないので分母から除いた · 優先株・転換社債・担保は反映していない · 非上場法人の株主はRaw Dataにない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

운전자본Working capital運転資本Daewoong (hold.): inventory and receivable days, net debt

Daewoong (hold.) — working capital daysdays · Data as of 2025-12 · Created 2026-11-13020.040.060.080.0FY18FY19FY20FY21FY22FY23FY24FY25daysInventory days (÷ COGS)Receivable days (÷ revenue)47.2

FY2025: 재고 0.44조 (0일), 매출채권 0.27조 (47일), 순차입금 0.59조 (차입금 기준).

FY2025: inventories KRW 0.44trn (0 days), receivables KRW 0.27trn (47 days), net debt KRW 0.59trn (borrowings basis).

FY2025:棚卸資産0.44兆ウォン(0日)、売上債権0.27兆ウォン(47日)、純有利子負債0.59兆ウォン(借入金ベース)。

Source: DART, Financial Supervisory Service.
Limitations: 연말 잔액 ÷ 연간 흐름 × 365(재고는 매출원가, 매출채권은 매출) — 결산일 계절성이 섞인다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: Year-end balance ÷ annual flow × 365 (cost of sales for inventories, revenue for receivables) — year-end seasonality is mixed in.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 年末残高 ÷ 年間フロー × 365(棚卸資産は売上原価、売上債権は売上高) — 決算日の季節性が混ざる。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

지분Ownership持株Daewoong (hold.): largest shareholder and treasury shares by quarter

Daewoong (hold.) — ownershippercent of common shares · Data as of 2026H1 · Created 2026-11-130%10%20%30%40%50%19Q119Q420Q321Q222Q122Q423Q324Q225Q125Q426Q2%Largest holder + related (%)Largest holder alone (%)+38.0%+11.6%
기간취득소각기말 자기주식
2023FY690,630017,251,270
2024H1690,630017,251,270
2024FY690,630017,251,270
2025H10017,251,270
2025Q30017,251,270
2025FY0016,669,850
2026Q10016,105,105
2026H10016,105,105
PeriodAcquiredCancelledTreasury shares at period end
2023FY690,630017,251,270
2024H1690,630017,251,270
2024FY690,630017,251,270
2025H10017,251,270
2025Q30017,251,270
2025FY0016,669,850
2026Q10016,105,105
2026H10016,105,105
期間取得消却期末自己株式
2023FY690,630017,251,270
2024H1690,630017,251,270
2024FY690,630017,251,270
2025H10017,251,270
2025Q30017,251,270
2025FY0016,669,850
2026Q10016,105,105
2026H10016,105,105

최신 2026H1: 윤재승(본인) 11.64% · 윤재용(친인척) 7.01% · 윤영(친인척) 5.42% · 대웅재단(재단) 9.98% · (주)하나누리(기타) 1.77% · (주)디엔홀딩스(기타) 1.77%. 자기주식 27.7% · 최대주주 변동: - - n/a.

Latest 2026H1: Yun Jaeseung (self) 11.64% · Yun Jaeyong (relative) 7.01% · Yun Yeong (relative) 5.42% · Daeungjaedan (foundation) 9.98% · Hananuri (other) 1.77% · Dienholdingseu (other) 1.77%. Treasury shares 27.7% · changes of largest shareholder: - - n/a.

最新2026H1:Yun Jaeseung(本人)11.64% · Yun Jaeyong(親族)7.01% · Yun Yeong(親族)5.42% · Daeungjaedan(財団)9.98% · Hananuri(その他)1.77% · Dienholdingseu(その他)1.77%。自己株式27.7% · 筆頭株主の変動:- - n/a。

⚠ 규율: 자기주식 소각은 발행주식을 줄여 최대주주 지분율을 올린다.

⚠ Discipline: Cancelling treasury shares reduces the shares in issue and raises the largest shareholder's percentage.

⚠ 規律:自己株式の消却は発行済株式を減らし、筆頭株主の持株比率を上げる。

Source: DART, Financial Supervisory Service.
Limitations: DART 최대주주 현황(보통주) · 개인 지배주주의 간접 지분은 이 표에 없다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: DART largest-shareholder table (common shares) · indirect stakes of individual controlling shareholders are not in this table.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: DART筆頭株主状況(普通株) · 個人の支配株主の間接持分はこの表にない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

지분도Ownership map持株関係図Daewoong (hold.): ownership chain (largest-shareholder tables)

Daewoong (hold.) — ownership chain from largest-shareholder tables, 2026H1percent · Data as of 2026H1 · Created 2026-11-1352.3%30.8%11.6%10.0%8.6%7.0%5.4%1.8%1.8%DaeungjaedanDienholdingseuHananuriYun JaeseungYun JaeyongYun YeongDaewoongDaewoong PharmaHanall Biopharma

(주)대웅 → 대웅제약 52.29% · (주)대웅제약 → 한올바이오파마 30.80% · 윤재승 → 대웅 11.64% · 대웅재단 → 대웅 9.98% · 윤재용 → 대웅 7.01% · 윤영 → 대웅 5.42% · (주)하나누리 → 대웅 1.77% · (주)디엔홀딩스 → 대웅 1.77%.

Daewoong → Daewoong Pharma 52.29% · Daewoong Pharma → Hanall Biopharma 30.80% · Yun Jaeseung → Daewoong 11.64% · Daeungjaedan → Daewoong 9.98% · Yun Jaeyong → Daewoong 7.01% · Yun Yeong → Daewoong 5.42% · Hananuri → Daewoong 1.77% · Dienholdingseu → Daewoong 1.77%.

Daewoong → Daewoong Pharma 52.29% · Daewoong Pharma → Hanall Biopharma 30.80% · Yun Jaeseung → Daewoong 11.64% · Daeungjaedan → Daewoong 9.98% · Yun Jaeyong → Daewoong 7.01% · Yun Yeong → Daewoong 5.42% · Hananuri → Daewoong 1.77% · Dienholdingseu → Daewoong 1.77%。

⚠ 규율: 이 그룹은 '계열회사간 출자현황'을 그림으로만 공시한다 — 각 회사 DART 최대주주 표(2026H1)를 이름으로 이었다. 개인 → 지주 → 사업회사 → 손자회사 순.

⚠ Discipline: This group files its 'cross-shareholdings among affiliates' only as an image — we joined each company's DART largest-shareholder table (2026H1) by name. Order: individuals → holding company → operating company → second-tier subsidiary.

⚠ 規律:このグループは「系列会社間の出資状況」を図でのみ開示する — 各社のDART筆頭株主表(2026H1)を名前でつないだ。個人 → 持株会社 → 事業会社 → 孫会社の順。

Source: DART, Financial Supervisory Service.
Limitations: 각 회사 DART 최대주주 현황(보통주, 최신 분기)을 이름으로 이었다 · 화살표 = 출자 → 피출자 · 1% 미만 지분은 그리지 않았다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: Each company's DART largest-shareholder table (common shares, latest quarter) joined by name · arrow = investor → investee · stakes below 1% are not drawn.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 各社のDART筆頭株主状況(普通株、最新四半期)を名前でつないだ · 矢印 = 出資者 → 出資先 · 1%未満の持分は描いていない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

설비Plant設備Daewoong (hold.): capacity, output and utilization (annual report tables)

표항목당기전기전전기
capacity8시간 / 161시간 / 1,936시간
production의약품1,936.01,160.060.0
utilization의약품1,936.01,160.060.0
TableItemCurrent periodPrior periodTwo periods ago
Capacity8시간 / 161시간 / 1,936시간
Output의약품1,936.01,160.060.0
Utilisation의약품1,936.01,160.060.0
表項目当期前期前々期
生産能力8시간 / 161시간 / 1,936시간
生産実績의약품1,936.01,160.060.0
稼働率의약품1,936.01,160.060.0

생산능력·생산실적·가동률 표(단위는 표 기준: 배치 등).

Capacity, output and utilisation tables (units as in each table: batches etc.).

生産能力・生産実績・稼働率の表(単位は表の基準:バッチ等)。

Source: DART, Financial Supervisory Service.
Limitations: 사업보고서 생산능력·생산실적·가동률 표 그대로(단위는 표 기준).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: Capacity, output and utilisation tables from the annual report as filed (units as in each table).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 事業報告書の生産能力・生産実績・稼働率の表のまま(単位は表の基準)。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

구조Structure構造Daewoong (hold.): structural events, pipeline and licenses (annual report text)

구 분품 목적응증연구시작일현재 진행단계비 고
바이오신약HL036안구건조증2016년임상 3-3상(미국)
DWP4571, 2형 당뇨병2013년전임상--
DWP713입술 볼륨 증대2021년비임상-공동연구(시지바이오)
DWP714연골조직수복2021년비임상-공동연구(시지바이오)
HL186/HL187불응성 고형암2016년HL186: 후보물질도출(중단)HL187: 전임상(중단)-공동연구(한올바이오파마)
DWP817S004근감소증2022년비임상--
DWP431퇴행성 추간판 질환(Degenerative DiscDisease)2019년융복합의료기기 임상시험(IDE) 신청 승인(미국)2025년 4월공동연구(시지바이오)
BiologicsDWP450(나보타)미간주름2012년품목허가(한국)2013년 11월
2013년품목허가(캐나다)품목허가(미국)품목허가(EU)2018년 8월2019년 2월2019년 9월-
2015년품목허가 신청(중국)--
뇌졸중 후 상지근육경직2013년적응증 추가(한국)2015년 11월-
눈가주름(외안각주름)2016년적응증 추가(한국)2018년 11월-

합병·분할 주석 없음.

No merger or spin-off note.

合併・分割の注記なし。

⚠ 규율: 파이프라인 17건 · 라이선스 아웃 11건 · 인 2건(원문 표 기준).

⚠ Discipline: Pipeline 17 · licence-out 11 · licence-in 2 (as in the original tables).

⚠ 規律:パイプライン17件 · ライセンスアウト11件 · イン2件(原文の表ベース)。

Source: DART, Financial Supervisory Service.
Limitations: 회사 공시 원문 값을 옮겼다 — 재표시·서식 변경·합병·분할이 있는 해는 앞뒤가 같은 범위가 아니다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: Values are taken from the companies' own filings — years with restatements, format changes, mergers or spin-offs do not cover the same scope as the years around them.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 企業の開示原文の値を転記した — 再表示・様式変更・合併・分割のある年は前後と同じ範囲ではない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

08

지분 구조 — 최대주주·자기주식Ownership structure — largest shareholders and treasury shares持株構造 — 筆頭株主・自己株式

지분Ownership持株Largest-shareholder group and treasury shares, latest quarter

Ownership snapshotpercent of common shares · Data as of 2026H1 · Created 2026-11-130%20%40%60%80%100%SamsungBioCelltrionYuhanDW HoldGC BioChongKDDW PharmHanmiSD BioSKBiopharmSKBioSciHanAll%Largest holder + related (%)Treasury shares (%)
회사최대주주본인 %특수관계인 포함 %자기주식 %기준
삼성바이오삼성물산43.06%74.30%0.1%2026H1
셀트리온(주)셀트리온홀딩스25.85%32.69%1.7%2026H1
유한양행유한재단15.93%16.03%7.6%2026H1
대웅(지주)윤재승11.64%38.04%27.7%2026H1
GC녹십자㈜녹십자홀딩스50.06%51.41%2.3%2026H1
종근당(주)종근당홀딩스26.70%40.15%4.5%2026H1
대웅제약(주)대웅52.29%61.33%0.7%2026H1
한미약품한미사이언스(주)41.42%50.09%1.0%2026H1
SD바이오센서조영식27.24%72.49%0.9%2026H1
SK바이오팜SK(주)50.10%50.10%n/a2026H1
SK바이오사이언스SK케미칼(주)66.35%66.44%0.5%2026H1
한올바이오파마(주)대웅제약30.80%31.20%2.6%2026H1
CompanyLargest shareholderOwn %Incl. related parties %Treasury shares %As of
Samsung BioSamsung C&T43.06%74.30%0.1%2026H1
CelltrionSelteurionholdingseu25.85%32.69%1.7%2026H1
YuhanYuhanjaedan15.93%16.03%7.6%2026H1
Daewoong (hold.)Yun Jaeseung11.64%38.04%27.7%2026H1
GC BiopharmaGC50.06%51.41%2.3%2026H1
Chong Kun DangChongkundang Holdings26.70%40.15%4.5%2026H1
Daewoong PharmDaewoong52.29%61.33%0.7%2026H1
HanmiHanmi Science41.42%50.09%1.0%2026H1
SD BiosensorJo Yeongsik27.24%72.49%0.9%2026H1
SK BiopharmSK50.10%50.10%n/a2026H1
SK BioscienceSK Chemicals66.35%66.44%0.5%2026H1
HanAllDaewoong Pharma30.80%31.20%2.6%2026H1
会社筆頭株主本人 %特別関係者を含む %自己株式 %基準
Samsung BioSamsung C&T43.06%74.30%0.1%2026H1
CelltrionSelteurionholdingseu25.85%32.69%1.7%2026H1
YuhanYuhanjaedan15.93%16.03%7.6%2026H1
Daewoong (hold.)Yun Jaeseung11.64%38.04%27.7%2026H1
GC BiopharmaGC50.06%51.41%2.3%2026H1
Chong Kun DangChongkundang Holdings26.70%40.15%4.5%2026H1
Daewoong PharmDaewoong52.29%61.33%0.7%2026H1
HanmiHanmi Science41.42%50.09%1.0%2026H1
SD BiosensorJo Yeongsik27.24%72.49%0.9%2026H1
SK BiopharmSK50.10%50.10%n/a2026H1
SK BioscienceSK Chemicals66.35%66.44%0.5%2026H1
HanAllDaewoong Pharma30.80%31.20%2.6%2026H1

삼성바이오: 삼성물산 43.1% (계 74.3%) · 셀트리온: (주)셀트리온홀딩스 25.9% (계 32.7%) · 유한양행: 유한재단 15.9% (계 16.0%) · 대웅(지주): 윤재승 11.6% (계 38.0%) · GC녹십자: ㈜녹십자홀딩스 50.1% (계 51.4%) · 종근당: (주)종근당홀딩스 26.7% (계 40.1%) · 대웅제약: (주)대웅 52.3% (계 61.3%) · 한미약품: 한미사이언스(주) 41.4% (계 50.1%) · SD바이오센서: 조영식 27.2% (계 72.5%) · SK바이오팜: SK(주) 50.1% (계 50.1%) · SK바이오사이언스: SK케미칼(주) 66.3% (계 66.4%) · 한올바이오파마: (주)대웅제약 30.8% (계 31.2%).

Samsung Bio: Samsung C&T 43.1% (total 74.3%) · Celltrion: Selteurionholdingseu 25.9% (total 32.7%) · Yuhan: Yuhanjaedan 15.9% (total 16.0%) · Daewoong (hold.): Yun Jaeseung 11.6% (total 38.0%) · GC Biopharma: GC 50.1% (total 51.4%) · Chong Kun Dang: Chongkundang Holdings 26.7% (total 40.1%) · Daewoong Pharm: Daewoong 52.3% (total 61.3%) · Hanmi: Hanmi Science 41.4% (total 50.1%) · SD Biosensor: Jo Yeongsik 27.2% (total 72.5%) · SK Biopharm: SK 50.1% (total 50.1%) · SK Bioscience: SK Chemicals 66.3% (total 66.4%) · HanAll: Daewoong Pharma 30.8% (total 31.2%).

Samsung Bio:Samsung C&T 43.1%(計74.3%) · Celltrion:Selteurionholdingseu 25.9%(計32.7%) · Yuhan:Yuhanjaedan 15.9%(計16.0%) · Daewoong (hold.):Yun Jaeseung 11.6%(計38.0%) · GC Biopharma:GC 50.1%(計51.4%) · Chong Kun Dang:Chongkundang Holdings 26.7%(計40.1%) · Daewoong Pharm:Daewoong 52.3%(計61.3%) · Hanmi:Hanmi Science 41.4%(計50.1%) · SD Biosensor:Jo Yeongsik 27.2%(計72.5%) · SK Biopharm:SK 50.1%(計50.1%) · SK Bioscience:SK Chemicals 66.3%(計66.4%) · HanAll:Daewoong Pharma 30.8%(計31.2%)。

Source: DART, Financial Supervisory Service.
Limitations: DART 최대주주 현황·주식총수(보통주) · 회사마다 기준 분기가 다를 수 있다(표의 기준 열).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: DART largest-shareholder and total-shares tables (common shares) · the reference quarter may differ by company (the 'As of' column).
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: DART筆頭株主状況・株式総数(普通株) · 会社ごとに基準四半期が異なりうる(表の基準列)。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

이익의 주인Who owns the earnings利益の持ち主Who owns the earnings: look-through economic interest by holder type (treasury shares excluded)

Economic interest by holder typepercent of shares outstanding ex-treasury · Data as of 2026_H1 · Created 2026-11-13025.050.075.0100125Samsung C&TSamsung LifeSamsung ElecSamsung BioCelltrionDW HoldDW PharmHanAll%Controlling family (look-through)Group foundationsUnlisted corporates (owners not in ledger)Executives / insurance special accountsOther shareholders35.762.310027.08.164.91008.790.210018.180.610028.566.810033.313.847.410018.015.963.210087.9100

삼성물산 가족 35.7% · 비상장 법인 0.0% · 삼성생명 가족 27.0% · 비상장 법인 0.0% · 삼성전자 가족 8.7% · 비상장 법인 0.0% · 삼성바이오로직스 가족 18.1% · 비상장 법인 0.0% · 셀트리온 가족 4.4% · 비상장 법인 28.5% · 대웅 가족 33.3% · 비상장 법인 5.3% · 대웅제약 가족 18.0% · 비상장 법인 2.8% · 한올바이오파마 가족 5.7% · 비상장 법인 0.9%.

Samsung C&T family 35.7% · unlisted corporates 0.0% · Samsung Life family 27.0% · unlisted corporates 0.0% · Samsung Elec family 8.7% · unlisted corporates 0.0% · Samsung Bio family 18.1% · unlisted corporates 0.0% · Celltrion family 4.4% · unlisted corporates 28.5% · DW Hold family 33.3% · unlisted corporates 5.3% · DW Pharm family 18.0% · unlisted corporates 2.8% · HanAll family 5.7% · unlisted corporates 0.9%.

Samsung C&T 家族35.7% · 非上場法人0.0% · Samsung Life 家族27.0% · 非上場法人0.0% · Samsung Elec 家族8.7% · 非上場法人0.0% · Samsung Bio 家族18.1% · 非上場法人0.0% · Celltrion 家族4.4% · 非上場法人28.5% · DW Hold 家族33.3% · 非上場法人5.3% · DW Pharm 家族18.0% · 非上場法人2.8% · HanAll 家族5.7% · 非上場法人0.9%。

⚠ 규율: 셀트리온의 회색(비상장 법인) 몫은 셀트리온홀딩스·스킨큐어 — 그 주주가 Raw Data 에 없어 가족 몫으로 옮기지 못했다.

⚠ Discipline: Celltrion's grey (unlisted corporates) share is Celltrion Holdings and Celltrion Skincare — their shareholders are not in the Raw Data, so it could not be moved into the family's share.

⚠ 規律:Celltrionの灰色(非上場法人)の持分はCelltrion HoldingsとCelltrion Skincareである — その株主がRaw Dataにないため家族の持分に移せなかった。

Source: DART, Financial Supervisory Service.
Limitations: DART 최대주주 현황(보통주)을 상장사끼리 이어 경로별 몫을 곱해 더했다 · 최대주주 표 밖의 주주는 '그 밖'에 들어간다 · 우선주·전환사채는 반영하지 않았다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: DART largest-shareholder tables (common shares) linked between listed companies, multiplying and adding the share along each path · shareholders outside the largest-shareholder tables fall under 'Other shareholders' · preferred shares and convertible bonds are not reflected.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: DART筆頭株主状況(普通株)を上場会社同士でつなぎ、経路ごとの持分を掛けて足した · 筆頭株主表の外の株主は「Other shareholders」に入る · 優先株・転換社債は反映していない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

지배 vs 소유Control vs ownership支配 vs 所有Voting control of the controlling group vs. the family's economic interest

Control vs. cash-flow rightspercent · Data as of 2026_H1 · Created 2026-11-13020.040.060.080.0100Samsung C&TSamsung LifeSamsung ElecSamsung BioCelltrionDW HoldDW PharmHanAll%Controlling group, voting basisFamily economic interest (look-through)37.748.520.074.433.252.661.832.035.727.08.718.14.433.318.05.7

삼성물산 지배 37.7% vs 몫 35.7% (괴리 2.0%p) · 삼성생명 지배 48.5% vs 몫 27.0% (괴리 21.5%p) · 삼성전자 지배 20.0% vs 몫 8.7% (괴리 11.2%p) · 삼성바이오로직스 지배 74.4% vs 몫 18.1% (괴리 56.3%p) · 셀트리온 지배 33.2% vs 몫 4.4% (괴리 28.8%p) · 대웅 지배 52.6% vs 몫 33.3% (괴리 19.3%p) · 대웅제약 지배 61.8% vs 몫 18.0% (괴리 43.8%p) · 한올바이오파마 지배 32.0% vs 몫 5.7% (괴리 26.4%p).

Samsung C&T control 37.7% vs interest 35.7% (wedge 2.0pp) · Samsung Life control 48.5% vs interest 27.0% (wedge 21.5pp) · Samsung Elec control 20.0% vs interest 8.7% (wedge 11.2pp) · Samsung Bio control 74.4% vs interest 18.1% (wedge 56.3pp) · Celltrion control 33.2% vs interest 4.4% (wedge 28.8pp) · DW Hold control 52.6% vs interest 33.3% (wedge 19.3pp) · DW Pharm control 61.8% vs interest 18.0% (wedge 43.8pp) · HanAll control 32.0% vs interest 5.7% (wedge 26.4pp).

Samsung C&T 支配37.7% vs 持分35.7%(乖離2.0%pt) · Samsung Life 支配48.5% vs 持分27.0%(乖離21.5%pt) · Samsung Elec 支配20.0% vs 持分8.7%(乖離11.2%pt) · Samsung Bio 支配74.4% vs 持分18.1%(乖離56.3%pt) · Celltrion 支配33.2% vs 持分4.4%(乖離28.8%pt) · DW Hold 支配52.6% vs 持分33.3%(乖離19.3%pt) · DW Pharm 支配61.8% vs 持分18.0%(乖離43.8%pt) · HanAll 支配32.0% vs 持分5.7%(乖離26.4%pt)。

⚠ 규율: 괴리가 큰 곳일수록 가족이 적은 경제적 몫으로 많은 의결권을 쥔다(계열사·재단을 거쳐). 셀트리온은 홀딩스 주주가 Raw Data 에 없어 괴리가 실제보다 크게 나온다.

⚠ Discipline: The wider the wedge, the more votes the family holds with a small economic interest (through affiliates and foundations). For Celltrion the wedge comes out larger than it really is because Celltrion Holdings' shareholders are not in the Raw Data.

⚠ 規律:乖離が大きいほど、家族は小さな経済的持分で多くの議決権を握る(系列会社・財団を通じて)。CelltrionはCelltrion Holdingsの株主がRaw Dataにないため、乖離が実際より大きく出る。

Source: DART, Financial Supervisory Service.
Limitations: 의결권 기준 = 최대주주 측 지분 ÷ (1 − 자기주식 비율) · 가족 몫 = 사슬 경로별 곱의 합 · 재단·계열사 지분은 지배 측에는 들어가고 가족 몫에는 안 들어간다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: Voting basis = largest-shareholder group stake ÷ (1 − treasury-share ratio) · family interest = sum of the products along the chain paths · stakes held by foundations and affiliates count towards the controlling side but not the family's interest.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 議決権ベース = 筆頭株主側の持分 ÷(1 − 自己株式比率) · 家族の持分 = チェーン経路ごとの積の合計 · 財団・系列会社の持分は支配側には入るが家族の持分には入らない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

지분도Ownership map持株関係図Yuhan: parent / subsidiaries / associates (annual report list)

지배기업 1개: ㈜유한양행 · 종속기업(연결대상) 15개: ㈜유한화학, ㈜유한메디카, ㈜와이즈메디, ㈜유한건강생활, 애드파마㈜, YUHAN USA CORPORATION… · 관계기업 및 공동기업 3개: (주)유한클로락스(舊, (주)유한크로락스), ㈜프로젠, 류신(칭다오)건강(유).

Parent (1): Yuhan · Subsidiaries (consolidated) (15): Yuhanhwahak, Yuhanmedika, Waijeumedi, Yuhangeongangsaenghwal, Aedeupama, YUHAN USA CORPORATION… · Associates and joint ventures (3): Yuhankeullorakseu(舊, Yuhankeurorakseu), ProGen, Ryusin(chingdao)geongang(yu).

親会社1社:Yuhan · 子会社(連結対象)15社:Yuhanhwahak、Yuhanmedika、Waijeumedi、Yuhangeongangsaenghwal、Aedeupama、YUHAN USA CORPORATION… · 関連会社及び共同支配企業3社:Yuhankeullorakseu(舊, Yuhankeurorakseu)、ProGen、Ryusin(chingdao)geongang(yu)。

⚠ 규율: 이 회사는 계열회사간 출자 행렬 대신 지배·종속 목록을 낸다 — 최대주주(유한재단 15.9%)는 법인이 아닌 경우 이 목록에 없다.

⚠ Discipline: This company files a parent/subsidiary list instead of a cross-shareholding matrix — the largest shareholder (Yuhanjaedan 15.9%) is not on this list if it is not a corporation.

⚠ 規律:この会社は系列会社間の出資行列の代わりに支配・従属の一覧を出す — 筆頭株主(Yuhanjaedan 15.9%)は法人でなければこの一覧にない。

Source: DART, Financial Supervisory Service.
Limitations: 회사 공시 원문 값을 옮겼다 — 재표시·서식 변경·합병·분할이 있는 해는 앞뒤가 같은 범위가 아니다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: Values are taken from the companies' own filings — years with restatements, format changes, mergers or spin-offs do not cover the same scope as the years around them.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 企業の開示原文の値を転記した — 再表示・様式変更・合併・分割のある年は前後と同じ範囲ではない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

지분도Ownership map持株関係図GC Biopharma: ownership map

GC Biopharma — domestic cross-shareholdings, FY2020percent · Data as of FY2020 · Created 2026-11-13100%100%90.0%81.4%53.1%50.1%46.9%41.5%GCGC BiopharmaCurevo, Inc.GC DO BRASIL PA…GC MOGAM, Inc.GC Medical Scie…Green Cross Nor…Nongeophoesabeo…

㈜녹십자 → GC MOGAM, Inc. 100.00% · ㈜녹십자 → GC DO BRASIL PARTICIPACOES LTDA 99.99% · ㈜녹십자 → 농업회사법인 인백팜㈜ 89.98% · ㈜녹십자 → Curevo, Inc. 81.36% · ㈜녹십자 홀딩스 → ㈜녹십자 50.06% · ㈜녹십자 → Green Cross North America Inc 46.85% · ㈜녹십자 → ㈜녹십자엠에스 41.51% · ㈜녹십자 → ㈜녹십자랩셀 38.66%.

GC Biopharma → GC MOGAM, Inc. 100.00% · GC Biopharma → GC DO BRASIL PARTICIPACOES LTDA 99.99% · GC Biopharma → Nongeophoesabeopin Inbaekpam 89.98% · GC Biopharma → Curevo, Inc. 81.36% · GC → GC Biopharma 50.06% · GC Biopharma → Green Cross North America Inc 46.85% · GC Biopharma → GC Medical Science 41.51% · GC Biopharma → Noksipjaraepsel 38.66%.

GC Biopharma → GC MOGAM, Inc. 100.00% · GC Biopharma → GC DO BRASIL PARTICIPACOES LTDA 99.99% · GC Biopharma → Nongeophoesabeopin Inbaekpam 89.98% · GC Biopharma → Curevo, Inc. 81.36% · GC → GC Biopharma 50.06% · GC Biopharma → Green Cross North America Inc 46.85% · GC Biopharma → GC Medical Science 41.51% · GC Biopharma → Noksipjaraepsel 38.66%。

⚠ 규율: 원문 '계열회사간 출자현황'(FY2020). 개인 지배주주의 지주회사 지분은 지주회사 자신의 공시에 있다.

⚠ Discipline: Original 'cross-shareholdings among affiliates' table (FY2020). Individual controlling shareholders' stakes in the holding company are in the holding company's own filings.

⚠ 規律:原文「系列会社間の出資状況」(FY2020)。個人の支配株主の持株会社への持分は持株会社自身の開示にある。

Source: DART, Financial Supervisory Service.
Limitations: 출자 행렬 또는 각 회사 최대주주 표를 이름으로 이었다 · 화살표 = 출자 → 피출자 · 1% 미만 지분은 그리지 않았다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: The investment matrix or each company's largest-shareholder table, joined by name · arrow = investor → investee · stakes below 1% are not drawn.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 出資行列または各社の筆頭株主表を名前でつないだ · 矢印 = 出資者 → 出資先 · 1%未満の持分は描いていない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

지분도Ownership map持株関係図Chong Kun Dang: ownership map

Chong Kun Dang — ownership chain from largest-shareholder tables, 2026H1percent · Data as of 2026H1 · Created 2026-11-1326.7%9.6%1.5%1.2%1.2%Chongkundang Holdin…I JanghanI JuaI JugyeongI JuwonChong Kun Dang Pharmaceutical

(주)종근당홀딩스 → 종근당 26.70% · 이장한 → 종근당 9.55% · 이주원 → 종근당 1.48% · 이주경 → 종근당 1.18% · 이주아 → 종근당 1.18%.

Chongkundang Holdings → Chong Kun Dang Pharmaceutical 26.70% · I Janghan → Chong Kun Dang Pharmaceutical 9.55% · I Juwon → Chong Kun Dang Pharmaceutical 1.48% · I Jugyeong → Chong Kun Dang Pharmaceutical 1.18% · I Jua → Chong Kun Dang Pharmaceutical 1.18%.

Chongkundang Holdings → Chong Kun Dang Pharmaceutical 26.70% · I Janghan → Chong Kun Dang Pharmaceutical 9.55% · I Juwon → Chong Kun Dang Pharmaceutical 1.48% · I Jugyeong → Chong Kun Dang Pharmaceutical 1.18% · I Jua → Chong Kun Dang Pharmaceutical 1.18%。

⚠ 규율: 각 회사 DART '최대주주 현황'(2026H1)을 이름으로 이어 붙였다 — 이 회사는 계열 출자 현황을 표로 내지 않는다(그림 또는 미기재). 개인 지배주주의 지주회사 지분은 지주회사 자신의 공시에 있다.

⚠ Discipline: Each company's DART 'largest shareholder status' table (2026H1) joined by name — this company does not file its affiliate shareholdings as a table (image only or not stated). Individual controlling shareholders' stakes in the holding company are in the holding company's own filings.

⚠ 規律:各社のDART「筆頭株主状況」(2026H1)を名前でつないだ — この会社は系列出資状況を表で出さない(図のみ、または未記載)。個人の支配株主の持株会社への持分は持株会社自身の開示にある。

Source: DART, Financial Supervisory Service.
Limitations: 출자 행렬 또는 각 회사 최대주주 표를 이름으로 이었다 · 화살표 = 출자 → 피출자 · 1% 미만 지분은 그리지 않았다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: The investment matrix or each company's largest-shareholder table, joined by name · arrow = investor → investee · stakes below 1% are not drawn.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 出資行列または各社の筆頭株主表を名前でつないだ · 矢印 = 出資者 → 出資先 · 1%未満の持分は描いていない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

지분도Ownership map持株関係図Hanmi: ownership map

Hanmi — domestic cross-shareholdings, FY2025percent · Data as of FY2025 · Created 2026-11-13100%100%100%63.0%41.4%Hanmi ScienceHanmi PharmBukgyeonghanmiITyuhangong…Hanmi Europe Ltd.HanmijeongmilhwahakIlbonhanmiyakpum

한미약품(주) → 일본한미약품(주) 100.00% · 한미약품(주) → Hanmi Europe Ltd. 100.00% · 한미약품(주) → 북경한미IT유한공사 100.00% · 한미약품(주) → 한미정밀화학(주) 63.00% · 한미사이언스(주) → 한미약품(주) 41.40%.

Hanmi Pharm → Ilbonhanmiyakpum 100.00% · Hanmi Pharm → Hanmi Europe Ltd. 100.00% · Hanmi Pharm → BukgyeonghanmiITyuhangongsa 100.00% · Hanmi Pharm → Hanmijeongmilhwahak 63.00% · Hanmi Science → Hanmi Pharm 41.40%.

Hanmi Pharm → Ilbonhanmiyakpum 100.00% · Hanmi Pharm → Hanmi Europe Ltd. 100.00% · Hanmi Pharm → BukgyeonghanmiITyuhangongsa 100.00% · Hanmi Pharm → Hanmijeongmilhwahak 63.00% · Hanmi Science → Hanmi Pharm 41.40%。

⚠ 규율: 원문 '계열회사간 출자현황'(FY2025). 개인 지배주주의 지주회사 지분은 지주회사 자신의 공시에 있다.

⚠ Discipline: Original 'cross-shareholdings among affiliates' table (FY2025). Individual controlling shareholders' stakes in the holding company are in the holding company's own filings.

⚠ 規律:原文「系列会社間の出資状況」(FY2025)。個人の支配株主の持株会社への持分は持株会社自身の開示にある。

Source: DART, Financial Supervisory Service.
Limitations: 출자 행렬 또는 각 회사 최대주주 표를 이름으로 이었다 · 화살표 = 출자 → 피출자 · 1% 미만 지분은 그리지 않았다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: The investment matrix or each company's largest-shareholder table, joined by name · arrow = investor → investee · stakes below 1% are not drawn.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 出資行列または各社の筆頭株主表を名前でつないだ · 矢印 = 出資者 → 出資先 · 1%未満の持分は描いていない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

지분도Ownership map持株関係図SD Biosensor: ownership map

SD Biosensor — ownership chain from largest-shareholder tables, 2026H1percent · Data as of 2026H1 · Created 2026-11-1337.7%27.2%3.5%2.6%BioNoteEseudibiinbeseuteumeonteuI HyogeunJo YeongsikSD Biosensor

주식회사 바이오노트 → 에스디바이오센서 37.66% · 조영식 → 에스디바이오센서 27.24% · 이효근 → 에스디바이오센서 3.50% · 에스디비인베스트먼트 주식회사 → 에스디바이오센서 2.63%.

BioNote → SD Biosensor 37.66% · Jo Yeongsik → SD Biosensor 27.24% · I Hyogeun → SD Biosensor 3.50% · Eseudibiinbeseuteumeonteu → SD Biosensor 2.63%.

BioNote → SD Biosensor 37.66% · Jo Yeongsik → SD Biosensor 27.24% · I Hyogeun → SD Biosensor 3.50% · Eseudibiinbeseuteumeonteu → SD Biosensor 2.63%。

⚠ 규율: 각 회사 DART '최대주주 현황'(2026H1)을 이름으로 이어 붙였다 — 이 회사는 계열 출자 현황을 표로 내지 않는다(그림 또는 미기재). 개인 지배주주의 지주회사 지분은 지주회사 자신의 공시에 있다.

⚠ Discipline: Each company's DART 'largest shareholder status' table (2026H1) joined by name — this company does not file its affiliate shareholdings as a table (image only or not stated). Individual controlling shareholders' stakes in the holding company are in the holding company's own filings.

⚠ 規律:各社のDART「筆頭株主状況」(2026H1)を名前でつないだ — この会社は系列出資状況を表で出さない(図のみ、または未記載)。個人の支配株主の持株会社への持分は持株会社自身の開示にある。

Source: DART, Financial Supervisory Service.
Limitations: 출자 행렬 또는 각 회사 최대주주 표를 이름으로 이었다 · 화살표 = 출자 → 피출자 · 1% 미만 지분은 그리지 않았다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: The investment matrix or each company's largest-shareholder table, joined by name · arrow = investor → investee · stakes below 1% are not drawn.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 出資行列または各社の筆頭株主表を名前でつないだ · 矢印 = 出資者 → 出資先 · 1%未満の持分は描いていない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

지분도Ownership map持株関係図SK Biopharm: ownership map

SK Biopharm — domestic cross-shareholdings, FY2025percent · Data as of FY2025 · Created 2026-11-1364.0%SKSKbaiopam

SK(주) → SK바이오팜 64.00%.

SK → SKbaiopam 64.00%.

SK → SKbaiopam 64.00%。

⚠ 규율: 원문 '계열회사간 출자현황'(FY2025). 개인 지배주주의 지주회사 지분은 지주회사 자신의 공시에 있다.

⚠ Discipline: Original 'cross-shareholdings among affiliates' table (FY2025). Individual controlling shareholders' stakes in the holding company are in the holding company's own filings.

⚠ 規律:原文「系列会社間の出資状況」(FY2025)。個人の支配株主の持株会社への持分は持株会社自身の開示にある。

Source: DART, Financial Supervisory Service.
Limitations: 출자 행렬 또는 각 회사 최대주주 표를 이름으로 이었다 · 화살표 = 출자 → 피출자 · 1% 미만 지분은 그리지 않았다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: The investment matrix or each company's largest-shareholder table, joined by name · arrow = investor → investee · stakes below 1% are not drawn.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 出資行列または各社の筆頭株主表を名前でつないだ · 矢印 = 出資者 → 出資先 · 1%未満の持分は描いていない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

지분도Ownership map持株関係図SK Bioscience: ownership map

SK Bioscience — domestic cross-shareholdings, FY2025percent · Data as of FY2025 · Created 2026-11-1366.4%40.8%SK DiscoverySK ChemicalsSK Bioscience

SK케미칼 → SK바이오사이언스 66.40%.

SK Chemicals → SK Bioscience 66.40%.

SK Chemicals → SK Bioscience 66.40%。

⚠ 규율: 원문 '계열회사간 출자현황'(FY2025). 개인 지배주주의 지주회사 지분은 지주회사 자신의 공시에 있다.

⚠ Discipline: Original 'cross-shareholdings among affiliates' table (FY2025). Individual controlling shareholders' stakes in the holding company are in the holding company's own filings.

⚠ 規律:原文「系列会社間の出資状況」(FY2025)。個人の支配株主の持株会社への持分は持株会社自身の開示にある。

Source: DART, Financial Supervisory Service.
Limitations: 출자 행렬 또는 각 회사 최대주주 표를 이름으로 이었다 · 화살표 = 출자 → 피출자 · 1% 미만 지분은 그리지 않았다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: The investment matrix or each company's largest-shareholder table, joined by name · arrow = investor → investee · stakes below 1% are not drawn.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 出資行列または各社の筆頭株主表を名前でつないだ · 矢印 = 出資者 → 出資先 · 1%未満の持分は描いていない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

09

Raw Data 상태Raw Data statusRaw Dataの状態

검증Check検証Ledger status

셀트리온: 패널 FY2018~2025 PASS1 OK · 원문 31건 · 삼성바이오: 패널 FY2019~2025 PASS1 OK · 원문 31건 · 유한양행: 패널 FY2018~2025 PASS1 OK · 원문 31건 · 한미약품: 패널 FY2018~2025 PASS1 OK · 원문 30건 · SK바이오팜: 패널 FY2019~2025 PASS1 OK · 원문 25건 · SK바이오사이언스: 패널 FY2021~2025 PASS1 OK · 원문 31건 · GC녹십자: 패널 FY2018~2025 PASS1 OK · 원문 31건 · 종근당: 패널 FY2018~2025 PASS1 OK · 원문 30건 · 대웅제약: 패널 FY2018~2025 PASS1 OK · 원문 31건 · 대웅(지주): 패널 FY2018~2025 PASS1 OK · 원문 31건 · 한올바이오파마: 패널 FY2018~2025 PASS1 OK · 원문 31건 · SD바이오센서: 패널 FY2020~2025 PASS1 OK · 원문 23건.

Celltrion: panel FY2018–2025 PASS1 OK · original filings 31 · Samsung Bio: panel FY2019–2025 PASS1 OK · original filings 31 · Yuhan: panel FY2018–2025 PASS1 OK · original filings 31 · Hanmi: panel FY2018–2025 PASS1 OK · original filings 30 · SK Biopharm: panel FY2019–2025 PASS1 OK · original filings 25 · SK Bioscience: panel FY2021–2025 PASS1 OK · original filings 31 · GC Biopharma: panel FY2018–2025 PASS1 OK · original filings 31 · Chong Kun Dang: panel FY2018–2025 PASS1 OK · original filings 30 · Daewoong Pharm: panel FY2018–2025 PASS1 OK · original filings 31 · Daewoong (hold.): panel FY2018–2025 PASS1 OK · original filings 31 · HanAll: panel FY2018–2025 PASS1 OK · original filings 31 · SD Biosensor: panel FY2020–2025 PASS1 OK · original filings 23.

Celltrion:パネルFY2018〜2025 PASS1 OK · 原文31件 · Samsung Bio:パネルFY2019〜2025 PASS1 OK · 原文31件 · Yuhan:パネルFY2018〜2025 PASS1 OK · 原文31件 · Hanmi:パネルFY2018〜2025 PASS1 OK · 原文30件 · SK Biopharm:パネルFY2019〜2025 PASS1 OK · 原文25件 · SK Bioscience:パネルFY2021〜2025 PASS1 OK · 原文31件 · GC Biopharma:パネルFY2018〜2025 PASS1 OK · 原文31件 · Chong Kun Dang:パネルFY2018〜2025 PASS1 OK · 原文30件 · Daewoong Pharm:パネルFY2018〜2025 PASS1 OK · 原文31件 · Daewoong (hold.):パネルFY2018〜2025 PASS1 OK · 原文31件 · HanAll:パネルFY2018〜2025 PASS1 OK · 原文31件 · SD Biosensor:パネルFY2020〜2025 PASS1 OK · 原文23件。

Source: DART, Financial Supervisory Service.
Limitations: 회사 공시 원문 값을 옮겼다 — 재표시·서식 변경·합병·분할이 있는 해는 앞뒤가 같은 범위가 아니다.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: Values are taken from the companies' own filings — years with restatements, format changes, mergers or spin-offs do not cover the same scope as the years around them.
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

Source: DART, Financial Supervisory Service.
Limitations: 企業の開示原文の値を転記した — 再表示・様式変更・合併・分割のある年は前後と同じ範囲ではない。
Processing: derived figures calculated by Adrenalin Baby; the source agencies are not responsible for them.
DISCLOSURE

Disclosure: Adrenalin Baby is the personal research activity of an individual. It is not, and is not affiliated with, any investment adviser, financial adviser, broker-dealer or financial institution. The information reflects the author's views, opinions and analyses as of the creation date shown and is provided for informational purposes only; it does not constitute an offer to sell or a solicitation of an offer to buy any security or investment product. Derived figures are calculated by Adrenalin Baby from third-party sources believed to be reliable but not independently verified; Adrenalin Baby makes no representation or warranty of any kind, express or implied, as to their accuracy, consistency, completeness or timeliness, and figures and calculations may contain errors. Any forward-looking statements involve risks and uncertainties, and actual results may differ materially. Nothing herein is legal, tax, accounting or investment advice; recipients should consult their own advisers. Past performance is not a guarantee or indicator of future results; every investment carries the risk of loss. Data sources, terms and attribution: www.adrenalinbaby.com/Adrenalinbaby_DataUsage

∞

천장 — 이 페이지가 말할 수 없는 것Ceilings — what this page cannot say限界 — このページが言えないこと

  • 시세(KRX 시가총액)는 심층 세 종목(셀트리온·삼성바이오로직스·대웅)과 지분 사슬 카드에만 붙였다. 나머지 회사의 이익수익률은 배당 있는 회사만(배당수익률로 역산).
  • 지분 사슬은 상장사 최대주주 표까지. 셀트리온홀딩스·셀트리온스킨큐어·하나누리·디엔홀딩스 같은 비상장 법인의 주주는 Raw Data 에 없다(확인 안 함) — 그 위 개인 몫은 빠진다.
  • 잠정실적은 회사 발표값이다. 외부감사인 검토 전 — 분기보고서가 나오면 그 값으로 바꾼다.
  • 관세청 수출은 한국 전체다. 삼성바이오로직스 몫을 가르지 못한다 — 우리 Fcst 는 과거 탄력성으로 잇는 추정이다.
  • 합병·분할 해는 성장이 아니다. 셀트리온 2023(헬스케어 합병), 삼성바이오로직스 2025(에피스 인적분할·재표시).
  • R&D 표는 회사 서식. 옛 해(2019~21)와 일부 회사는 아직 못 잡았다. 파이프라인·라이선스는 목록만(가치 평가 없음).
  • 셀트리온 관세청 연결은 우리 Fcst 를 내지 않았다. 합병 뒤 전진 검증에서 직전 분기 유지를 과반 분기에서 못 이겼다.
  • 도쿄해상·EDINET 트랙과 별개.
  • Market prices (KRX market cap) are attached only to the three deep-dive companies (Celltrion, Samsung Biologics, Daewoong) and to the ownership-chain cards. For the other companies the earnings yield covers dividend payers only (backed out from the dividend yield).
  • The ownership chain stops at the listed companies' largest-shareholder tables. The shareholders of unlisted corporates such as Celltrion Holdings, Celltrion Skincare, Hananuri and DN Holdings are not in the Raw Data (not checked) — the individuals' share above them is missing.
  • Preliminary results are company announcements. They come before the external auditor's review and are replaced once the quarterly report is out.
  • Customs exports are Korea-wide. Samsung Biologics' share cannot be separated out — our Fcst is an estimate that carries past elasticity forward.
  • A merger or spin-off year is not growth. Celltrion 2023 (Celltrion Healthcare merger), Samsung Biologics 2025 (Samsung Bioepis spin-off and restatement).
  • The R&D tables follow each company's own format. Older years (2019–21) and some companies are not yet captured. Pipelines and licences are lists only (no valuation).
  • The Celltrion customs link did not produce our Fcst. In the post-merger forward test it did not beat holding the previous quarter in a majority of quarters.
  • Separate from the Tokio Marine / EDINET track.
  • 株価(KRX時価総額)は深掘りの3銘柄(Celltrion・Samsung Biologics・Daewoong)と持株チェーンのカードにだけ付けた。その他の会社の益回りは配当のある会社のみ(配当利回りから逆算)。
  • 持株チェーンは上場会社の筆頭株主表まで。Celltrion Holdings・Celltrion Skincare・Hananuri・DN Holdingsのような非上場法人の株主はRaw Dataにない(未確認) — その上の個人の持分は抜けている。
  • 速報値は会社発表値である。外部監査人のレビュー前 — 四半期報告書が出ればその値に置き換える。
  • 関税庁の輸出は韓国全体である。Samsung Biologicsの取り分は分けられない — 当サイトFcstは過去の弾性値でつなぐ推計である。
  • 合併・分割の年は成長ではない。Celltrion 2023年(Celltrion Healthcare合併)、Samsung Biologics 2025年(Samsung Bioepisの人的分割・再表示)。
  • R&Dの表は会社ごとの様式。古い年(2019〜21年)と一部の会社はまだ取得できていない。パイプライン・ライセンスは一覧のみ(価値評価なし)。
  • Celltrionの関税庁データとの連動からは当サイトFcstを出さなかった。合併後のフォワードテストで、過半の四半期で前四半期据え置きに勝てなかった。
  • Tokio Marine・EDINETトラックとは別。

Source: DART, Financial Supervisory Service. 출처 : ECOS(한국은행, 시장금리(일별)), 2026.11.13 Source: Board of Governors of the Federal Reserve System (US) via FRED®, Federal Reserve Bank of St. Louis. Source: Korea Customs Service (관세청), trade statistics via Public Data Portal (data.go.kr). Source: Korea Exchange (KRX). 본 차트는 “한국거래소 통계정보”를 사용한 결과임.